Category: COVID-19 Vaccine

  • MIL-OSI Economics: Committee on Market Access marks 30th anniversary amid trade tensions

    Source: World Trade Organization

    30 years of the CMA

    Deputy Director-General Angela Ellard spoke at an event prior to the start of the meeting to mark the 30th anniversary of the CMA. Her remarks were followed by a panel discussion that included remarks from former chairs of the CMA.

    “Market access is one of the cornerstones of the multilateral trading system, and it lies at the heart of what the WTO seeks to achieve: enabling trade to flow as smoothly, predictably and transparently as possible through agreed rules,” DDG Ellard said.

    “This is why the work of the Committee on Market Access is not merely technical; it is foundational to the integrity and effectiveness of the entire WTO framework,” she continued. “Even amid widespread uncertainty these days surrounding tariff levels, this Committee provides stability for governments and traders on a wide variety of nuts-and-bolts issues, such as tariff classification, trade restrictions, and information sharing through databases and other means by operationalizing a durable system of rules and a mechanism to address concerns.”

    Achievements of the CMA include enabling members to make their commitments more accessible and ensuring the legal clarity and comparability of concessions across time and among members through the transposition of commitments into updated versions of the Harmonized System used to classify traded goods. Other achievements include strengthening the transparency around applied tariffs and import data through initiatives such as the Integrated Database and, more recently, the new Tariff and Trade Data platform.

    Linked with this event, a special exhibition was set up at the WTO headquarters to mark the 30th anniversary.  The exhibition highlights key historical milestones of the Committee’s work. In particular, it looks at how technology has shaped the preparation of members’ goods schedules, the development of trade and tariff databases, and the broader work of the WTO Secretariat in making trade information accessible to WTO members and the public.

    Joint work on Harmonized System codes for vaccines

    The interim Chair of the CMA, Nicola Waterfield (Canada), welcomed the progress made in the joint effort by the World Customs Organization (WCO), World Health Organization (WHO) and the WTO to establish new tariff headings for vaccines under the Harmonized System (HS). 

    “The new HS codes, which will be adopted by the WCO Council in June for implementation on 1 January 2028, help better identify and classify goods vital for responding to health crises and support coherence between trade policies and public health objectives, including ensuring global equitable access to vaccines,” the Chair said.

    Gael Grooby, Acting Director of the Tariff and Trade Affairs Directorate of the WCO, said the aim of the exercise is to make the covered goods more visible within trade so that they can be tracked and appropriate measures put into place as needed. She emphasized that the work between the CMA and the WCO on this matter “has been unprecedented”.

    The Chair proposed that the CMA invite representatives from the three organizations to discuss the insights gained from this experience and to collectively reflect on the key elements that facilitated such a successful example of collaboration.

    Committee report on supply chain resilience

    The CMA adopted a report on supply chain resilience, the outcome of a series of thematic sessions on the topic held between 2023 and 2025. Specifically, the report defines supply chain resilience, identifies supply chain vulnerabilities, and describes how members measure and monitor global supply chains and what measures support supply chain resilience. The report also examines the role of international and regional cooperation, and the role of the CMA.  

    The Chair observed that the CMA has created a unique approach to thematic sessions, where members have a space to exchange information, learn from each other and produce concrete results that can be used for future reference.

    Trade fragmentation, EU deforestation regulation

    Canada, the European Union and Norway introduced an agenda item addressing fragmentation of global trade through tariffs and the associated global costs. They voiced concerns about the impact of recent tariff measures and the resulting uncertainty on global trade for businesses, consumers and workers. They also underlined the importance of the rules-based multilateral trading system. Ten other members took the floor on this item, with most echoing these concerns. Several also underlined the importance of WTO reform and improvement of its functions so that it remains a central pillar of the global trading system.

    Brazil, Colombia, Paraguay and Peru introduced a joint communication regarding the European Union’s Regulation on Deforestation-Free Supply Chains (EUDR). The four members contend the regulation is a quantitative restriction (QR) on imports and therefore should be notified to the CMA as such. They reiterated their belief that the regulation imposes cumbersome obligations and will virtually ban from the EU market the importation of beef, wood, palm oil, soya, coffee, cocoa and rubber that do not comply with the regulation’s requirements.  The EU said the EUDR is not a market access measure but rather an internal regulation measure designed in line with WTO rules.

    Trade concerns

    Members discussed 33 trade concerns, eight of which were raised for the first time. New concerns dealt with exports of coffee beans and macadamia nuts to China, proposed export restrictions on raw minerals by the Philippines and measures equivalent to quantitative restrictions on the import of wooden boards and viscose staple fibre in India.  Other new concerns covered market access issues for agricultural commodities and food products as well as market access issues faced by the pharmaceutical sector in Thailand, and import restrictions on pocket lighters in India.

    New concerns were also raised in relation to reciprocal tariffs and other tariff measures in the United States and the treatment of like products under the Agreement on Climate Change, Trade and Sustainability (ACCTS) concluded by Costa Rica, Iceland, New Zealand and Switzerland.

    The list of specific trade concerns discussed during the meeting is available here.

    Notifications on quantitative restrictions

    The interim Chair drew members’ attention to a new WTO Secretariat report, “Notification Status of Regular/Period and One-Time Only Notifications in the Goods Area (1995-2024)” (G/C/W/859 ). While the document found that there has been an overall submission rate of 68.9% for regular or periodic notifications, compliance with quantitative restrictions notifications, pursuant to the 2012 Decision  on Notification Procedure for Quantitative Restrictions, was the lowest at just over 26%.

    The Chair said she was aware that various initiatives have been undertaken over time by members and the WTO Secretariat to improve the overall compliance record but members still struggle to comply with certain notification requirements. As a result, she invited members to consider what barriers impact compliance and what possible steps could be taken to improve the submission rate and the quality of such notifications. The Committee agreed to hold such discussions at its next informal meeting scheduled in June.

    Next meeting

    The next formal meeting of the Committee on Market Access will take place on 15-16 October.

    Share

    MIL OSI Economics

  • MIL-OSI United Nations: Experts of the Committee on the Rights of the Child Praise Iraq’s Child Rights Strategy, Raise Issues Concerning Child Marriage and Corporal Punishment

    Source: United Nations – Geneva

    The Committee on the Rights of the Child today concluded its consideration of the fifth and sixth combined periodic reports of Iraq under the Convention on the Rights of the Child, with Committee Experts praising the State’s national child rights strategy and raising questions about child marriage and corporal punishment.

    Benoit Van Keirsbilck, Committee Expert and Taskforce Coordinator for Iraq, said that Iraq had devoted efforts to improving its situation after periods of violence.  The Committee had seen several improvements in terms of the rights of the child, including the State’s commendable strategy on children’s rights.

    Several Experts expressed concern regarding the amendment in 2025 to the civil status law, which reportedly allowed for children to marry from the age of nine.  They asked whether appeals had been made to nullify the amendment.  Mr. Van Keirsbilck said 28 per cent of Iraqi girls were married before the age of 18 and seven per cent before the age of 15. What measures were in place to prevent child marriage?

    Mr. Van Keirsbilck also said the Penal Code allowed parents and educators to use corporal punishment in family and educational settings.  Some 81 per cent of children had reportedly been subjected to some form of corporal punishment.  How was the State party addressing this?

    In an opening statement, Abdulkarim Hashem Mustafa, Permanent Representative of Iraq to the United Nations Office at Geneva, said the Government placed the rights of the child at the heart of its national priorities, and had adopted the national strategy for child protection, which aimed to create a safe and inclusive environment that ensured the well-being and development of children.

    Khalid Salam Saeed, Minster of Justice of Iraq and head of the delegation, in his opening statement, said Iraq had exerted efforts to comply with the Convention and the Committee’s recommendations, despite the major challenges it had faced due to aggression from the terrorist group Daesh.  As a result of its efforts for children, Iraq had been removed from the United Nations Secretary-General’s list of countries that violated children’s rights.

    On child marriage, the delegation said Iraq considered cultural circumstances when setting the minimum age of marriage.  The amendment to the civil status law had been assessed by Parliament and workshops with civil society.  Marriage from nine years of age was not permitted by the law, which permitted marriages from 18 years, or from 15 years when the children involved petitioned courts directly.  Persons who facilitated marriages outside the legal framework were liable for punishment.

    Regarding corporal punishment, the delegation said the Higher Supreme Court had ruled that the Criminal Code did not allow the use of violence against children or students in any context.  There were many cases in which parents and teachers who treated children violently had been punished.

    In closing remarks, Mr. Van Keirsbilck said the dialogue had revealed areas in which Iraq had made important progress since 2015, as well as issues that needed to be addressed.  The future law on child protection seemed extremely promising; the Committee hoped that it would be adopted soon and fully implemented, he said.

    In his concluding remarks, Mr. Saeed said Iraq had presented its progress in implementing the Convention and the recommendations of the Committee. The State party looked forward to receiving the Committee’s recommendations, which would help to consolidate children’s rights in the country.  Iraq was determined to promote human rights based on the principles of equality and social justice.

    Sopio Kiladze, Committee Chair, said in concluding remarks that the Committee and the State party shared a common goal of improving the situation of children in Iraq.  The Committee congratulated the State party on the progress it had made and looked forward to hearing about the future progress that the State would make for children in the next dialogue.

    The delegation of Iraq consisted of representatives from the Prime Minister’s Office; General Secretariat of the Iraqi Cabinet; Ministry of Foreign Affairs; Ministry of Labour and Social Affairs; Ministry of Justice; Scientific Supervision and Evaluation Agency; Directorate-General for Curricula; Directorate-General of Planning and Follow-Up; Human Rights Directorate; Kurdistan Regional Government; and the Permanent Mission of Iraq to the United Nations Office at Geneva.

    The Committee will issue concluding observations on the report of Iraq at the end of its ninety-ninth session on 30 May. Those, and other documents relating to the Committee’s work, including reports submitted by States parties, will be available on the session’s webpage.  Summaries of the public meetings of the Committee can be found here, while webcasts of the public meetings can be found here.

    The Committee will next meet in public on Tuesday, 20 May at 3 p.m. to consider the combined sixth and seventh periodic reports of Romania (CRC/C/ROU/6-7).

    Report

    The Committee has before it the fifth and sixth combined periodic reports of Iraq (CRC/C/IRQ/5-6).

    Presentation of Report

    ABDULKARIM HASHEM MUSTAFA, Permanent Representative of Iraq to the United Nations Office at Geneva, said Iraq reaffirmed its commitment to respect and implement its international obligations under the Convention and to include its provisions in national policies, despite the complex challenges that the country had faced during the past decades. The Government placed the rights of the child at the heart of its national priorities, and had adopted the national strategy for child protection, which aimed to create a safe and inclusive environment that ensured the well-being and development of children. The State party had strengthened the national legislative framework by amending several relevant laws to ensure their compatibility with international standards, including the draft child protection law currently before the Parliament.  Iraq affirmed that the protection of children’s rights was both a national responsibility and a humanitarian and moral obligation.

    KHALID SALAM SAEED, Minster of Justice of Iraq and head of the delegation, said Iraq had exerted efforts to comply with the Convention and the Committee’s recommendations. Iraq faced major challenges due to aggression from the terrorist group Daesh, which had led to violations of the rights of the child.  Iraq had undertaken efforts to prevent the spread of terrorism and violence in the country, provide reparation to victims, support the transfer of displaced persons, and prosecute terrorist crimes.  The State party had transferred or rehabilitated more than 17,000 victims of the violence.

    Seeking to bring its legislation in line with international standards, the State party had implemented several laws, including the legal aid act, the amendment to the act on people with disabilities, the health coverage act, the social services act, the act on the integration of minors, and a draft law against domestic violence.

    Several policies and strategies had also been developed, including the technical development strategy.  The State party had developed policies on the protection of families, and had continued work to investigate human trafficking.  It had set up a hotline for reporting gender-based violence and had also established women’s and girls’ welfare units to combat violence against women and girls. The State party had developed strategies to improve the security environment, reduce poverty and support families, which included measures to increase the number of persons receiving social protection assistance, establish family protection units, and expand the provision of vaccinations.

    The Iraqi Government was promoting access to education for all by implementing the act on compulsory education and providing school supplies and scholarships to children in need.  The Government had completed the construction and renovation of 6,500 schools, and construction was continuing.  Iraq aimed to increase the resources and capacities of educational institutions to improve the quality of education they provided.

    The State party had also developed a strategy for the rehabilitation of minors, establishing juvenile rehabilitation units.  The Constitution had been amended and laws established to criminalise prostitution, trafficking in illegal substances, and the sale of children.  Iraqi laws prohibited the conscription of young people under the age of 18, and many policies had been implemented to prevent the involvement of children in terrorist activities.  The State party had also set up a body to monitor the recommendations of international bodies.  As a result of these efforts, Iraq had been removed from the United Nations Secretary-General’s list of countries that violated children’s rights.

    DINDAR ZEBARI, Coordinator of International Recommendations, Kurdistan Regional Government, said Kurdistan had developed a regional development plan for 2021–2025, which included 11 recommendations on children’s rights, of which nine had been implemented.  In 2023, the Kurdistan Council of Ministers approved a policy aimed at protecting children. Kurdistan had raised the age of criminal responsibility to 11 years, banned the death penalty for children, converted detention sentences to rehabilitation programmes, and reactivated juvenile courts. 

    In the fight against human trafficking, a national campaign was launched that had led to the arrest of 79 people and the sentencing of 12 traffickers.  Kurdistan hosted 865,000 internally displaced persons and refugees, and the Government provided this population with shelter, education, and health care. 

    Measures implemented by the Government had led to a 42 per cent reduction in under-five mortality; the rate was now far lower than the global average.  The Government provided social welfare services to approximately 130 children annually, and new care homes for girls had been opened.  Some 550 children from government nurseries and 53 from the surrogacy system had been placed in foster families.  Procedures for issuing parental certificates to children of unknown origin were carried out in accordance with the civil status law, in a manner that respected their privacy and preserved their dignity.

    Questions by Committee Experts 

    BENOIT VAN KEIRSBILCK, Committee Expert and Taskforce Coordinator for Iraq, said that Iraq had devoted a range of efforts to improving its situation after periods of violence.  The Committee had seen several improvements in terms of the rights of the child, including the State’s commendable strategy on children’s rights.  However, challenges remained, and the Committee would address these.

    Iraq maintained its reservation to article 14 of the Convention.  Why did it oppose children having the right to protest?  Was the Convention used by courts and the Parliament?  When would the planned child protection law be adopted? Would this law address all forms of violence against children?  How did legislation on refugees that would soon be adopted address refugee children’s rights?

    Who was responsible for coordinating and implementing the State’s strategy for children?  What budget was set aside for the strategy and how would its implementation be assessed?  How would the State party implement the proposed child protection information management system?  Did it calculate the percentage of the budget dedicated to children’s policies, and was it working on addressing issues with tax collection to increase funds for children’s policies?  How did the State party ensure that the data it collected on children was accurate?

    Did the State party plan to ratify the Optional Protocol on the individual complaints procedure?  Did children whose rights were violated have access to reparations?  How could they lodge complaints?  There were reports that police had refused to register some children’s complaints.

    The Committee welcomed that Iraq’s National Human Rights Commission had “A” status under the Paris Principles. There had been a legal complaint against the former Commissioner of the National Human Rights Commission.  What progress had been made in investigating this case?  Were there plans to set up an ombudsperson for children?  How had cuts in international funding affected programmes promoting children’s rights in Iraq?

    Sexual exploitation of children remained a major concern.  What measures were in place to support child victims?  The Penal Code allowed parents and educators to use corporal punishment in family and educational settings.  Some 81 per cent of children had reportedly been subjected to some form of corporal punishment.  How was the State party addressing this?

    Iraqi law still allowed children to marry from age 15, and there had been a draft law that sought to lower the age of marriage for girls to nine.  What was the status of this law?  What measures were in place to prevent child marriage?  Sexual slavery was still practiced in some parts of the country.  How did the State party support child victims of sexual slavery?  How many children who were affected by the activities of Daesh had the State party rehabilitated?

    MARIANA IANACHEVICI, Committee Expert and Taskforce Member, welcomed the State party’s efforts to incorporate the principles of the Convention in its legal and policy frameworks, and to prevent discrimination.  The State party taught minority languages in schools and had implemented measures to prevent discrimination against children with disabilities in schools.  Were there plans to develop exclusive anti-discrimination legislation that addressed discrimination against children?  How would the State promote access to social services for girls in remote communities? How was the principle of the best interests of the child reflected in national legislation?  What mechanisms were in place to ensure that children’s views were considered when assessing what was in their best interests?

    What measures were in place to ensure that no children were sentenced to the death penalty?  How was the civil registration system being strengthened to ensure that all children, including children born in areas formerly controlled by Daesh, were registered?  What measures were in place to prevent infanticide?

    How was the State party ensuring that the views of children were considered in laws, policies and practices?  How was the State party promoting the meaningful participation of children from disadvantaged groups in the development of policies and laws?

    The Expert welcomed efforts to support children returning from northern Syria.  What was the rationale behind 2025 amendments to the personal status law?  There were concerns that these amendments could undermine existing safeguards for women and children.  How did the State party ensure that this legislation was in line with the Convention, and that women-led households would continue to receive adequate social support?  What efforts were being made to harmonise religious court rulings with international standards? 

    What efforts were being made to expand family-based care for children whose parents could no longer care for them, and to make foster care a viable alternative for families? Did the State party pursue systematic family reunification when appropriate?

    RINCHEN CHOPHEL, Committee Expert and Taskforce Member, welcomed legislation from 2006 that allowed women to pass on their nationality to their children.  Did children born to unmarried parents receive birth certificates?  What measures were in place to regulate the registration of children born in armed conflict situations?  The Expert expressed concern about reports that the children of parents who were not of Muslim faith, particularly persons of the Baha’i faith, were not registered.  What measures were in place to prevent this?  What measures had been adopted to protect children from online risks? What was the status of the draft cybercrime law?

    BENYAM DAWIT MEZMUR, Committee Expert and Taskforce Member, said that there had been significant progress for children in Iraq over the last 10 years.  What awareness raising campaigns were being carried out to address negative societal attitudes related to children with disabilities?  What had been the impact of legislative revisions related to persons with disabilities?  How had the State party mainstreamed disability rights?  What progress had been made in developing a central database on children with disabilities?  The Committee welcomed the “disability stipend” for children with disabilities who attended schools.  Were there plans to extend this to children with disabilities who did not attend school? Assessments of children with disabilities tended to focus on medical impairments; were there plans to change this approach?  The Kurdistan Government had introduced a universal stipend for children, but its reach appeared to be limited.  What efforts had been made to extend it?

    Responses by the Delegation

    The delegation said most of the Iraqi population was Muslim, but the Government respected religious plurality and had implemented mechanisms to protect religious diversity.  Iraq had expressed reservations related to article 14 of the Convention as its law was based on the Islamic Sharia, but the State party’s laws promoted the freedom of religion.  There was one case related to the rights of a 15-year-old girl in which the court had referenced the Convention.

    The State party paid salaries to carers of children with disabilities; recently, this salary had been increased. Assistive devices were provided to children with disabilities, who were integrated into public schools.  Mobile teams aided children with disabilities in their homes and smart identification cards facilitated access to social services for children with disabilities.  The State party also provided primary care to children with disabilities in conflict settings.

    The Government had adopted several measures promoting the participation of children in decision-making processes, establishing children’s parliaments in more than 420 schools. Non-governmental organizations promoted the participation of children in decision-making, providing them with training on advocacy.

    Around 30 shelters had been established that provided services to vulnerable children, including orphans and victims of domestic violence.  The shelters provided food and access to education and technical training.  Health examinations were provided for children in these shelters every three months.

    The Constitution included articles that prohibited discrimination and guaranteed protection for women and children. Several laws had been adopted to protect minorities, including a law on reparations for Yezidi refugees who had suffered human rights violations during armed conflict.

    The State party sought to adopt a draft law on anti-discrimination that was currently before Parliament.  The law would prevent discrimination based on religion and other factors.  There were several schools that taught Christian values.  A centre had been established that taught the minority Assyrian language, and several public schools also taught the language.

    The Ministry of Interior accepted complaints from children through a dedicated hotline, which complied with international standards; the children’s support unit; and through hospitals and schools.  A range of legal measures had been adopted to combat sexual exploitation.  State legislation stipulated punishments for violations of children’s rights online.

    Children were guaranteed the right to an identity by the law on identity and other legislative measures.  The State party had sought to identify children with unknown parents born in the Daesh era and provide them with identity documents; 120,000 persons in this situation had been registered to date.

    The State party considered cultural circumstances when setting the minimum age of marriage.  It was re-evaluating the law on child marriage. Marriage could be approved from age 15 if it was in the child’s interests.  There was currently no draft law defining the best interests of the child, but some texts recognised the principle, such as the personal status law, which called for an assessment of the best interests of the child in foster arrangements.

    The State party was proud of its achievements in rehabilitating child refugees.  A centre had been established in 2021 that hosted 17,000 individuals. Currently, 7,000 children resided in the centre, who benefited from cultural activities, education and social rehabilitation services.  More than 6,000 children had been supported to return to their homes.  Most refugees who came from Syrian camps were women and children.  They were provided with various support services, and more than 6,000 of these persons had been supported to return to their homes.

    More than nine trillion dinars had been allocated to the health sector, more than 70 per cent of which benefitted women and children.  Hospital workers had been trained on dealing with victims of violence against women and children, and medical units providing care to victims had been established. In refugee camps, more than 30,000 vaccinations had been provided to children.  There were governorate programmes on sexual and reproductive health and nutrition that benefitted youth.  A draft law on mental health had been developed and programmes were in place to provide psychosocial care for students in schools and universities.

    Training sessions had been organised on the Convention, international humanitarian law, and the rights of children in armed conflict, for members of the armed forces.  The Government had contributed to demining more than 18 million cluster munitions in former conflict zones.

    The Constitutional Court had ruled that article 41 of the Criminal Code did not allow the use of violence against children or students in any context; it aimed only at imposing discipline and rehabilitation.  There were many cases in which parents and teachers who treated children violently had been punished.

    Child benefits were allocated to more than 3.5 million children, while around 3,000 orphaned children also received benefits, and more than two million children received scholarships. Around 154,000 children received disability benefits.  Some 12 trillion dinars were invested in children’s education in 2024.  Children with disabilities were integrated into mainstream education.

    Questions by Committee Experts

    BENYAM DAWIT MEZMUR, Committee Expert and Taskforce Member, said that Iraq relied on external support for health sector financing.  What measures were in place to reduce reliance on external support?  The Committee commended the State party’s efforts in immunisation, but there were low immunisation rates in conflict areas and rural areas.  How was the Government addressing this?

    Obesity rates were rising among Iraqi children, anaemia was an issue for women, and Iraq had low breastfeeding rates. How were these issues being addressed? How was the State party working to reduce the exposure of children to tobacco and unhealthy food marketing, strengthening children’s mental health and reducing health costs for families? The adolescent birth rate was concerningly high.  How was the State party addressing teenage pregnancy?

    Iraqi schools were fully closed for 51 weeks during the COVID-19 pandemic.  What catch-up measures had been implemented?  Access to online services was limited in schools in Kurdistan; how was this being addressed?  Mr. Mezmur congratulated the State party on implementing legislation on pre-primary education.  Enrolment in this education was still at around 10 per cent; how was the Government promoting increased access?  What was being done to identify children who were out of school and encourage their return? How could children without documentation access education and health care?

    MARIANA IANACHEVICI, Committee Expert and Taskforce Member, asked about care being provided for children returning from northeast Syria.  What training was provided to professionals who worked with children coming from abusive family environments?  How were the rights of incarcerated children protected?  Did they have access to education and mental health care?  The Expert welcomed efforts to improve the standards of living for children through social safety net programmes.  Were there plans to strengthen the programmes to support vulnerable children?  How was the Government promoting access to safe drinking water for vulnerable children and families, particularly in conflict-affected areas?

    RINCHEN CHOPHEL, Committee Expert and Taskforce Member, said children in Iraq were exposed to extremely high temperatures.  Were there national initiatives to monitor children’s environmental health, and reduce and monitor air and water pollutants?  What measures were in place to increase children’s preparedness for disasters?

    BENOIT VAN KEIRSBILCK, Committee Expert and Taskforce Coordinator, asked whether the State party was considering ratifying the 1951 Refugee Convention or the Convention on the Status of Stateless Persons?  What protections were provided to asylum seekers and migrants in Iraq?  Had the State party conducted analysis into the causes of child labour and developed measures to address the issue?  Were labour inspectors trained to deal with child labour?  Why had the number of inspections decreased recently?  What was being done to reintegrate victims of child labour into society and support their access to rehabilitation?  How were children in street situations identified and supported to return to their families?  Were there referral services for child victims of trafficking?  Were the perpetrators of child trafficking brought to justice?  How did the State party ensure that child victims of trafficking were not treated as perpetrators?

    Had the State party assessed legislation on child justice and considered establishing juvenile courts?  The minimum age of criminal responsibility was 11; were there plans to raise this to 14?  What happened to children below 11 years of age who committed crimes? The treatment of children in detention was very worrying.  How many children were detained?  What non-custodial measures were in place?  How did the State party assess the age of children in conflict with the law? Were there still children detained with adults?

    There had been improvements regarding children involved in armed conflict.  How was this issue monitored and how was the recruitment of children criminalised in practice?  Were there military schools in Iraq?  Was the State party considering incorporating the Safe Schools Declaration in national policy?

    Responses by the Delegation

    The delegation said Iraq had taken numerous measures to address child labour, which was prohibited for children under 15 years old, and there were strict measures regulating work for children aged 15 to 18.  Iraq had ratified the International Labour Organization Conventions 138 and 182 on child labour.  The State party was working to raise awareness of the risks of employing children and the punishments imposed.  Social support programmes had been bolstered to reduce the need for children to engage in labour; around 1.5 million households benefitted from these programmes. 

    There was a workplace oversight and monitoring programme that sought to protect children from economic exploitation. Employers could be fined or punished for using child labour.  Children who were authorised to work could only work reduced hours and could not work at night.  These children had the right to equal pay and a safe and healthy workplace.  An exceptional surprise inspection campaign had been carried out since 2019, which had identified more than 600 cases of child labour in total, with several employers of children transferred to judicial authorities.

    The budget for the Ministry of Health had increased to over nine trillion dinars in 2024.  This budget was devoted to health care programmes for women and children, constructing and rehabilitating medical centres, and other areas.  The Government was implementing the national vaccination programme to provide vaccinations to vulnerable populations, including asylum seekers and refugees. The Government provided equal access to health services regardless of religion, ethnicity or other characteristics. In 2023 and 2024, more than 43,000 children in refugee camps received vaccinations against polio.  Iraq had become one of the first countries in the Middle East to become free from polio.  More than 88 per cent of children in kindergarten and 91 per cent of primary school students had been vaccinated.

    Awareness raising campaigns on the importance of healthy diets were carried out in schools.  The nutritional quality of school meals was examined and the safety of schools’ drinking water was tested.  Schools were supported to organise sports activities.  The State party also supported non-governmental organizations working to improve children’s nutrition.  The Government had adopted a law prohibiting the sale of cigarettes to children under the age of 15 and a law prohibited the sale and production of e-cigarettes.  A smoking ban had been imposed in schools.

    The State party promoted exclusive breastfeeding in the first six months of life, and there had been a 10 per cent rise in breastfeeding recently.  Iron supplements were provided to pregnant women and vitamin A supplements were provided to children, blood test campaigns were carried out to detect anaemia, and awareness raising campaigns on the dangers of anaemia were carried out. Since 2021, there had been a 46 per cent decrease in maternal mortality, influenced by a 96 per cent rise in the number of specialised doctors covering deliveries.

    Iraq’s nationally determined contribution, approved in 2021, spelled out the State party’s goal of developing renewable energy sources and transitioning to a low-carbon economy.  The State party was pursuing climate change mitigation and adaptation measures in its policies and programmes, including the national development strategy.  Projects and programmes to cut pollution and minimise the effects of greenhouse gases were being developed.  A technological action plan on the energy transition had also been drafted.

    All persons from minority groups enjoyed the rights and privileges guaranteed to all Iraqi citizens. Electoral laws ensured quotas for minority representatives, and there were also quotas for minorities in the civil service.  There were nine seats in Parliament reserved for minority representatives, and there were also minority representatives in the Council of Ministers.  The State party had encouraged Yezidi and Christian minorities to return to their places of residence.  There were 79 non-governmental organizations working tirelessly to protect minority children’s rights.  A programme to restore minority religious buildings had been implemented following the destructive campaign of Daesh, which had led to the reconstruction of four Christian churches and more than 20 mosques.

    The Kurdistan Government had provided support to 185,000 children abducted by Daesh.  Around 1,000 survivors were sent to Germany to receive additional healthcare.  Many cases had been submitted related to the crimes of Daesh.

    Follow-Up Questions by Committee Experts

    BENOIT VAN KEIRSBILCK, Committee Expert and Taskforce Coordinator, asked when the child protection law would be adopted.  Some 28 per cent of girls were married before the age of 18 and seven per cent before the age of 15.  What were the rights of former wives after divorce?  Was the State working to prevent the practice of forcing girls to marry their cousins?  Corporal punishment by parents and teachers appeared to be permitted by the Criminal Code. Was there an awareness raising campaign on the prohibition of corporal punishment?  There were reports of female genital mutilation still being practiced in some regions; how was this being addressed?  How was the State party pursuing demining activities to make land safe for children?

    BENYAM DAWIT MEZMUR, Committee Expert and Taskforce Member, asked about the implementation of legislation on illegal drugs, which had increased in prevalence in Iraq in recent years. How was Iraq addressing the impact of drugs on children?

    MARIANA IANACHEVICI, Committee Expert and Taskforce Member, asked about amendments in 2025 to the civil status law and the expanded role of religious courts in family matters.  How did the decisions of these courts affect children?

    Other Committee Experts asked about why Iraq was not present at the Bogota interministerial conference on violence against children; how it was expanding coverage of the hotline for reporting violence; whether marriages between people of different religions were permitted; plans to revise legislation allowing husbands to beat their wives; whether there was an authority monitoring standards in residential homes; whether children incarcerated with their parents benefitted from support programmes; whether there was a disease surveillance system in place; how the State party was combatting tuberculosis in children, obstetric fistula and child obesity; measures to prevent child road deaths; and screening programmes to assess disability in children.

    Several Experts expressed concern regarding the amendment in 2025 to the civil status law allowing for children to marry from age nine.  They asked how the State party determined the best interests of the child in decisions authorising marriages under age 18?  What measures were implemented to protect vulnerable girls from forced marriages? Had appeals been made to immediately nullify the amendment?

    Responses by the Delegation

    The delegation said the amendment to the law on personal status had been assessed by Parliament and workshops with civil society.  Marriage from nine years was not permitted by the civil status law, which permitted marriages from 18 years of age, or from 15 years when the children involved petitioned courts directly, with their parents’ permission.  Such children were required to undergo medical examinations to ensure that they were mentally and physically capable of marriage.  The new civil status law ensured that only judges had the ability to sign minors’ marriage contracts.  There were no religious courts or judges in Iraq. Persons who facilitated marriages outside the legal framework were liable for punishment.

    The Supreme Court had issued a clear verdict on article 41 of the Criminal Code, finding that it did not allow violence against children in any form.  Courts were bound to follow this interpretation of the law.  When parents exercised corporal punishment, they faced legal punishment.  Civil police monitored cases of corporal punishment and had responded to around 100 cases.

    State legislation regulated disciplinary measures imposed against school principals and teachers who harmed children’s health.  Perpetrators of such acts could be brought before the courts.  The Ministry of Education combatted all forms of violence in schools.  School management boards included experts on preventing violence.

    The Ministry of Interior had departments fighting trafficking in persons and supporting victims, and departments supporting poor families and children to keep them out of street situations. The law on trafficking in persons specified that minors involved in trafficking were victims.  The national strategy for 2023 to 2026 on child protection included measures to combat trafficking.  In 2024, the State party had arrested more than 1,000 persons involved in trafficking in persons.  The department combatting trafficking had been linked with the secret services department to strengthen transnational activities to combat the crime.

    The Ministry of Interior had implemented measures to prevent the spread of illegal drugs under the national strategy to combat drugs for 2025 to 2030.  Educational programmes were carried out to strengthen public servants’ capacity to treat drug addicts.  Some 16 rehabilitation centres had been established for drug addicts, who were treated as victims rather than criminals and supported to reintegrate into society. The State party had cooperated with other States to dismantle international drug trafficking networks. The volume of confiscated drugs had increased recently.

    Parliamentary committees were examining the draft law on children’s protection, which promoted children’s rights and prohibited all forms of abuse against children.  The law would ensure that children enjoyed protection from discrimination regardless of their ethnicity, religion or other characteristics, and the right to live in a safe family environment.

    Concluding Remarks 

    BENOIT VAN KEIRSBILCK, Committee Expert and Taskforce Coordinator, said that the size and high level of the delegation showed that Iraq highly valued children’s rights.  The dialogue had revealed areas in which Iraq had made important progress since 2015, as well as issues that needed to be addressed. Based on it, the Committee would develop recommendations to help the State party better implement the Convention. The future law on child protection seemed extremely promising; the Committee hoped that it would be adopted soon and fully implemented.  It was important that children knew their rights and were able to implement them. Iraq still faced many challenges. The Committee looked forward to the future progress that it hoped the State would make.

    KHALID SALAM SAEED, Minster of Justice of Iraq and head of the delegation, said Iraq had presented its progress in implementing the Convention and the recommendations of the Committee.  The State party looked forward to receiving the Committee’s recommendations, which would help to consolidate children’s rights in the country.  The concluding observations would be carefully studied by authorities drafting policies and plans on the rights of the child.  Iraq was determined to promote human rights based on the principles of equality and social justice.  The Government cooperated with various stakeholders to implement the Committee’s recommendations and its international obligations.  Iraq thanked all persons who had facilitated the dialogue.

    ABDULKARIM HASHEM MUSTAFA, Permanent Representative of Iraq to the United Nations Office at Geneva, said the dialogue reflected the Iraqi Government’s resolve to protect the rights of the child pursuant to the provisions of the Convention.  Iraq thanked the Committee for its moral support, which encouraged it to further improve the situation of its children.

    SOPIO KILADZE, Committee Chair, said that the Committee and the State party shared a common goal of improving the situation of children in Iraq.  The Committee congratulated the State party on the progress it had made and looked forward to hearing about the future progress that the State would make for children in the next dialogue.

    ___________

    Produced by the United Nations Information Service in Geneva for use of the media; 
    not an official record. English and French versions of our releases are different as they are the product of two separate coverage teams that work independently.

     

     

     

    CRC25.012E

    MIL OSI United Nations News

  • MIL-OSI USA: Durbin Joins Health Care Leaders To Discuss Cost Of Prescription Drugs And Republican Cuts To Medicaid

    US Senate News:

    Source: United States Senator for Illinois Dick Durbin
    May 16, 2025
    SPRINGFIELD — U.S. Senate Democratic Whip Dick Durbin (D-IL) today joined health leaders at Springfield Memorial Hospital to highlight efforts to address high prescription drug prices, and how health insurance coverage for nearly 14 million Americans is at risk because of Republican plans to provide tax breaks for billionaires.
    Americans are paying the highest prices for prescriptions in the world. In addition to unjustifiable pricing and anticompetitive tactics by pharmaceutical manufacturers, this is partly due to Pharmacy Benefit Managers (PBMs), who control the flow of prescriptions for 200 million Americans. PBMs abuse rebates and fees to manipulate their formularies, ensuring they, not doctors, often decide which drugs patients receive.
    President Trump’s recent executive order on Big Pharma does little to address the issue of high drug costs, unlike the Inflation Reduction Act, which was passed during the Biden Administration and capped costs for covered insulin at $35 per month under Medicare, made recommended vaccines available at no costs for 1.4 million seniors in Illinois, established a limit on annual out-of-pocket cost at $2,000, and required drug companies to pay a rebate to Medicare if they raise prices faster than the rate of inflation. It also provided the Biden-Harris Administration with the authority to negotiate drug prices with Big Pharma, resulting in price reductions of up to 79 percent for some medications last year.
    Durbin has also been outspoken on Republicans’ dangerous proposal to fund tax breaks for billionaires by slashing Medicaid funding. Medicaid covers nearly half of all births, two-thirds of nursing homes residents, and the majority of patients with behavioral health needs, while being a lifeline for children’s and rural hospitals. Last week, the non-partisan Congressional Budget Office (CBO) report on Republicans’ proposed budget plan concluded that, if Republicans push the plan forward, 13.7 million Americans would lose health care coverage.
    “People in the United States are paying four times more than people in similar countries pay for life-saving medications,” said Durbin. “I was proud to pass the Inflation Reduction Act during the Biden Administration to cap out-of-pocket costs for prescription drugs and empower Medicare to bargain with Big Pharma for lower prices, but there’s still work to be done to address PBMs and their high fees. Instead of focusing on lowering prices for Americans, Republicans in Congress are focused on cutting Medicaid to give tax breaks to billionaires—which would rip away health coverage for nearly 14 million Americans. Hospitals in the Memorial system that rely on Medicaid, whether here in Springfield, or in Decatur or Jacksonville, are the backbone of their community. I’ll continue fighting to protect Medicaid and lower the cost of prescription drugs for Illinoisans.”
    “The 340B program helps stretch scarce federal resources, but even that safety net is being undermined by opaque pricing practices and the growing power of pharmacy benefit managers. It’s clear that without action, these problems will only worsen,” said Dr. Chris McDowell, Executive Associate Dean, SIU School of Medicine. “That’s why we are deeply grateful to Senator Durbin for his leadership in calling out these systemic failures—and for championing policies that prioritize patients over profit.”
    “PBM reform is urgently needed to protect patient access and lower drug costs. Independent pharmacies are often the only source of care in underserved areas, and pharmacists play a vital role in guiding safe, effective treatment. Without action now, communities risk losing access to essential medications and trusted healthcare professionals,” said David Bagot, President, Illinois Pharmacists Association.
    “As physicians, we focus on providing the very best care we can for our patients. We prescribe medications based on an individual patient’s unique needs and conditions. However, drug pricing and availability too often influence the options available to our patients,” said Dr. Ted Clark, Chief Medical Officer, Decatur Memorial Hospital.
    Earlier this week, Durbin, as the Ranking Member of the Senate Judiciary Committee, questioned witnesses during a hearing that investigated the role PBMs play in the drug supply chain and their impact on competition, patients, providers, and pharmacies.
    -30-

    MIL OSI USA News

  • MIL-OSI USA: FDA to Host Inaugural, Independent, Scientific Expert Panel Open to Public

    Source: US Department of Health and Human Services – 3

    For Immediate Release:
    May 16, 2025

    As part of the Trump Administration’s commitment to transform American health care and rebuild trust in public health, the U.S. Food and Drug Administration’s Commissioner Martin A. Makary, M.D., M.P.H., will lead a roundtable discussion of an independent panel of scientific experts to discuss the safety and necessity of talc as an additive in food, drug, and cosmetic products. This public roundtable, taking place on Tuesday, May 20, 2025 at 10 a.m. ET, will follow a transparent process grounded in gold standard science, setting precedents for future discussions.
    The group, comprised of world-renowned experts in their respective fields, will review the latest scientific evidence, evaluate potential health risks, explore safer alternatives, and individual experts may offer their recommendations for regulatory action. Unlike under the previous administration, members of the media and public are welcome and encouraged to attend and listen to the discussion.  
    Talc, a naturally occurring mineral used in a variety of consumer products, has come under increased scrutiny due to concerns about potential health effects, especially when contaminated with asbestos or consumed over prolonged periods. The panel will review data related to talc exposure and evaluate its continued use within the context of public health needs and available alternatives.
    “Despite the potential carcinogenic harm with topical talc, it continues to be ingested by children and adults through food and some medications. We are bringing together a group of leading independent experts to assess the available evidence around talc and consider whether its continued use is necessary given modern alternatives,” said FDA Commissioner Martin A. Makary, M.D., M.P.H. “This is a critical step toward ensuring that ingredients in products used every day by Americans meet the highest standards for safety.”
    The decision to convene this panel follows a growing call from public health leaders for a systematic reevaluation of talc’s use in consumer products. In July 2024, the International Agency for Research on Cancer concluded that talc is “probably carcinogenic” with the second highest level of scientific certainty leading to European authorities announcing a ban of talc from cosmetics by 2027. A recent commentary, “Reviewing the Safety of Our Foods and Drugs: An Urgent Need For A Comprehensive Reevaluation by FDA of Talc in the American Food and Drug Supply”, collating the works of many of the global talc experts joining the panel, underscored this need specifically.
    The expert panel discussion will take place at the FDA’s White Oak Campus in Silver Spring, Maryland. The public and members of the media may attend the roundtable. Registration is required as seating is limited. The session will be livestreamed. Meeting and registration information can be found here: FDA Expert Panel on Talc.  
    This initiative is part of the FDA’s broader efforts to apply rigorous, evidence-based standards to ingredient safety and modernize regulatory oversight, thoroughly considering evolving science and consumer health. In the coming weeks, the agency will announce additional FDA Expert Panel roundtables on a variety of topics.

    Consumer:888-INFO-FDA

    ###

    Boilerplate

    The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, radiation-emitting electronic products, and for regulating tobacco products.

    Content current as of:
    05/16/2025

    Follow FDA

    MIL OSI USA News

  • MIL-OSI USA: FDA Clears First Blood Test Used in Diagnosing Alzheimer’s Disease

    Source: US Department of Health and Human Services – 3

    For Immediate Release:
    May 16, 2025

    The U.S. Food and Drug Administration today cleared for marketing the first in vitro diagnostic device that tests blood to aid in diagnosing Alzheimer’s disease. The Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio is for the early detection of amyloid plaques associated with Alzheimer’s disease in adult patients, aged 55 years and older, exhibiting signs and symptoms of the disease.
    “Alzheimer’s disease impacts too many people, more than breast cancer and prostate cancer combined,” said FDA Commissioner Martin A. Makary, M.D., M.P.H. “Knowing that 10% of people aged 65 and older have Alzheimer’s, and that by 2050 that number is expected to double, I am hopeful that new medical products such as this one will help patients.”
    Alzheimer’s disease, a brain disorder known to slowly destroy memory and thinking skills, and, eventually, the ability to carry out the simplest tasks, is progressive, meaning that the disease gets worse over time. In most people with Alzheimer’s disease, clinical symptoms first appear later in life. Amyloid plaques in a patient’s brain are a hallmark sign of Alzheimer’s disease. While amyloid plaques can occur in other diseases, being able to detect the presence of plaque, along with other evaluations, helps the doctor determine the probable cause of the patient’s symptoms and findings. These plaques can be detected and visualized using amyloid positron emission tomography (PET) brain scans, often years before clinical symptom onset, to aid in diagnosing Alzheimer’s disease. PET scans, however, are a costly and time-consuming option and expose patients to radiation.
    The Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio measures two proteins, pTau217 and β-amyloid 1-42, found in human plasma, a component of blood, and calculates the numerical ratio of the levels of the two proteins. This ratio is correlated to the presence or absence of amyloid plaques in the patient’s brain, reducing the need for a PET scan. Similar FDA-authorized/cleared tests, one from the same company as this new test, are used with cerebrospinal fluid (CSF) samples, which are collected through an invasive lumbar puncture, also called a spinal tap. This new Lumipulse test only requires a simple blood draw, making it less invasive and much easier for patients to access.  
    “Nearly 7 million Americans are living with Alzheimer’s disease and this number is projected to rise to nearly 13 million,” said Center for Devices and Radiological Health Director Michelle Tarver, M.D., Ph.D. “Today’s clearance is an important step for Alzheimer’s disease diagnosis, making it easier and potentially more accessible for U.S. patients earlier in the disease.”
    During review of the Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio, the FDA evaluated data from a multi-center clinical study of 499 individual plasma samples from adults who were cognitively impaired. The samples were tested by the Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio and compared with amyloid PET scan or CSF test results.
    In this clinical study, 91.7% of individuals with Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio positive results had the presence of amyloid plaques by PET scan or CSF test result, and 97.3 % of individuals with negative results had a negative amyloid PET scan or CSF test result. Less than 20% of the 499 patients tested received an indeterminate Lumipulse G pTau217/β-Amyloid 1-42 Plasma Ratio result.
    These findings indicate that the new blood test can reliably predict the presence or absence of amyloid pathology associated with Alzheimer’s disease at the time of the test in patients who are cognitively impaired. The test is intended for patients presenting at a specialized care setting with signs and symptoms of cognitive decline. The results must be interpreted in conjunction with other patient clinical information.
    The risks associated with the Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio are mainly the possibility of false positive and false negative test results.
    False positive results, in conjunction with other clinical information, could lead to an inappropriate diagnosis of, and unnecessary treatment for, Alzheimer’s disease. This could lead to psychological distress, delay in receiving a correct diagnosis as well as expense and the risk for side effects from unnecessary treatment.
    False negative results could result in additional unnecessary diagnostic tests and potential delay in effective treatment. Importantly, the Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio is not intended as a screening or stand-alone diagnostic test and other clinical evaluations or additional tests should be used for determining treatment options.
    The FDA reviewed the Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio through the 510(k) premarket notification pathway. A 510(k) notification is a premarket submission made to the FDA to demonstrate that a new device is substantially equivalent to a legally marketed predicate device. The FDA found that the Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio is substantially equivalent to the Lumipulse G β-amyloid Ratio (1-42/1-40), which is the previously authorized test that uses CSF samples.
    The Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio was granted Breakthrough Device designation, a process designed to expedite the development and review of devices that provide for more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases or conditions.
    The FDA issued clearance of the Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio to Fujirebio Diagnostics, Inc.

    Consumer:888-INFO-FDA

    ###

    Boilerplate

    The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, radiation-emitting electronic products, and for regulating tobacco products.

    MIL OSI USA News

  • MIL-OSI United Kingdom: MHRA approves guselkumab for Crohn’s disease and ulcerative colitis

    Source: United Kingdom – Executive Government & Departments

    Press release

    MHRA approves guselkumab for Crohn’s disease and ulcerative colitis

    As with all products, we will keep its safety under close review

    The Medicines and Healthcare products Regulatory Agency (MHRA) has today, 16 May 2025, approved guselkumab (Tremfya) to treat Crohn’s disease and ulcerative colitis (UC).

    Guselkumab is currently approved to treat plaque psoriasis and psoriatic arthritis. However, clinical studies have shown that guselkumab is also efficacious in treating adults with moderately to severely active Crohn’s disease and UC who have not responded well to other treatments or experienced unacceptable side effects.

    Using guselkumab in Crohn’s disease can benefit patients by reducing the signs and symptoms of the disease, which can include diarrhoea and abdominal pain. In UC it helps to reduce abdominal pain and inflammation of the intestinal lining. These effects can improve a patient’s ability to do normal daily activities and reduce fatigue.

    Guselkumab can be administered either by intravenous infusion or injection for the initial treatment of Crohn’s disease. For UC, initial treatment will be administered via an intravenous infusion.

    Julian Beach, MHRA Interim Executive Director of Healthcare Quality and Access, said:  

    “Patient safety is our top priority, which is why I am pleased to confirm the approval of guselkumab to treat Crohn’s disease and ulcerative colitis.

    “We’re assured that the appropriate regulatory standards of safety, quality and efficacy for the approval of this new formulation have been met.

    “As with all products, we will keep its safety under close review.”   

    In Crohn’s disease, three major studies involving around 1,400 patients found that up to 56% of those treated with guselkumab achieved clinical remission after 12 weeks, compared to 15–22% with placebo. Endoscopic response, indicating reduced inflammation in the intestines, was seen in up to 41% of guselkumab-treated patients, compared to 11–21% receiving placebo. 

    In a clinical study for UC, 23% of patients receiving guselkumab achieved clinical remission after 12 weeks of induction treatment, compared to 8% on placebo. Continued maintenance treatment led to remission in up to 50% of patients after 44 weeks, versus 19% with placebo.

    A full list of side effects can be found in the Patient Information Leaflet (PIL) or the Summary of Product Characteristics (SmPC), available on the MHRA website within 7 days of approval.  

    As with any medicine, the MHRA will keep the safety and effectiveness of guselkumab under close review.  Anyone who suspects they are having a side effect from this medicine is encouraged to talk to their doctor, pharmacist or nurse and report it directly to the MHRA Yellow Card scheme, either through the website (https://yellowcard.mhra.gov.uk/) or by searching the Google Play or Apple App stores for MHRA Yellow Card.   

    ENDS    

    Notes to editors     

    • The approval was granted on 16 May 2025 to Janssen-Cilag Limited.
    • This product was submitted and approved via national procedure.
    • A randomised, open-label Phase 3 clinical trial is a large, late-stage study where participants are randomly assigned to different treatment groups, both doctors and patients know which treatment is being given (open-label), and the goal is to confirm the treatment’s effectiveness and safety before potential regulatory approval.
    • More information can be found in the Summary of Product Characteristics and Patient Information leaflets which will be published on the MHRA Products website within 7 days of approval.
    • The Medicines and Healthcare products Regulatory Agency (MHRA) is responsible for regulating all medicines and medical devices in the UK by ensuring they work and are acceptably safe.  All our work is underpinned by robust and fact-based judgements to ensure that the benefits justify any risks.
    • The MHRA is an executive agency of the Department of Health and Social Care.
    • For media enquiries, please contact the newscentre@mhra.gov.uk, or call on 020 3080 7651.

    Updates to this page

    Published 16 May 2025

    MIL OSI United Kingdom

  • MIL-OSI: Best Payday Loans for Bad Credit Guaranteed Approval Direct Lenders No Credit Check – IOnline Payday Loan

    Source: GlobeNewswire (MIL-OSI)

    SHERIDAN, Wyo., May 16, 2025 (GLOBE NEWSWIRE) — Struggling with bad credit and need cash fast? You’re not alone. Many Americans face financial emergencies and turn to payday loans when traditional banks say no. Thankfully, there are several best online payday loans available today that cater specifically to individuals with poor credit histories. Whether you’re looking for no credit check payday loans, 1 hour payday loans no credit check, or even quick $255 payday loans online same day, there are trusted options you can explore.

    >>> Click Here to Apply for Instant Payday Loans >>>

    These lenders understand that credit scores don’t tell the whole story. That’s why no credit check personal loans direct lenders are becoming increasingly popular—they offer quick approvals, fast funding, and minimal eligibility criteria. In this guide, we’ll walk you through the best payday loan for bad credit in 2025, helping you choose a lender that’s safe, fast, and hassle-free.

    >>> Click Here to Apply for Instant Payday Loans >>>

    What Are Best Payday Loans for Bad Credit?

    Payday loans for bad credit are short-term loans designed to help individuals manage urgent financial needs when traditional lenders turn them away. These loans focus on your current income rather than your credit history, making them accessible even if you have a low credit score.

    >>> Click Here to Apply for Instant Payday Loans >>>

    The best payday loans for bad credit are those that offer quick approvals, simple online applications, and transparent terms. They are ideal for situations where you think, I need a payday loan immediately, but don’t want to deal with credit checks or long waiting periods.

    Online platforms like Ionline Payday Loans streamline the process by connecting borrowers to a wide network of lenders. These lenders specialize in no credit check payday loans, giving you a higher chance of approval based on your ability to repay, not your credit score.

    Whether it’s a small emergency or an unexpected bill, payday loans offer fast financial relief. The key is choosing the right lender, one that offers clear terms, fast processing, and flexible repayment options.

    With trusted services like Ionline Payday Loans, finding the best online payday loans becomes simple, quick, and stress-free, even for borrowers with bad credit.

    Other Types of Payday Loans No Credit Check

    • No Credit Check Payday Loans direct lenders: Though the traditional payday loans are highly sought after, there are alternatives to no credit check payday loans that cater to various financial purposes. They are all unique to a specific goal but share the benefit of access to funds fast without a tough credit check.
    • $255 payday loans same day online: For small, emergency purchases, online same-day $255 payday loans are the way to go. These tiny loans are disbursed promptly, sometimes with same-day transfer of funds, and are perfect for emergencies.
    • $500 Loan no credit check direct lenders: If you need a little more, alternatives such as a $500 loan no credit check direct lender also abound. These loans impose more restrictions while maintaining the easy, no credit check approval process.
    • No credit check personal loans direct lenders: For individuals requiring flexible repayment periods, there are companies that offer No credit check personal loans direct lenders. The loans offer extended repayment periods as opposed to normal payday loans, affording you adequate time to settle payments.
    • 1 hour payday loans no credit check: When time is of the essence, 1 hour payday loans no credit check give nearly instant approval, and money is deposited within an hour of applying.

    Sites such as Ionline Payday Loans put it at your fingertips, allowing you to search through these variations and determine the most effective online payday loans for your case.

    How to Apply for Payday Loans No Credit Check?

    Applying for a payday loan with no credit check is a simple and fast process. Here’s how you can do it in a few easy steps:

    1. Visit Ionline Payday Loans

    Go to Ionline Payday Loans and navigate to their application page. The platform connects you with lenders offering best payday loans for bad credit and fast approvals.

    2. Choose Your Loan Amount

    Decide how much money you need. Whether you’re looking for a $255 payday loan online same day or a larger $500 loan no credit check direct lender, select a realistic amount you can repay.

    3. Complete the Online Application

    Fill out the online form with your personal details, employment information, and monthly income. This simple form takes only a few minutes to complete.

    4. Submit and Get Instant Matching

    Once submitted, Ionline Payday Loans matches you with suitable no credit check payday loans lenders. Approval decisions are often made instantly.

    5. Review Loan Offers and Accept

    Carefully read through the loan terms, including repayment schedules and fees. If satisfied, accept the offer electronically.

    6. Receive Funds in Your Account

    After acceptance, funds are typically deposited into your bank account on the same day. For urgent needs, 1 hour payday loans no credit check options are also available.

    This quick process ensures you get the money you need without the stress of credit checks or complicated paperwork.

    Features & Benefits of Best Payday Loans for Bad Credit

    • No Credit Check Required: Borrowers with poor credit scores can apply without worrying about hard credit checks affecting their rating.
    • Instant Approval Process: Ionline connects you with lenders offering instant payday loans online guaranteed approval, ensuring quick decisions.
    • Same Day Fund Transfers: Options like $255 payday loans online same day and 1 hour payday loans no credit check ensure you get funds when you need them the most.
    • Fully Online Application: No need for in-person visits or paperwork; everything is done online for your convenience.
      Flexible Loan Amounts: From small urgent needs to larger amounts like a $500 loan no credit check direct lender, you can choose what suits you best.
    • Transparent Terms & Conditions: Loan offers clearly outline fees, repayment dates, and terms, no hidden charges.
    • Trusted Lender Network: Ionline partners with reliable and verified lenders, giving you access to the best online payday loans in one place.
    • High Approval Chances: The focus is on your income and ability to repay, making approvals easier even if you’ve been declined elsewhere.

    Why are Instant Payday Loans Online Guaranteed Approval the Best Choice for You?

    When you think, I need a payday loan immediately, Ionline Payday Loans becomes the go-to platform. Unlike traditional lenders, Ionline doesn’t judge you by your credit score. Instead, it focuses on what matters, your current income and ability to repay.

    The platform simplifies the borrowing process by connecting you with a network of trusted lenders offering no credit check payday loans. You don’t need to waste time applying at multiple places. Ionline does the heavy lifting, matching you with the best lender for small payday loans online that fits your needs.

    Speed is another big plus. From application to fund transfer, everything happens fast. Whether you’re looking for best online loans instant approval or emergency options like 1 hour payday loans no credit check, Ionline ensures you get quick access to funds.

    What sets Ionline apart is its transparency. Loan offers are clear, straightforward, and free of hidden fees. You’ll know exactly what you’re signing up for.

    In short, Ionline Payday Loans offers a hassle-free, reliable way to get instant financial help, especially when bad credit stands in your way.

    Eligibility Criteria for Best Payday Loans for Bad Credit

    Applying for a payday loan through Ionline Payday Loans is easy because the eligibility requirements are straightforward. Unlike traditional lenders who rely on credit scores, also $255 payday loans online same day approvced Ionline focuses on basic qualifications to ensure faster approvals.

    To be eligible, you must:

    • Be at least 18 years old.
    • Be a U.S. resident with a valid address.
    • Have a steady source of income, either from employment or benefits.
    • Hold an active checking account to receive funds and make repayments.
    • Provide valid contact information (phone number and email) for communication.

    Since the platform specializes in no credit check payday loans, your credit score won’t be a barrier. The primary focus is on your ability to repay, making Ionline a practical choice for those seeking the best payday loans for bad credit.

    Tips to Increase Approval Chances for Best Online Loans Instant Approvals

    Getting approved for the best payday loans for bad credit is easier when you prepare well. Start by ensuring your income information is accurate and up-to-date. Lenders base their approval on your current earnings, so clarity here is crucial.

    Having an active checking account is also essential. Many lenders use this for fund transfers and repayments. Ensure your contact details, phone and email, are correct to avoid communication delays.

    Using a platform like Ionline Payday Loans also boosts your chances. It connects you with the best lender for small payday loans online, ensuring you meet the right lenders without multiple failed applications.

    Wrapping Up

    When financial emergencies arise, having access to fast, reliable loans becomes crucial. The best payday loans for bad credit provide a practical solution for those who struggle with traditional credit-based approvals. Platforms like Ionline Payday Loans simplify this process, connecting borrowers to trusted lenders who offer quick approvals, transparent terms, and same-day fund transfers.

    Whether you’re in need of a small $255 payday loan online same day, a larger $500 loan no credit check direct lender, or simply want the peace of mind that comes with no credit check payday loans, Ionline ensures you get the help you need without delays.

    Remember, borrowing responsibly is key. Understand the terms, repay on time, and use these loans as a safety net for genuine financial needs.

    Frequently Asked Questions – Best Payday Loans for Bad Credit

    1. Can I get the best payday loans for bad credit without a credit check?

    Yes, many lenders offer payday loans for bad credit without performing hard credit checks. Platforms like Ionline Payday Loans connect you with lenders who focus on your income and repayment ability, not your credit score, giving you a strong chance of approval.

    2. How quickly can I receive funds after approval?

    With instant payday loans online guaranteed approval, funds can be transferred to your account on the same day. Some lenders even offer 1 hour payday loans no credit check, ensuring you get the money within an hour of approval, depending on your bank’s processing time.

    3. What if I need a small loan urgently?

    If you’re facing a small financial emergency, you can apply for a $255 payday loan online same day through Ionline. These microloans are designed for quick approvals and fast fund transfers, helping you manage immediate expenses.

    4. Are there options for slightly larger loans?

    Yes, you can also apply for a $500 loan no credit check direct lender through Ionline’s platform. These loans provide higher limits while still maintaining a simple, no credit check application process for faster approvals.

    5. Will applying for these loans affect my credit score?

    No. Lenders offering no credit check payday loans typically perform soft checks or income verifications that do not impact your credit score. Applying through Ionline Payday Loans is safe and won’t harm your credit profile.

    Project Name: IOnline Payday Loans

    Disclaimer: This announcement contains general information about Ionline payday loan services and should not be considered financial advice. Ionline Payday Loans does not guarantee loan approval, and loan terms may vary by applicant and lender requirements. Loans are available to U.S. residents only.

    A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/e774ab2e-966a-48c2-92dc-78ab35b5c9fb

    The MIL Network

  • MIL-OSI Economics: ICON retains lead as most active CRO in Q1 2025, reveals GlobalData

    Source: GlobalData

    ICON retains lead as most active CRO in Q1 2025, reveals GlobalData

    Posted in Pharma

    ICON maintains its place as the most active contract research organization (CRO) for Q1 2025 and Russia keeps its spot with the most clinical trials initiated in Europe despite the ongoing war with Ukraine, according to a report by GlobalData, a leading data and analytics company.

    GlobalData’s latest report “Q1 2025 Clinical Trials: CRO, Sponsor & Country Winners,” reveals that France moved up its position from fourth place in Q1 2024 to second in the region.

    Kathryn Kinch, Pharma Product Manager at GlobalData, comments: “AstraZeneca led among large- and mega-cap sponsors of drug trials. Oncology trials dominated the landscape, making up the largest share of new trials, with solid tumors as the most studied indication and pain leading in central nervous system research.”

    The report also identifies the top 10 trial sites in North America, Europe, and the rest of the world based on the number of trials initiated. On a global scale, oncology was the leading therapeutic area of focus. 1,513 oncology-related clinical trials were either launched or scheduled to commence in Q1 2025. Following closely behind, central nervous system (CNS) diseases accounted for 1,421 trials, reflecting a robust commitment to addressing complex neurological challenges.

    However, the quarter did see a slight dip in both oncology and CNS trials compared to the previous year, where 1,573 and 1,438 trials were recorded, respectively. Within oncology, solid tumors dominated the landscape with 1,194 trials, while pain management emerged as the most studied indication in the CNS category, boasting 671 trials.

    The CRO Activity and Intel report is published on a quarterly basis. The data presented in this report reflects the database as of April 10, 2025.

    MIL OSI Economics

  • MIL-OSI Global: Why we fall for fake health information – and how it spreads faster than facts

    Source: The Conversation – USA – By Angshuman K. Kashyap, PhD candidate in Health Communication, University of Maryland

    Should you share that health-related Instagram post? Catherine McQueen/Moment via Getty Images

    In today’s digital world, people routinely turn to the internet for health or medical information. In addition to actively searching online, they often come across health-related information on social media or receive it through emails or messages from family or friends.

    It can be tempting to share such messages with loved ones – often with the best of intentions.

    As a global health communication scholar studying the effects of media on health and development, I explore artistic and creative ways to make health information more engaging and accessible, empowering people to make informed decisions.

    Although there is a fire hose of health-related content online, not all of it is factual. In fact, much of it is inaccurate or misleading, raising a serious health communication problem: Fake health information – whether shared unknowingly and innocently, or deliberately to mislead or cause harm – can be far more captivating than accurate information.

    This makes it difficult for people to know which sources to trust and which content is worthy of sharing.

    The allure of fake health information

    Fake health information can take many forms. For example, it may be misleading content that distorts facts to frame an issue or individual in a certain context. Or it may be based on false connections, where headlines, visuals or captions don’t align with the content. Despite this variation, such content often shares a few common characteristics that make it seem believable and more shareable than facts.

    For one thing, fake health information often appears to be true because it mixes a grain of truth with misleading claims.

    For example, early in the COVID-19 pandemic, false rumors suggested that drinking ethanol or bleach could protect people from the virus. While ethanol or bleach can indeed kill viruses on surfaces such as countertops, it is extremely dangerous when it comes into contact with skin or gets inside the body.

    Stopping to check the facts helps stem the spread of misinformation.
    World Health Organization adaptation from Siouxsie Wiles and Toby Morris in The Spinoff, CC BY-SA

    Another marker of fake health information is that it presents ideas that are simply too good to be true. There is something appealingly counterintuitive in certain types of fake health information that can make people feel they have access to valuable or exclusive knowledge that others may not know. For example, a claim such as “chocolate helps you lose weight” can be especially appealing because it offers a sense of permission to indulge and taps into a simple, feel-good solution to a complex problem. Such information often spreads faster because it sounds both surprising and hopeful, validating what some people want to believe.

    Sensationalism also drives the spread of fake health information. For instance, when critics falsely claimed that Anthony Fauci, the director of the National Institute of Allergy and Infectious Diseases and the chief medical adviser to the president at the time, was responsible for the COVID-19 pandemic, it generated a lot of public attention.

    In a study on vaccine hesitancy published in 2020, my colleagues and I found that controversial headlines in news reports that go viral before national vaccination campaigns can discourage parents from getting their children vaccinated. These headlines seem to reveal sensational and secret information that can falsely boost the message’s credibility.

    The pull to share

    The internet has created fertile ground for spreading fake health information. Professional-looking websites and social media posts with misleading headlines can lure people into clicking or quickly sharing, which drives more and more readers to the falsehood. People tend to share information they believe is relevant to them or their social circles.

    In 2019, an article with the false headline “Ginger is 10,000x more effective at killing cancer than chemo” was shared more than 800,000 times on Facebook. The article contained several factors that make people feel an urgency to react and share without checking the facts: compelling visuals, emotional stories, misleading graphs, quotes from experts with omitted context and outdated content that is recirculated.

    Visual cues like the logos of reputable organizations or photos of people wearing white medical coats add credibility to these posts. This kind of content is highly shareable, often reaching far more people than scientifically accurate studies that may lack eye-catching headlines or visuals, easy-to-understand words or dramatic storylines.

    But sharing content without verifying it first has real-world consequences. For example, studies have found that COVID-19-related fake information reduces people’s trust in the government and in health care systems, making people less likely to use or seek out health services.

    Unfounded claims about vaccine side effects have led to reduced vaccination rates globally, fueling the return of dangerous diseases, including measles.

    Check it out before you share.

    Social media misinformation, such as false claims about cinnamon being a treatment for cancer, has caused hospitalizations and even deaths. The spread of health misinformation has reduced cooperation with important prevention and treatment recommendations, prompting a growing need for medical professionals to receive proper training and develop skills to effectively debunk fake health information.

    How to combat the spread of fake health information

    In today’s era of information overload in which anyone can create and share content, being able to distinguish between credible and misleading health information before sharing is more important than ever. Researchers and public health organizations have outlined several strategies to help people make better-informed decisions.

    Whether health care consumers come across health information on social media, in an email or through a messaging app, here are three reliable ways to verify its accuracy and credibility before sharing:

    • Use a search engine to cross-check health claims. Never rely on a single source. Instead, enter the health claim into a reputable search engine like Google and see what trusted sources have to say. Prioritize information from established organizations like the World Health Organization, Centers for Disease Control and Prevention, United Nations Children’s Fund or peer-reviewed journals like The Lancet or Journal of the American Medical Association. If multiple reputable sources agree, the information is more likely to be reliable. Reliable fact-checking websites such as FactCheck.org and Snopes can also help root out fake information.

    • Evaluate the source’s credibility. A quick way to assess a website’s trustworthiness is to check its “About Us” page. This section usually explains who is behind the content, their mission and their credentials. Also, search the name of the author. Do they have recognized expertise or affiliations with credible institutions? Reliable websites often have domains ending in .gov or .edu, indicating government or educational institutions. Finally, check the publication date. Information on the internet keeps circulating for years and may not be the most accurate or relevant in the present context.

    • If you’re still unsure, don’t share. If you’re still uncertain about the accuracy of a claim, it’s better to keep it to yourself. Forwarding unverified information can unintentionally contribute to the spread of misinformation and potentially cause harm, especially when it comes to health.

    Questioning dubious claims and sharing only verified information not only protects against unsafe behaviors and panic, but it also helps curb the spread of fake health information. At a time when misinformation can spread faster than a virus, taking a moment to pause and fact-check can make a big difference.

    Angshuman K. Kashyap does not work for, consult, own shares in or receive funding from any company or organization that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.

    ref. Why we fall for fake health information – and how it spreads faster than facts – https://theconversation.com/why-we-fall-for-fake-health-information-and-how-it-spreads-faster-than-facts-250718

    MIL OSI – Global Reports

  • MIL-OSI Global: Placenta bandages have far more health benefits than risky placenta pills − a bioengineer explains

    Source: The Conversation – USA – By Marley Dewey, Assistant Professor of Bioengineering, University of California, Santa Barbara

    With some bioengineering, placentas can be recycled for various medical treatments. mikroman6/Moment via Getty Images

    Eating a placenta may not give you the health benefits some people want you to believe it has, but using it as a bandage might.

    The placenta is an organ created during pregnancy that provides nutrients to a growing fetus through an umbilical cord. It’s usually large and relatively flat, composed of blood vessels, stem and immune cells, and collagen. It doesn’t look particularly appetizing to most people, and those who have eaten placentas often mention an unpleasant taste or smell.

    But in the early 2000s, the practice of mothers eating their placenta after childbirth, claiming health benefits and mood improvement, gained mainstream attention. This trend typically involves putting your placenta into capsules you can take as pills, and there are even companies selling custom-made and do-it-yourself products online.

    While some mammals may eat their own placentas due to limited nutritional resources in the wild, the benefits people might get from eating placentas is unclear.

    If boiled and dehydrated, the useful components of the placenta may be altered and reduced. If ingested raw, pathogens may remain on the surface of the placenta. In 2016, after a newborn was hospitalized multiple times from an infection potentially resulting from the mother ingesting her placenta, the Centers for Disease Control and Prevention recommended mothers avoid taking placenta pills.

    I can’t personally speak to the taste of placentas. However, as a bioengineer who designs materials to regenerate injured bones and other tissues, I along with my colleagues have uncovered a much clearer picture of the benefits placentas can offer as a biomaterial to repair wounds – if used properly.

    The placenta contains many medically useful components – just not when eaten.
    Sinhyu/iStock via Getty Images Plus

    Placenta as biomaterial

    Biomaterials are materials designed to interface with your body to repair damage. If you burned your skin, for example, your doctor may use a biomaterial such as a skin graft to help your body repair the damaged tissue, ideally providing nutrients to the damaged area to promote cell growth.

    Researchers have been exploring recycling placentas, which are often thrown away after delivery, as a type of biomaterial to regrow wounded tissue in patients. Because the placenta is rich in nutrients and stem cells that give it antimicrobial, anti-inflammatory and pro-regenerative properties, this organ is a particularly good candidate for medical applications.

    Your body normally responds to a wound with inflammation, which is an immune reaction that clears harmful stimuli and pathogens, often resulting in swelling and pain around the injury site.

    Unfortunately, sometimes this inflammatory process can get out of hand and lead to chronic wounds and prevent healing. But the active biomolecules within the placenta work with your immune system to promote repair by reducing inflammation and preventing scar formation.

    For example, chronic diabetic foot ulcers are a challenging injury that sometimes never closes and leads to foot amputation. Researchers found that using biomaterials made of parts of the placenta to treat these injuries resulted in a wound closure rate 6.24 times higher than conventional treatments. Researchers have also found that placenta-based biomaterials can reduce scarring after heart injury.

    I have used human placentas in my own research to study how they work in a variety of wound repair scenarios. I can take a volunteer patient’s donated placenta and remove factors that may negatively affect healing, such as all cells, blood and other components that may cause inflammation. Then I can take the material that’s left – primarily containing essential growth nutrients and the tissue foundation that cells used to live in – and use it to improve bone or tendon repair.

    Placentas undergo significant processing before they can be used in biomaterials.
    Kolliopoulos et al./Frontiers in Bioengineering and Biotechnology, CC BY-SA

    Moreover, placentas contain stem cells that can also be useful for medicine. These cells are able to turn into various other types of cells of your body. This can be particularly helpful for repairing organs that are difficult to directly harvest cells from, such as the heart, liver and nerves. For example, placental stem cells can be added to an injured heart and become heart cells themselves to aid in repair.

    Researchers have also used stem cells from the placenta and the umbilical cord for applications such as stem cell transplantation to treat disease and injury. Studies have found that placenta-derived stem cells transplanted into rats could reverse Parkinson’s and nerve death. Stem cells from the placenta can also serve as a more promising source of cells for cell transplantation therapies compared with stem cells from fat and bone marrow.

    On your skin, not in your stomach

    So placentas do have some clear health benefits. But why are they more useful as a biomaterial bandage than as a pill or food, taste considerations aside?

    Unlike placenta products that are ingested – pills, dried jerky or raw placenta – biomaterials have undergone rigorous testing to ensure they are safe and effective. They are processed and handled in a controlled laboratory environment and often sterilized to ensure no bacteria or other pathogens can enter the patient. The Food and Drug Administration has approved several placenta-based biomaterials for use in the clinic, including to treat diabetic foot wounds, surgical wounds and tissue replacement.

    In contrast, placentas and placenta products eaten at home may not receive proper treatment to kill the many harmful pathogens that may be present during transport. The processing to turn placentas into something ingestible may also damage their beneficial components, leading to increased health risks and reduced benefits. No ingested placenta products have received FDA approval to date.

    Eating placentas won’t make you any healthier. But science says applying a lab-processed, placenta-based biomaterial to a recent wound might speed up healing and result in smoother, scar-free skin.

    Marley Dewey receives funding from the National Science Foundation and the National Institutes of Health.

    ref. Placenta bandages have far more health benefits than risky placenta pills − a bioengineer explains – https://theconversation.com/placenta-bandages-have-far-more-health-benefits-than-risky-placenta-pills-a-bioengineer-explains-256075

    MIL OSI – Global Reports

  • Novel approach to HIV vaccine shows early promise

    Source: Government of India

    Source: Government of India (4)

    The first human clinical trials testing a new strategy to protect against HIV infections have yielded promising early results, according to two separate reports published on Thursday in Science.
     
    The trials tested “germline targeting” HIV vaccines, which aim to activate immune system B cells in their naive, or germline, state, inducing them to become specialized cells that produce broadly neutralizing antibodies (bnAbs).
     
    By delivering a variety of HIV immunogens – typically, viral protein fragments – germline vaccines train the B cells to produce antibodies that can recognize and block a broad range of different strains of HIV from infecting healthy cells.
     
    Germline targeting requires an initial dose to prime the correct B cells, and subsequent doses to guide their maturation until they can produce effective bnAbs, the researchers reported.
     
    “Across the participants we saw an immune response that indicates that we’re on the right track,” Rogier Sanders of Amsterdam UMC, senior investigator on one of the trials, said in a statement.
     
    “We saw that we can target the cells that we need to target with atomic precision. The next step is to further stimulate these cells to secrete broadly neutralizing antibodies,” Sanders said.
     
    In a separate paper, a different team of researchers reported on two early trials that used mRNA-encoded nanoparticles produced by Moderna to successfully prime the germline B cells, although a small proportion of patients had skin reactions to the vaccines.
     
    The mRNA technology, similar to that used in Moderna’s COVID-19 shots, would allow for faster vaccine development, the study authors said.
     
    One of the trials was conducted in the United States and the other in Rwanda and South Africa. The majority of HIV patients live in Africa, but germline targeting has not previously been attempted there.
     
    The researchers said the mRNA approach appeared to work with both North American and African populations, opening the door to further testing of germline-targeting vaccines for “African populations in most need of an HIV vaccine.”
     
    EASING THERAPIES FOR SOME PROSTATE, CERVIX CANCERS
     
    Two new studies suggest that patients with certain cancers might do just as well with a shorter course of radiation or a less extensive surgery as with standard treatments.
     
    In JAMA Oncology, researchers reported that in men who require radiation after undergoing the most extensive type of surgery for prostate cancer, a form of high-dose radiation delivered in just five sessions known as stereotactic body radiotherapy (SBRT) appears to be as safe as conventional treatment delivered daily for up to seven weeks.
     
    SBRT is a well-established treatment for prostate cancer, but its use after a radical prostatectomy has been limited due to concerns about the shifting position of the prostate bed and nearby healthy tissues.
     
    The researchers tracked 100 men treated with SBRT in the single-arm study. Two years after the treatment, outcomes and side effects were similar to what the researchers had seen in the past from patients who received the longer-course treatments.
     
    If randomized studies and longer follow-up confirm the results, “this approach could remove a major barrier to post-surgery radiation therapy,” study leader Dr. Amar Kishan of the David Geffen School of Medicine at UCLA said in a statement.
     
    In JAMA Network Open, a separate team of researchers reported that women with low-risk early-stage cancer of the cervix do as well after simple hysterectomy as after modified radical hysterectomy or radical hysterectomy.
     
    Among 2,636 carefully selected patients treated for stage IA2 or IB1 cervical carcinoma at accredited cancer hospitals, there was no difference in survival rates at 3 years, 5 years, 7 years or 10, or in postoperative outcomes after the three types of surgery.
     
    (Reuters)
  • MIL-OSI USA: FDA Advances Robust, Transparent Post-Market Chemical Review Program to Keep Food Supply Safe and Healthy

    Source: US Food and Drug Administration

    For Immediate Release:
    May 15, 2025

    The U.S. Food and Drug Administration today is taking a major step to increase transparency and ensure the safety of chemicals in our food. The agency is launching a stronger, more systematic review process for food chemicals already on the market—especially those that concern consumers most.
    “No parent should ever worry about what’s in their child’s food,” said HHS Secretary Robert F. Kennedy, Jr. “We’re taking decisive action and using every authority we have to clean up the food supply and protect American families.”
    Under the leadership of Secretary Kennedy and FDA Commissioner Martin A. Makary, M.D., M.P.H., the FDA will roll out several key actions over the coming months:

    A modernized, evidence-based prioritization scheme for reviewing existing chemicals. A draft will be released for public comment soon.
    A final, systematic post-market review process shaped by stakeholder input.
    An updated list of chemicals under review, including BHT, BHA, and ADA. The FDA will also take steps to expedite its review of chemicals currently under review like phthalates, propylparaben, and titanium dioxide. FDA will continue to share information about the status of this work on its public website as part the agency’s push for greater transparency.

    Until now, the FDA has conducted post-market reviews on a case-by-case basis, often in response to citizen petitions or new scientific evidence. This new framework will be proactive, science-based, and built for long-term impact. Americans are demanding more transparency and accountability around food safety and the FDA is doing just that.
    “We are prioritizing our resources and leveraging gold standard science to create, for the first time, a systematic post-market review program that consumers can trust and rely on,” said FDA Commissioner Martin A. Makary, M.D., M.P.H. “Only by improving the safety and transparency of the food supply and ensuring consumers can make healthful food choices will we overcome the long-standing trajectory of chronic diseases.”
    This post-market review effort is part of a larger initiative to improve food chemical oversight. Last month, the FDA announced plans to phase out petroleum-based synthetic dyes from the U.S. food supply. Earlier this year, the agency also began exploring rulemaking to eliminate the process that allows companies to self-affirm substances as “generally recognized as safe” (GRAS) without FDA oversight.

    Consumer:888-INFO-FDA

    ###

    Boilerplate

    The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, radiation-emitting electronic products, and for regulating tobacco products.

    Inquiries

    Consumer:
    888-INFO-FDA

    Content current as of:
    05/15/2025

    Regulated Product(s)

    Follow FDA

    MIL OSI USA News

  • MIL-OSI Australia: Press conference, Strathpine

    Source: Australian Parliamentary Secretary to the Minister for Industry

    Ali France:

    It will come as no surprise to anyone here that cost of living is the biggest issue for people in my electorate of Dickson, paying the bills has been a real struggle. Labor went to the election with a really great plan to address cost‑of‑living issues and part of that was supporting wage increases.

    I was really, really pleased to see the figures this week that showed 18 months of real wage growth, and that’s all down to 3 years of really hard work by Jim and his team.

    We know that under the Coalition that wages were falling and that people were going backwards. So it’s really great to have the Treasurer here today in Dickson, as well as all of my other Queensland colleagues, and I’m now going to hand over to Senator Chisholm.

    Anthony Chisholm:

    Thanks Ali, it’s great to be with you, and the growing Northside Labor team in Emma and Corrine, and we welcome Jim from the Southside to the Northside.

    Ali, Emma, Corrine and myself are all based on this side of town and in outer suburbia. We understand that the Petrie and Dickson electorates and those on this side of town are full of people who work hard every day, want to provide for their families and get ahead in life.

    A defining feature of the Albanese government in the first term has been support for wage increases. We saw it during the 2022 campaign, and we saw it during the 2025 campaign as well, and I think it was a defining element to us receiving a good vote like we did here in Dickson and Petrie to help us win these seats to be part of an Albanese Labor government.

    So I’m really pleased that the Treasurer is here today to talk to us but also outline the role the government is going to play supporting those people on award wages to get ahead in life. They work hard, they deserve a decent pay as a result of that, and it’s important that the Albanese government supports them in that endeavour as well. So thanks, Treasurer.

    Jim Chalmers:

    Thanks very much, Chis, and it’s great to be here in Strathpine with really important parts of our much bigger, much better Queensland team now in the Albanese Labor government.

    I wanted to thank and congratulate Ali France on her stunning victory here in Dickson – similarly, Emma Comer in Petrie, we’re really looking forward to working with Corrine Mulholland when she joins the Senate in July, and I also congratulate Anthony Chisholm for being sworn in as a frontbencher in the Albanese Labor government as well.

    Wages and the cost of living were front and centre in our first term, they were front and centre in the campaign, and they will be front and centre in the second term as well.

    Decent pay, better wages, decent conditions, great jobs, these are Labor’s reasons for being, and you can see that in the progress that we’ve made together on wages, on jobs, in the labour market and the economy more broadly, and you can see it in the submission that we are lodging today.

    Today we are lodging our submission to the Fair Work Commission’s Annual Wage Review, which is all about recognising that millions of Australians on awards need and deserve decent pay so they can work hard and provide for their loved ones.

    The most important feature of today’s submission is we are seeking an economically sustainable real wage increase for Australians on awards.

    This is all about ensuring that 3 million Australians can get the decent pay that they need and deserve to provide for their loved ones.

    We’re very proud to be making this submission today, because it builds on the progress that we have made together when it comes to wages and jobs.

    This submission is responsible, it is fair, and it’s consistent with our efforts to provide tax cuts for every Australian taxpayer as well.

    This Albanese government is all about ensuring that Australians earn more and keep more of what they earn, and our submission today to the Fair Work Commission reflects that objective.

    It does build substantially on the very encouraging progress that we have been able to make together on wages and in the labour market more broadly.

    Already, people on the minimum wage are earning $143 a week more since Labor came to office. Australians on the medium wage are earning $206 a week more since Labor came to office. We’ve created 1.1 million jobs since we were elected. Participation is at or near record highs. Average unemployment has been historically low.

    Just this week, as Ali said, we got very encouraging news on wages, 18 consecutive months of annual real wages growth, the strongest real wages growth for 5 years. Another 89,000 jobs created in the data that we saw just yesterday. This shows we have been making progress together, and the submission we lodged today is about building on that progress.

    If you look more broadly across the economy since we came to office, real wages were falling sharply when we came to office, we’ve turned that around, but we’ve made progress more broadly on the economy as well.

    Inflation is down very substantially, real wages are up, unemployment is very low, growth is rebounding in our economy, we’ve got the debt down, interest rates have started to come down earlier in the year as well.

    We know that there’s more work to do because people are under pressure, and that’s why this submission today seeks a real wage increase for millions of Australians. We have made a lot of progress together, and we seek with this submission today to build on that progress so that Australians can earn more and keep more of what they earn, and so Australians can earn more to provide for their loved ones when they work hard and get ahead.

    Happy to take a few questions.

    Journalist:

    What do you mean by ‘economically sustainable amount’, is that in line with inflation, or is there a figure on that?

    Chalmers:

    Consistent with our earlier submissions, we don’t put a number in our submission, that’s been our practice for really quite a while now. What we are seeking is an economically sustainable real wage increase for millions of Australians on awards – and ‘economically sustainable’ reflects the fact, and you can see that in the detail of our submission, is that we want to make sure that this real wage increase is provided consistent with our other economic objectives, by getting inflation down and our other economic objectives as well.

    We’re obviously very focused on the fight against inflation, we have made a lot of progress there, but it’s not mission accomplished because people are still under pressure.

    I consulted with the Reserve Bank Governor as we finalised this submission. The Treasury also consulted with, I think, the Assistant Governor of the Reserve Bank to make sure that what we are proposing is responsible, it’s sensible, it’s sustainable, and it’s consistent with inflation being sustainably in the Reserve Bank’s target band, and I’m really confident that it is.

    Journalist:

    How will you avoid a budget black hole if your super tax goes through and people take capital offshore?

    Chalmers:

    A couple of things about that. What we’re proposing here is still very concessional treatment for Australians with very big superannuation balances, so we’re taking the current concessional treatment and making it slightly less concessional, but still concessional.

    This is a very modest change to the taxation of very large superannuation balances. It reflects about half a per cent of people. We announced it more than 2 years ago, we’ve done a bunch of consultation on it, it’s been in the Parliament for a big chunk of that time, and it means that there is still concessional tax treatment for people with big balances, but slightly less concessional.

    This is an important part of our efforts to make the budget more sustainable, and to fund our priorities, including strengthening Medicare, providing cost‑of‑living relief, the tax cuts for every Australian taxpayer. It’s responsible, it is modest, it only applies to a tiny sliver of people in superannuation, and it’s still concessional.

    Journalist:

    Why won’t you index, just with that indexation, start modest, and then creep up, and become [indistinct]?

    Chalmers:

    This is consistent with the treatment in a whole range of areas in the tax system. There are a lot of thresholds in the tax system and more broadly that aren’t indexed, and what that means is that governments of either political persuasion into the future can take decisions to lift the threshold; we’ve seen that, as I’ve said, in other parts of the tax system.

    Some of this analysis that you see about the thresholds in 30 or 40 years’ time, that assumes, I think wrongly, that no government of either persuasion would change that threshold.

    Journalist:

    Treasurer, can you –

    Chalmers:

    We’ll just go here and then to you.

    Journalist:

    On childcare, should taxpayers pay for these pay rises or parents out of pocket, and is that fair?

    Chalmers:

    We’ve provided billions of dollars to make sure that the early childhood educators who are doing such an incredible job for young people and for families in our communities, that they get the pay that they need and deserve.

    I was very proud to work very closely with Anne Aly and Jason Clare, and the Prime Minister and others in the course of the last term to make room for the Commonwealth contribution to these pay rises.

    This is an area with a lot of young families, so is the area that Emma represents, the area that I represent, and we know how important early childhood educators are. We want to make sure that they’re paid properly, we’ve made room in the Budget for billions of dollars to make sure that that’s a reality.

    Journalist:

    Treasurer, can you explain how defined benefits pensions will be taxed? How’s it calculated, what’s in [indistinct].

    Chalmers:

    The actuarial calculation is similar to the calculation that currently applies to the changes that the Coalition made when they were in office. There’s a formula which is calculated by actuaries and applied by the Tax Office in a way that is not inconsistent with the way it’s currently calculated to some of the changes that my predecessors made.

    Journalist:

    Treasurer, what is your reaction to Gerry Harvey saying a tax on unrealised capital gains is gross stupidity of the highest order?

    Chalmers:

    It’s not unusual for him to criticise Labor governments. I try and listen respectfully when people make a contribution to the national public policy conversation, but I think in Gerry’s case, he’s a relatively frequent critic of Labor governments. I don’t get too carried away by it, nor do I dismiss it.

    If you look at some of the commentary over the last couple of days, you know, there was one piece that was pretending that Campbell Newman, of all people, was some kind of observer of Labor government policy.

    You had one Liberal politician, whose primary purpose was to raise campaign donations, you had another Liberal politician lie about there being no legislation available when he was on the Committee that scrutinised that legislation in detail.

    I understand that when you’re making a change, even a modest one like this one, people have views about it, and people with very large superannuation balances will have views about it, political opponents will have views about it as well.

    This is a modest change, it makes a meaningful difference to the budget, but it still provides very concessional treatment for people with more than $3 million in superannuation, and it helps make the budget more sustainable and fund our priorities.

    Journalist:

    The vaccination rates among children and teenagers have dropped to critical levels across the country. Will the government put more money into urgent campaigns or other awareness campaigns to encourage parents to get their kids vaccinated?

    Chalmers:

    I’m sure that that’s something that Mark Butler, the Health Minister, is considering, but we already put a lot of effort into educating and encouraging people to get vaccinated.

    I personally found that story to be quite confronting to think that after all of the progress that’s been made in recent decades that we’re going backwards, I personally find that very troubling, very concerning and very confronting, and I’m sure the Health Minister’s in the same boat, and he’s working out what, if anything, else we could do to try and arrest that slide.

    Journalist:

    The $150 electricity rebate’s due to run out at the end of the year. Is the government open to considering extending that, considering the affordability crisis?

    Chalmers:

    Well, we’ve already extended those electricity bill rebates, that’s the $150 you refer to in your question. They were otherwise due to run out at the end of next month, and now they’ll be extended for another 6 months.

    From budget to budget, we evaluate the circumstances we’re in, we look at the pressures on people and the pressures on the Budget as well, and we do what we can to help out. That’s why, and my colleagues here would know this, having spent so much time engaging with people in their own communities, the highest priority of the Labor government in the first time was to get on top of inflation and help people with the cost of living.

    Electricity bill rebates are an important port of that, 3 rounds of tax cuts, cheaper medicines, cheaper early childhood education, fee‑free TAFE, all of these things are about recognising that when people are under pressure, there is a role for governments to step in and help where they can responsibly do that.

    So from budget to budget, and we’ve had 4 already, and the fifth one will be in May next year, from budget to budget, we see if we can do more, if we can afford to do more to help people with the cost of living, and people can expect that next May, just like they could expect that in the first 4 budgets.

    Journalist:

    Treasurer, Andrew Bragg says that ‘If Mr Chalmers is so sure his unrealised gains tax will apply to Mr Albanese’s pension, he should say exactly how much tax will be paid in the first year of his pension’. Can you nominate that figure?

    Chalmers:

    One of the reasons why nobody takes that guy seriously is because when it comes to the Prime Minister, his pension’s not yet known. Now we don’t know his circumstances into the future.

    He should know, he’s on the Committee that scrutinised the legislation that Andrew Bragg lied about and said didn’t exist. He also said that there’s no allowance in the legislation for defined benefit schemes for politicians.

    Those are lies. And you need to be really careful not just to read out whatever he tweets, because he’s been caught out lying in the last day or so. I would encourage you respectfully not to take his word for it, especially this week, after he’s been caught out lying so egregiously.

    There is provision for defined benefit schemes, there are calculations, those calculations are very similar to the ones that the Liberals and Nationals put in when they changed superannuation in the last term of the government, and that will apply to the Prime Minister, it will apply to any politician who’s got the equivalent of more than $3 million in super.

    Journalist:

    What do you make of Allan Fels’ call for an ACCC Inquiry into Bunnings?

    Chalmers:

    I’ve got a lot of time for Allan Fels, I respect him, I speak with him from time to time, he’s a great person with a substantial record of achievement.

    We’re already acting on competition, funding the ACCC much more substantially, I provided another $30 million to empower one of Allan’s successors in that role, Gina Cass‑Gottlieb, doing a wonderful job, we’ve found more resources for her.

    Our primary focus is on the supermarkets, we’ve made that really clear, price gouging and the Food and Grocery Code, but we have the ability, should we want to, to expand some of that focus, and the extra resources that I provided the ACCC will help ensure that where there’s more work to be done, it can be done.

    Journalist:

    Treasurer, there’s –

    Chalmers:

    We might just take 2 more. One more, and then another Andrew Bragg tweet, and then we’re done.

    Journalist:

    There’s an issue unfolding with the disability company, Cocoon SDA Care that operates partly in your electorate. Do you have any concerns about what’s going on with Cocoon and have any of your constituents raised concerns?

    Chalmers:

    Not that I’m aware of, but I’ll look into that, that’s the first I’ve been aware of that particular issue, but I’ll make sure I look into it, and if there’s anything I can say publicly at some future point, I’ll do that.

    Journalist:

    What do you say to the leading independent economists, just not Gerry Harvey or Andrew Bragg, who say that this will hurt investment, wealthy people will take their investments away from, you know, venture capital and start‑ups, and it could ruin the tech industry?

    Chalmers:

    First of all, there’s not a unanimous view amongst economists about that, or about the worthiness of the change that we’re proposing. I think Chris Richardson, for example, wrote something supporting it, and so always, when you’re making a change like this, there’s always a range of views, and obviously I follow closely the comments made by the peak groups and others.

    It really comes back to the question I gave earlier to your colleague; we’re still providing concessional tax treatment for people with big balances in superannuation, it’s just slightly less concessional, but it’s concessional compared to the marginal rate that people would be paying.

    And so I think we need a little bit of perspective here, I know that this is seen in some quarters as contentious, but again, I mean we announced this policy almost 2 and a half years ago, it’s been in the Parliament for a big chunk of that, we’ve been consulting on it, it’s a modest change, it still leaves concessional tax arrangements in there for people who have more than $3 million in super.

    I expect that there’s a campaign run about it, I expect that people have got views about it, but I do think we need a bit of perspective here. It is a modest change, it does impact only a very small amount of people, and it still provides concessional tax treatment.

    Journalist:

    Treasurer, just on –

    Chalmers:

    I might just take one more here because you’ve been light on, and then we’ll go.

    Journalist:

    Thank you, sir. Just about the wage review again.Have you spoken to the Reserve Bank about the wage review and whether or not it’s inflationary?

    Chalmers:

    Thank you. I have had discussions with the Governor of the Reserve Bank and the Treasury has been engaging with the Assistant Governor as well.

    We wanted to make sure that the submission that we’re putting forward, which is about a sustainable real wage increase for millions of Australians on awards, that that’s consistent with our other objectives, including getting on top of this inflation, which has impacted economies around the world over recent years.

    So I consulted the Governor, I think towards the end of March, I gave her a heads‑up today that we were making our submission today, the Treasury’s been engaging with the Reserve Bank and its staff, and that’s because we have made sure that this is consistent with inflation remaining sustainably in the band; that’s our objective.

    One of the things I’m really pleased about and proud of collectively in our economy, is we’ve managed to get real wages up over a sustained period of time at the same time as we’ve got inflation down, kept unemployment low, got the economy growing again, we’ve seen interest rates started to come down earlier this year, we’ve got the debt down in the Budget, so we’re paying less interest on it.

    So this, I think, does reflect the very substantial progress that Australians have made together in our economy. We know that there’s more work to do because people are under pressure, the global environment is still uncertain, but the submission that we take today reflects all of our economic objectives and primarily making sure that when people work hard, they can get ahead.

    I’ll take one more from you, then we’re done.

    Journalist:

    The ACTU want it to be 4.5 per cent, ARA says no more than 2.5 per cent. Is it somewhere in between that you kind of want it?

    Chalmers:

    It’s unusual, and in fact it’s welcome for different groups, including the union movement, to make submissions to the Fair Work Commission’s process. Those submissions close today, there will be hearings next week, a decision next month, it will kick in in July, and it’s a good and welcome part of the process that everyone’s got the ability to make a submission, like the government has today.

    Some organisations nominate numbers, others like the government don’t nominate numbers. The Fair Work Commission in its wisdom will weigh up all of that and come to a decision.

    Journalist:

    Leaning more towards the union, or the business bodies?

    Chalmers:

    Well, that’s not how we make our submission. You know, we’ve made a detailed submission today. You know, I’ve worked really closely with Amanda Rishworth on it, before that with Murray Watt, before that with Tony Burke. We put a lot of effort, a lot of thinking, we apply a lot of consideration to the submission that we make, we don’t put a number on it like other groups do.

    And I also welcome the fact that when we’ve been through this process on a number of occasions already in the life of this government, that the Fair Work Commission has provided, you know, decent pay increases for Australians who are low paid or on awards. That’s a very good thing, and we hope to see that again. More than that, we hope to see a real wage increase.

    Thanks very much everyone.

    MIL OSI News

  • MIL-OSI New Zealand: NZ to subject Pandemic Treaty to full National Interest Test

    Source: NZ Music Month takes to the streets

    The Government will subject a draft Pandemic Treaty to a full National Interest Test before deciding whether or not New Zealand should sign up to it, Foreign Minister Winston Peters and Health Minister Simeon Brown say. 

    The draft Treaty will be discussed at the annual meeting of the World Health Assembly in Geneva from next week 

    “Decisions about how New Zealand responds to any health emergency are made in Wellington, not Geneva, and we are determined to preserve our sovereign decision-making ability,” Mr Peters says.

    “While negotiations on the draft Treaty have been completed, there are a number of steps remaining – which are likely to take some years – before the New Zealand Government will take a decision on whether or not we should sign up.”

    Mr Brown noted that, after three years of negotiation, the World Health Assembly next week would have the Pandemic Treaty presented to it for adoption.

    “New Zealand supports the aim of strengthening global health systems and to improve pandemic preparedness and response,” Mr Brown says.

    “This will also help New Zealand support our Pacific partners to better manage future pandemic responses in our region.”

    Mr Peters says that it is very important to New Zealand that its sovereign decision making on health is protected. 

    “Any Treaty needs to confirm the sovereignty of countries to address public health matters within their borders and gives no power to the WHO or any other international body to direct, order, or change national laws or policies, or to direct countries to take specific actions, such as ban or accept travellers, impose vaccination mandates, or implement lockdowns.”

    “For these reasons, any future decision on whether or not to sign and ratify the Pandemic Treaty will be informed by a full National Interest Test.” 

    MIL OSI New Zealand News

  • MIL-OSI Russia: Dmitry Chernyshenko: The creation of fundamental models makes Russia a leader in the field of artificial intelligence

    Translation. Region: Russian Federal

    Source: Government of the Russian Federation – An important disclaimer is at the bottom of this article.

    Previous news Next news

    Dmitry Chernyshenko opened the plenary session of the VII International Scientific Forum

    The Plekhanov Russian University of Economics is hosting the 7th International Scientific Forum “Step into the Future: Global Foresight, Artificial Intelligence, and Strategic Leadership.” It is dedicated to the development of artificial intelligence (AI) technologies and achieving Russia’s strategic leadership in the context of globalization and geopolitical challenges.

    Deputy Prime Minister Dmitry Chernyshenko opened the plenary session on the topic of international foresight – a joint study to update priority areas of fundamental and exploratory research in the field of AI within the framework of strategic objectives defined by the President and the Government.

    The Deputy Prime Minister called the words of President Vladimir Putin a strategic guideline: “Our direct responsibility is to participate equally in the global race to create strong AI.” He emphasized that it is necessary to agree at the Plekhanov Russian University of Economics, as well as at regional and international sessions: what goals should be “hit” so that Russia remains a leader among other countries in strong AI. The Ministry of Economic Development and the Ministry of Education and Science are preparing a unified research program in the field of AI, within the framework of which funds will be allocated for research that falls within the foresight areas. Universities must definitely get involved in the work.

    According to Dmitry Chernyshenko, AI is already changing our professional landscape, especially in those areas in which flagship AI research centers (RCs) operate: transport and logistics, construction and smart city, medicine, industry, etc.

    “We need to look ahead and foresee which niches are most in demand by our economy. There are areas where we can help with developments in the field of artificial intelligence that meet our Russian specifics, including cultural, social, and technological ones. To do this, we need to create domestic datasets. The groundwork is already in place, we need to popularize our “data lakes”. Collaboration between universities and students is an ideal support for creating domestic datasets as part of an educational program and research projects. Not only is the technology itself changing, there is a shift in the paradigm of thinking,” the Deputy Prime Minister noted.

    He also added that the world is constantly looking for improvements. The pace requires not just watching, but getting involved: “We are proud that Russia is one of the few countries that has its own fundamental AI models. This is a great achievement.”

    The top 15 models of the MERA benchmark, which was created and is being run by the Russian Alliance in the field of AI, include models from several members of the AI Alliance. According to the Deputy Prime Minister, there is healthy competition for leadership within the Russian AI community – this is the path to development, as is world-class collaboration, which does not stop in science.

    The state already supports 12 research centers in the field of AI. Now the selection of flagship RCs of the third wave is underway, and an assessment by experts is underway.

    Dmitry Chernyshenko emphasized the role of science in advancing frontiers in various fields, such as the study of matter, vaccines, and cancer drugs.

    “On the instructions of the President, the International AI Alliance together with SAPFIR are currently working on preparing an international foresight. We are targeting two tracks: foresight in Russia and abroad. We are conducting a foreign foresight to synchronize our watches with the international community and set up cooperation. Third-wave AI centers are focused specifically on foresight areas. After holding individual foresight sessions, a pool of proposals will be formed to update the composition of sub-areas and research tasks,” the Deputy Prime Minister said.

    In conclusion, Dmitry Chernyshenko noted the need to include universities in the organization of the international scientific foresight and instructed them to organize such discussions by inviting foreign experts, scientists and researchers from the field of AI. Each of the invited universities will have time to hold its own foresight session from May to September 2025. The results of the discussions will be consolidated by SAPFIR under the leadership of the Ministry of Economic Development of Russia. The results are planned to be presented to Russian President Vladimir Putin.

    Rector of the Plekhanov Russian University of Economics Ivan Lobanov thanked the Government and Dmitry Chernyshenko personally for their trust and emphasized that the university pays special attention to the development of AI. According to him, Plekhanov University is always in the vector of fulfilling the tasks set by the President and the Government, so the university plans to actively implement the announced approaches and solutions.

    “Today, Plekhanov Russian University of Economics is one of the flagships of the development of the artificial intelligence industry in Russia, we are actively integrating AI into the educational process. The Center for Advanced Research in Artificial Intelligence was created at Plekhanov University, which is engaged in scientific research in the field of explainable and generative AI, implements AI in the field of medicine, develops security solutions based on neural networks, and applied research is also conducted in the Educational and Scientific Laboratory of Artificial Intelligence, Neurotechnology and Business Analytics. Plekhanov Russian University of Economics trains highly qualified specialists in the field of AI, big data and machine learning, and our students test the use of AI in the educational process, learn to work with data and train neural network models,” the rector said.

    The forum brought together leading experts from Russia and abroad, including representatives of the Ministry of Economic Development of Russia, specialized scientific institutes, large companies and international organizations. The event was also attended by First Deputy Minister of Economic Development Maxim Kolesnikov, Deputy Head of the Presidential Administration for the Development of Information and Communication Technologies and Communications Infrastructure Oleg Khorokhordin, Director of the Strategic Agency for Support and Formation of AI Developments Tatyana Soyuznova, representatives of Sberbank PJSC, the Alliance in the Sphere of Artificial Intelligence Association, and the Union of Chinese Entrepreneurs in the Russian Federation.

    The key organizers of foresight in Russia are the International AI Alliance, which includes 17 industry associations from 14 countries, including the Russian AI Alliance, and the Strategic Agency for Support and Formation of AI Developments (SAPFIR), created on the basis of the Skolkovo Foundation in early 2025.

    It is planned that the results of the foresight will be summed up at the annual conference “Journey into the World of Artificial Intelligence” at the end of 2025.

    Please note: This information is raw content directly from the source of the information. It is exactly what the source states and does not reflect the position of MIL-OSI or its clients.

    MIL OSI Russia News

  • MIL-OSI Global: Birthright citizenship case at Supreme Court reveals deeper questions about judicial authority to halt unlawful policies

    Source: The Conversation – USA – By Cassandra Burke Robertson, Professor of Law and Director of the Center for Professional Ethics, Case Western Reserve University

    The U.S. Supreme Court is considering whether a single federal judge should have the power to temporarily halt presidential policies across the entire country. Rudy Sulgan, The Image Bank/Getty Images

    When one judge blocks a president’s policies nationwide, alarm bells ring. Should a single judge wield this much power? Can they halt policies across the entire country after just a quick first look at whether they might be illegal? The Supreme Court now faces these critical questions.

    In a lively session on May 15, 2025, filled with justices’ questions that at times interrupted the attorneys appearing before them, the Supreme Court heard arguments in a case stemming from President Donald Trump’s executive order aimed at ending birthright citizenship, the provision in the Constitution’s 14th Amendment that says all children born in the United States are granted citizenship.

    While the underlying lawsuit involves birthright citizenship, the immediate question before the court was about a legal tool called a “nationwide preliminary injunction.” This allows a single federal judge to temporarily halt presidential policies across the entire country – even before fully considering whether those policies are constitutional.

    Three judges had stopped the president’s attempt to deny birthright citizenship to babies born to mothers who lack legal permanent residency in the United States. It was the Trump administration’s appeal of those injunctions that was argued before the justices on May 15, with the administration asserting that “universal injunctions compromise the Executive Branch’s ability to carry out its functions,” and that it’s unconstitutional for federal judges to issue them.

    The justices also grappled with a key question: How much should judges consider whether a policy is likely constitutional when deciding whether to issue these temporary blocks? The National Immigration Law Center, which supports the use of nationwide injunctions, wrote in its filing with the court that granting the administration’s request to bar such injunctions would “tie the hands of the judicial branch in the face of unlawful executive action.”

    What exactly are these injunctions, and why do they matter to everyday Americans?

    Immediate, irreparable harm

    When presidents try to make big changes through executive orders, they often hit a roadblock: A single federal judge, whether located in Seattle or Miami or anywhere in between, can stop these policies across the entire country.

    These court orders have increasingly become a political battleground, increasingly sought by both Republicans and Democrats to fight presidential policies they oppose.

    And while the Trump administration asked the Supreme Court to limit judges’ power to issue nationwide preliminary injunctions, Congress has also held hearings on curtailing judges’ ability to issue the injunctions.

    When the government creates a policy that might violate the Constitution or federal law, affected people can sue in federal court to stop it. While these lawsuits work their way through the courts – a process that often takes years – judges can issue what are called “preliminary injunctions” to temporarily pause the policy if they determine it might cause immediate, irreparable harm.

    A “nationwide” injunction – sometimes called a “universal” injunction – goes further by stopping the policy for everyone across the country, not just for the people who filed the lawsuit.

    Importantly, these injunctions are designed to be temporary. They merely preserve the status quo until courts can fully examine the case’s merits. But in practice, litigation proceeds so slowly that executive actions blocked by the courts often expire when successor administrations abandon the policies.

    Legislation introduced by GOP Sen. Chuck Grassley would ban judges from issuing most nationwide injunctions.
    Sen. Chuck Grassley office

    More executive orders, more injunctions

    Nationwide injunctions aren’t new, but several things have made them more contentious recently.

    First, since a closely divided and polarized Congress rarely passes major legislation anymore, presidents rely more on executive orders to get substantive things done. This creates more opportunities to challenge presidential actions in court.

    Second, lawyers who want to challenge these orders have gotten better at “judge shopping” – filing cases in districts where they’re likely to get judges who agree with their client’s views.

    Third, with growing political division, both parties aim to use these injunctions more aggressively whenever the other party controls the White House.

    Affecting real people

    These legal fights have tangible consequences for millions of Americans.

    Take DACA, the common name for the program formally called Deferred Action for Childhood Arrivals, which protects about 500,000 young immigrants from deportation. For more than 10 years, these young immigrants, known as “Dreamers,” have faced constant uncertainty.

    That’s because, when President Barack Obama created DACA in 2012 and sought to expand it via executive order in 2015, a Texas judge blocked the expansion with a nationwide injunction. When Trump tried to end DACA, judges in California, New York and Washington, D.C. blocked that move. The program, and the legal challenges to it, continued under President Joe Biden. Now, the second Trump administration faces continued legal challenges over the constitutionality of the DACA program.

    More recently, judges have used nationwide injunctions to block several Donald Trump policies.

    While much of the current debate focuses on presidential policies, nationwide injunctions have also blocked congressional legislation.

    The Corporate Transparency Act, passed in 2021 and originally scheduled to go into effect in 2024, combats financial crimes by requiring businesses to disclose their true owners to the government. A Texas judge blocked this law in 2024 after gun stores challenged it.

    In early 2025, the Supreme Court allowed the law to take effect, but the Trump administration announced it simply wouldn’t enforce it – showing how these legal battles can become political power struggles.

    A polarized Congress rarely passes major legislation anymore, so presidents – including Donald Trump – have relied on executive orders to get things done.
    Christopher Furlong/Getty Images

    Too much power or necessary protection?

    Some critics say nationwide injunctions give too much power to a single judge. If lawyers can pick which judges hear their cases, this raises serious questions about fairness.

    Supporters argue that these injunctions protect important rights. For example, without nationwide injunctions in the citizenship cases, babies born to mothers without legal permanent residency would be American citizens in some states but not others – an impossible situation.

    Congress is considering legislation to limit judges’ ability to grant nationwide injunctions.

    The Trump administration has also tried to make it expensive and difficult to challenge its policies in court. In March 2025, Trump ordered government lawyers to demand large cash deposits – called “security bonds” – from anyone seeking an injunction. Though these bonds are already part of existing court rules, judges usually set them at just a few hundred dollars or waive them entirely when people raise constitutional concerns.

    Under the new policy, critics worry that “plaintiffs who sue the government could be forced to put up enormous sums of money in order to proceed with their cases.”

    Another way to address the concerns about a single judge blocking government action would be to require a three-judge panel to hear cases involving nationwide injunctions, requiring at least two of them to agree. This is similar to how courts handled major civil rights cases in the 1950s and 1960s.

    My research on this topic suggests that three judges working together would be less likely to make partisan decisions, while still being able to protect constitutional rights when necessary. Today’s technology also makes it easier for judges in different locations to work together than it was decades ago.

    As the Supreme Court weighs in on this debate, the outcome will affect how presidents can implement policies and how much power individual judges have to stop them. Though it might seem like a technical legal issue, it will shape how government works for years to come – as well as the lives of those who live in the U.S.

    This is an updated version of a story originally published on April 3, 2025.

    Cassandra Burke Robertson does not work for, consult, own shares in or receive funding from any company or organization that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.

    ref. Birthright citizenship case at Supreme Court reveals deeper questions about judicial authority to halt unlawful policies – https://theconversation.com/birthright-citizenship-case-at-supreme-court-reveals-deeper-questions-about-judicial-authority-to-halt-unlawful-policies-256726

    MIL OSI – Global Reports

  • MIL-OSI Europe: Answer to a written question – Bovine tuberculosis: is a vaccine in sight? – E-000857/2025(ASW)

    Source: European Parliament

    1. Commission Delegated Regulation (EU) 2023/361[1] prohibits Member States from allowing the use of vaccines against tuberculosis in bovine animals. This EU rule is based on decades of experience with eradication, on robust scientific advice, and on expert opinions. Currently available vaccines for bovine tuberculosis do not confer full protection and compromise tuberculin skin tests or other immunological tests, for the distinction between vaccinated and infected animals, jeopardising current control and eradication of bovine tuberculosis and the ongoing approved eradication programmes of the Member States.

    2. The Commission has not communicated with the British authorities in this regard and has not received information from them on this topic.

    3. The Commission is constantly ensuring that the EU rules are based on the latest scientific knowledge and has consulted the European Food Safety Authority several times on the issue of bovine tuberculosis .

    • [1] Commission Delegated Regulation (EU) 2023/361 of 28 November 2022 supplementing Regulation (EU) 2016/429 of the European Parliament and the Council as regards rules for the use of certain veterinary medicinal products for the purpose of prevention and control of certain listed diseases.
    Last updated: 15 May 2025

    MIL OSI Europe News

  • MIL-OSI Europe: Written question – Transparency of the Commission’s actions in promoting its CSDP initiatives in Member States – E-001826/2025

    Source: European Parliament

    Question for written answer  E-001826/2025/rev.1
    to the Commission
    Rule 144
    Michał Dworczyk (ECR)

    The Commission is obliged to ensure transparency in the development and implementation of EU legislation and policies. However, in recent years, there have been numerous reports of a lack of transparency. One need only mention the Commission President’s secret SMS negotiations on the purchase of COVID-19 vaccines, or the Commission’s lobbying of MEPs on the Green Deal[1], which violated the principles of sincere cooperation between EU institutions.

    Another example is the Commission’s lobbying activities in Member States to promote its policies in the area of security and defence, including the arms industry. The EU’s competences in these areas are limited, yet more and more proposals put forward by the Commission indicate a systematic drive to secure greater decision-making powers at EU level. In particular, since the outbreak of the full-scale war in Ukraine, the Commission’s initiatives relating to the defence industry, while not formally changing the competences laid down in the Treaties, have de facto extended the EU’s influence in these areas through financial and regulatory instruments. Therefore, the Commission’s actions aimed at shaping public opinion and influencing the public debate in Member States on security and defence issues raise serious legal and ethical concerns.

    In light of the foregoing:

    How many contracts has the Commission concluded, for what amounts and in which countries for lobbying activities for its initiatives in the area of Common Security and Defence Policy (CSDP) and the arms industry in the Member States?

    Submitted: 6.5.2025

    • [1] According to the media, the Commission used European taxpayers’ money to commission lobbying activities aimed at influencing the views of MEPs. https://www.lepoint.fr/monde/la-commission-europeenne-a-paye-des-ong-pour-faire-son-lobbying-sur-le-pacte-vert-23-01-2025-2580637_24.php#11
    Last updated: 15 May 2025

    MIL OSI Europe News

  • MIL-OSI: Best Payday Loans Online: Fast $255 Payday Loans Near Me With Heart Paydays Loans And No Credit Check, Bad Credit

    Source: GlobeNewswire (MIL-OSI)

    ROMFORD, United Kingdom, May 15, 2025 (GLOBE NEWSWIRE) — Life happens quickly, and sometimes it throws us unexpected financial challenges. Whether it’s a car repair, an urgent medical bill, or just the need to make it to payday, these emergencies often require fast access to money. Unfortunately, not everyone has the savings to cover these sudden costs.

    This is where payday loans come in. Payday loans are short-term loans designed to help people bridge the gap between paychecks. They offer a quick solution when you need money fast. But with so many payday lenders available online, it can be tough to know where to turn.

    Need fast cash for emergencies? Click here to get started with Heart Paydays Loans and apply for payday loans online today!

    In this article, we will discuss the best payday loans online, focusing on Heart Paydays Loans as a top provider for quick, flexible, and trustworthy payday loans. Whether you’re looking for payday loans near me, payday loan bad credit, or quick payday loans no credit check, we’ll explore how Heart Paydays Loans stands out as a reliable option for urgent financial needs.

    Why Payday Loans Are a Great Option for Emergencies

    Emergencies can hit at any time, and often, they don’t come with a lot of warning. You may find yourself needing money for a car repair, hospital visit, or unexpected travel expenses. Traditional loan options can be slow, require lots of paperwork, and be out of reach for people with poor credit. That’s where payday loans come in as a lifeline.

    1. Quick and Easy Access to Funds

    When you need money fast, payday loans near me can be a great option. Online payday loans, especially through Heart Paydays Loans, are fast, with many people receiving their funds in as little as 1 hour. Whether it’s an emergency or a small unexpected cost, payday loans provide the speed you need.

    2. Accessible Even for Those with Bad Credit

    Not everyone has a perfect credit score, and some people may be dealing with payday loan bad credit situations. With traditional loans, a low credit score could mean an automatic rejection. But payday lenders like Heart Paydays Loans don’t just rely on credit scores. They look at your income and ability to repay the loan, making it easier for individuals with poor credit to get the money they need. Many lenders like Heart Paydays Loans offer best payday loans for bad credit, which is great news for those needing immediate funds.

    Worried about your credit score? Click here to check your credit score online for free and see where you stand!

    3. Simple Application Process

    Applying for a payday loan is often easier than applying for traditional bank loans. The application process is usually done online and can be completed in just a few minutes. Heart Paydays Loans offers a streamlined online application, meaning you can apply and get approved without leaving your house.

    4. Flexible Loan Terms

    Another benefit of payday loans is flexibility. You can choose the loan amount you need and select repayment terms that work for your budget. Whether you’re looking for a small loan or a larger one, payday loans offer flexibility to fit your needs.

    Looking for payday loans near you? Click here to find a Heart Paydays Loans location or apply online now!

    What to Look for in the Best Payday Loans Online

    When searching for the best payday loans online, it’s crucial to consider certain factors that can help you avoid excessive debt and ensure you’re getting the best deal for your financial situation. Here are some key features to look for:

    1. Low Interest Rates

    One of the most important aspects to consider when applying for payday loans is the interest rate. Many payday lenders charge high interest rates, which can make it difficult to repay the loan and avoid falling into a cycle of debt.

    Look for loans that offer reasonable Annual Percentage Rates (APR)—ideally, below 36%—to avoid sky-high rates that could leave you paying far more than you initially borrowed. Some online lenders, like Heart Paydays Loans, are known for offering competitive and transparent rates, making them a good option for those who need funds quickly without breaking the bank.

    2. Clear Terms and Transparency

    A reputable payday loan provider will offer clear terms with no hidden fees or surprises. Before agreeing to any loan, make sure you understand the full terms of repayment, including the APR, the total amount to be repaid, and any associated fees. Good payday loan providers will be transparent about the costs, ensuring that you know exactly what to expect from the start.

    For example, Heart Paydays Loans provides detailed loan terms up front, so borrowers don’t have to worry about hidden fees or unclear conditions. You’ll know how much you’re borrowing, what the interest rate is, and how much you’ll pay back at the end of the loan.

    3. Fast Disbursement

    When you need emergency funds, quick funding is essential. Look for payday loans that are approved and funded within hours, ideally within one business day or less. Many payday loan providers, like Heart Paydays Loans, offer fast approval and disbursement of funds, often as quickly as within 1 hour of approval. This is especially important when you’re dealing with an urgent financial situation, like medical bills or car repairs, where timing is critical.

    4. Flexible Repayment Terms

    Repayment terms that fit your budget are key to successfully managing a payday loan. The best payday loans offer flexible repayment schedules, allowing you to choose a plan that suits your pay frequency. For example, you may prefer weekly, bi-weekly, or monthly repayment options depending on how often you’re paid.

    Many payday lenders, like Heart Paydays Loans, offer repayment terms that are tailored to your needs. This flexibility helps you avoid falling behind on payments and makes it easier to manage the loan without straining your finances.

    5. Avoiding Predatory Lenders

    Unfortunately, some payday lenders engage in predatory lending practices by charging excessive fees and high interest rates that can trap borrowers in a cycle of debt. It’s important to avoid lenders who offer loans with extreme terms, such as 1-hour payday loans no credit check with hidden fees or quick payday loans no credit check that come with unreasonable interest rates.

    Reputable lenders like Heart Paydays Loans prioritize fair lending practices and transparent terms, helping you get the funds you need without getting stuck in a debt trap. Always read the fine print, and if something doesn’t seem right, don’t hesitate to look for another lender.

    Compare rates and get the best payday loans for bad credit today. Click here to apply with Heart Paydays Loans and find the perfect loan for your needs!

    Heart Paydays Loans: The Best Payday Loans Online

    When it comes to finding best payday loans online, Heart Paydays Loans stands out as a top choice. With a wide range of loan options and a focus on providing fast and reliable service, Heart Paydays Loans is ideal for those in need of quick cash.

    1. Fast Approval and Funding

    One of the standout features of Heart Paydays Loans is how quickly they process applications. Once you apply, the approval process is fast, often taking only minutes. If you are approved, funds can be transferred directly into your bank account in as little as 1 hour payday loans no credit check—giving you quick access to the money you need without unnecessary delays.

    2. No Credit Check or Bad Credit Accepted

    If you’re worried about your credit score, don’t be. Heart Paydays Loans provides quick payday loans no credit check. They understand that credit scores don’t always reflect your ability to repay a loan. As long as you have a steady income and are able to repay the loan, you can still qualify for the loan you need—even if your credit score is less than perfect. So, for anyone struggling with payday loan bad credit, Heart Paydays Loans offers a chance to get back on track.

    3. Flexible Loan Amounts and Terms

    With Heart Paydays Loans, you can borrow anywhere from $100 to $5,000, depending on your financial needs. Whether it’s a small emergency or a larger unexpected expense, they offer a range of loan options to suit different budgets. Repayment terms are typically flexible, with options ranging from a few weeks to several months, allowing you to select a plan that works best for you.

    4. No Hidden Fees

    One of the common complaints about payday loans is the hidden fees and high-interest rates. With Heart Paydays Loans, transparency is key. They outline all fees and rates upfront, so you can make an informed decision about your loan. There are no surprise charges, and you’ll know exactly what to expect before you sign any agreement.

    How to Apply for Payday Loans Online

    Getting a payday loan through Heart Paydays Loans is simple. Here’s a step-by-step guide to help you navigate the process:

    1. Visit the Website

    Start by visiting the Heart Paydays Loans website. Their platform is user-friendly and easy to navigate, making it simple to find the loan option that fits your needs. Whether you’re looking for payday loans near me or an online loan, Heart Paydays Loans provides a convenient solution.

    2. Fill Out the Application Form

    The application process is quick and straightforward. You’ll need to provide some basic personal details, such as your name, address, phone number, and employment information. You’ll also need to enter details about your income and bank account, so they can deposit the loan funds directly into your account.

    3. Review the Loan Terms

    Before submitting your application, you’ll be given the chance to review your loan offer. You’ll see the loan amount, the repayment terms, and any interest rates or fees. This is your opportunity to make sure the loan terms are right for you.

    4. Submit Your Application and Get Approved

    Once you’ve reviewed the terms, submit your application. Heart Paydays Loans will quickly review your information and give you an answer. If you’re approved, you’ll receive your loan funds within a very short time frame.

    Ready to apply? Click here to fill out your application with Heart Paydays Loans and get your payday loan funds in no time!

    The Advantages of Heart Paydays Loans

    Here are some key benefits of choosing Heart Paydays Loans for your payday loan needs:

    1. Speed and Convenience

    Need a payday loan quickly? Heart Paydays Loans is one of the best options for 1 hour payday loans no credit check. Their fast approval process and rapid funding mean you won’t have to wait long to get the cash you need.

    2. No Credit Checks or Cosigner Requirements

    Heart Paydays Loans doesn’t require a cosigner, and they don’t rely on credit scores alone to approve your application. This makes it a great option for individuals dealing with payday loan bad credit.

    3. Flexibility

    Heart Paydays Loans offers flexibility in both loan amounts and repayment terms, allowing you to tailor the loan to your specific needs.

    4. Safe and Secure

    Your personal and financial information is protected with top-notch encryption. Heart Paydays Loans is committed to keeping your data safe.

    5. Transparent Terms

    With clear and upfront terms, Heart Paydays Loans ensures that there are no hidden fees or unexpected charges. You’ll know exactly what you’re getting before you agree to the loan.

    What to Look for When Choosing Payday Loans Online

    When searching for best payday loans online, it’s important to consider a few key factors to ensure you’re getting the best deal:

    1. Interest Rates and Fees

    Make sure the payday loan provider offers competitive interest rates. While payday loans generally have higher interest rates than traditional loans, you can still find reasonable options. Always check the fees and make sure you understand what you’ll be paying.

    2. Loan Terms

    Look for payday loans with flexible terms that match your financial situation. Some lenders offer short repayment periods, while others may give you up to a year to repay the loan.

    3. Speed of Funding

    If you need money quickly, look for payday lenders who offer fast funding, such as 1 hour payday loans no credit check.

    4. Lender Reputation

    Choose a lender with a good reputation. Heart Paydays Loans is known for its transparent practices, fast service, and customer satisfaction.

    If you have bad credit, click here to see how Heart Paydays Loans can help you get approved for payday loans even with less-than-perfect credit!

    Frequently Asked Questions (FAQs)

    Q: What are payday loans?

    Payday loans are short-term loans designed to cover emergencies or unexpected expenses until your next paycheck. They are usually small loans that are paid back in full on your next payday or over a few months.

    Q: Can I get a payday loan with bad credit?

    Yes, Heart Paydays Loans offers payday loans bad credit options, meaning that even if you have a low credit score, you may still qualify for a loan.

    Q: How fast can I get my payday loan?

    Heart Paydays Loans offers fast approval and disbursement. In many cases, you can receive your loan within one hour after approval.

    Q: Is it possible to get payday loans with no credit check?

    Yes, Heart Paydays Loans offers quick payday loans no credit check, which means your credit score will not be the main deciding factor for approval.

    Q: How much can I borrow with Heart Paydays Loans?

    Heart Paydays Loans offers payday loans ranging from $100 to $5000, depending on your financial needs and eligibility.

    Conclusion

    When searching for best payday loans online, it’s crucial to prioritize lenders offering low interest rates, clear repayment terms, and fast disbursement. By focusing on these factors, you can ensure that the loan meets your immediate financial needs without becoming a long-term burden. Heart Paydays Loans offers fast and flexible loan options, including 1-hour payday loans no credit check, making it a great choice for those in urgent need of funds.

    If you have bad credit, don’t worry—there are still options available. Many online lenders specialize in providing payday loans for bad credit, helping you secure the funds you need without the high fees or stringent requirements of traditional lenders. However, it’s important to avoid predatory lenders with excessive rates or unclear terms that could leave you trapped in debt.

    Ultimately, choosing the best payday loans online is about finding a lender who offers reasonable terms, transparent fees, and quick funding. By researching and applying to trusted providers like Heart Paydays Loans, you can get the financial help you need while maintaining control of your budget. Apply now to see your loan options and get the support you need today!

    Don’t wait! Click here to apply for the best payday loans online with Heart Paydays Loans and get the funds you need today!

    Project name: Heart Paydays

    Email – support@heartpaydays.com

    Full Company address:Floor 2, 1-5 High Street, Romford, RM1 1JU, United Kingdom

    Company website: heartpaydays.com

    Contact person : Chloe Simon

    email : chloe@heartpaydays.com

    Disclaimer: The information provided in this article is for informational purposes only. Payday loans, including those offered through Heart Paydays Loans, may carry high-interest rates and fees, which can vary based on your location and the terms of the loan. It’s important to understand the full terms, fees, and repayment schedule before applying. Borrowers should only consider payday loans for short-term financial needs and ensure they are able to repay the loan on time to avoid further financial difficulties. Heart Paydays Loans is not responsible for any financial consequences resulting from the use of payday loans. We encourage you to explore all options, including traditional loans or financial counseling, before proceeding with payday loans. Always read the fine print and consult with a financial advisor if necessary.

    Photos accompanying this announcement are available at:

    https://www.globenewswire.com/NewsRoom/AttachmentNg/7ff1ca3b-e405-4107-8793-a65390cae147

    https://www.globenewswire.com/NewsRoom/AttachmentNg/b7dca294-2850-494d-b258-c6ee433e869b

    The MIL Network

  • MIL-OSI Asia-Pac: DH urges high-risk individuals to receive COVID-19 vaccines as soon as possible as COVID-19 activity hits one-year high in Hong Kong

    Source: Hong Kong Government special administrative region

    DH urges high-risk individuals to receive COVID-19 vaccines as soon as possible as COVID-19 activity hits one-year high in Hong Kong 
    “After the resumption of normalcy, Hong Kong experienced cycles of active periods of COVID-19 in every six to nine months. Taking into account local and global epidemiological data in recent years, the CHP is of the view that COVID-19 has evolved into an endemic disease with a periodic pattern. According to the CHP’s analysis, the active periods are associated with the changes in the predominant circulating strains and declining herd immunity in Hong Kong. In early 2024, the predominant strains circulated locally changed from XBB to JN.1; while in the third quarter of 2024, they changed from JN.1 to KP.2 and KP.3; and they have further changed to XDV since late March this year. There is no evidence suggesting that XDV will cause more severe disease. Nevertheless, the changing nature of the virus should not be taken lightly. The CHP will continue to closely monitor the situation of the variant strains in accordance with the World Health Organization’s recommendation, and be cautious of the possible emergence of more virulent or vaccine-mismatched strains of the virus in the future,” the Controller of the CHP, Dr Edwin Tsui, said.
     
    According to the latest surveillance data as of the week ending May 10, the viral load of the SARS-CoV-2 virus from sewage surveillance, the test positivity rate and the cases tested positive by nucleic acid tests in the laboratory have continued to rise over the past four weeks. In particular, the percentage of respiratory samples testing positive for the SARS-CoV-2 virus gradually increased to 13.66 per cent from 6.21 per cent four weeks ago (the week of April 6 to 12), which is a record high in the past year. For sewage surveillance, the per capita viral load of SARS-CoV-2 virus was around 710 000 copy/litre, which was also significantly higher than that of about 390 000 copy/litre four weeks ago. During the same period, the consultation rate of COVID-19 cases at Accident and Emergency departments, general out-patient clinics and sentinel private medical practitioner clinics also recorded a significant increase.
     
    “According to the surveillance data after the resumption of normalcy, there were two relatively active periods of COVID-19 in Hong Kong, which lasted for about 15 weeks from April to July 2023 and for about seven weeks from February to March last year. COVID-19 became more active in mid-April of this year (i.e. about four weeks ago). Based on previous statistics, we expect the activity level of COVID-19 to remain at a higher level for at least the next few weeks,” said Dr Tsui.
     
    Regarding severe and fatal cases, in the past four weeks, the CHP recorded a total of 81 COVID-19 severe cases (including 30 fatal cases) involving adults. Epidemiological investigation showed that 83 per cent of the patients being elderly persons aged 65 or above, and more than 90 per cent of these elderly cases had underlying illnesses. Only one case had received a booster dose of COVID-19 vaccine in the past six months.
     
    For children, the CHP has recorded five severe cases (no fatal case) so far this year. Of which, two have underlying illnesses and three cases have not received the initial dose of the COVID-19 vaccine. “This shows that even children who have been in good health can experience severe complications from COVID-19 infection. Therefore, I hope that parents will not hesitate to bring their children to complete the initial dose of the COVID-19 vaccine as soon as possible. The currently prevalent XDV strain is a related variant of JN.1. Therefore, the JN.1 vaccine used in Hong Kong is effective in preventing the disease, reducing the risk of severe illness and death, and enhancing herd immunity,” said Dr Tsui.
     
    “Currently, the proportion of high-risk groups, especially the elderly, receiving booster doses of the vaccine is relatively low. This suggests that the public does not attach much importance to vaccination. Based on the surveillance data and vaccination figures, the CHP projected that about 75 per cent of the elderly aged 65 or above living in Residential Care Homes for the Elderly and 90 per cent of those living in the community had not received booster dose of the COVID-19 vaccine timely according to the CHP’s recommendation. I would like to reiterate my appeal to the high-risk groups, especially the elderly and persons with underlying illnesses, to receive an additional booster dose of the COVID-19 vaccine as soon as possible,” Dr Tsui added.
     
    Apart from vaccination, the public should maintain stringent personal, environmental and hand hygiene at all times to minimise the risk of infecting COVID-19 and other respiratory infectious diseases. High-risk persons (e.g. persons with underlying medical conditions or persons who are immunocompromised) should wear surgical masks when visiting public places. The general public should also wear a surgical mask when travelling on public transport or staying in crowded places. When respiratory symptoms appear, one should wear a surgical mask, consider avoiding going to work or school, avoid going to crowded places and seek medical advice promptly.
    ???
    For the latest surveillance data, members of the public can refer to the CHP’s weekly COVID-19 & Flu ExpressIssued at HKT 20:36

    NNNN

    MIL OSI Asia Pacific News

  • MIL-OSI United Kingdom: MHRA approves vaccine to protect against pneumococcal infections such as pneumonia and meningitis

    Source: United Kingdom – Executive Government & Departments

    News story

    MHRA approves vaccine to protect against pneumococcal infections such as pneumonia and meningitis

    As with all products, the MHRA will keep its safety under close review.

    The Medicines and Healthcare products Regulatory Agency (MHRA) has today (15 May 2025) approved a vaccine (Capvaxive) for people aged 18 years and older to help protect against illnesses caused by bacteria called Streptococcus pneumoniae or pneumococcus.

    Illnesses caused by Streptococcus pneumoniae bacteria include lung infection (pneumonia), inflammation of the brain and spinal cord (meningitis) and infection in the blood (bacteraemia). The vaccine works by helping the body to make its own antibodies, which protect against these diseases.

    This vaccine has been approved through the International Recognition Procedure (IRP). The IRP allows the MHRA to take into account the expertise and decision-making of trusted regulatory partners for the benefit of UK patients. 

    The MHRA conducts a targeted assessment of IRP applications and retains the authority to reject applications if the evidence provided is not considered sufficiently robust.

    As with any medicine, the MHRA will keep the safety and effectiveness of this vaccine under close review. Anyone who suspects they are having a side effect from this medicine are encouraged to talk to their doctor, pharmacist or nurse and report it directly to the MHRA Yellow Card scheme, either through the website (https://yellowcard.mhra.gov.uk/) or by searching the Google Play or Apple App stores for MHRA Yellow Card. 

    Notes to editors  

    1. The marketing authorisation was granted on 15 May 2025 to Merck Sharp & Dohme (UK) Limited.
    2. More information can be found in the Summary of Product Characteristics and Patient Information leaflets which will be published on the MHRA Products website within 7 days of approval.
    3. The Medicines and Healthcare products Regulatory Agency (MHRA) is responsible for regulating all medicines and medical devices in the UK by ensuring they work and are acceptably safe.  All our work is underpinned by robust and fact-based judgments to ensure that the benefits justify any risks.
    4. The MHRA is an executive agency of the Department of Health and Social Care.
    5. For media enquiries, please contact the newscentre@mhra.gov.uk, or call on 020 3080 7651.

    Updates to this page

    Published 15 May 2025

    MIL OSI United Kingdom

  • MIL-OSI Asia-Pac: COVID-19 activity hits 1-year high

    Source: Hong Kong Information Services

    The Centre for Health Protection (CHP) today said the major surveillance indicators of COVID-19 reached a one-year high, urging all sectors of the community to heighten their vigilance and enhance personal hygiene and protection measures.

    In addition to advising citizens to receive the initial dose of the COVID-19 vaccine as soon as possible, the CHP also recommended people at high risk to receive a booster dose in a timely manner to minimise the risk of serious complications or death after infection.

    CHP Controller Dr Edwin Tsui pointed out that after the resumption of normalcy, Hong Kong experienced cycles of active periods of COVID-19 in every six to nine months.

    “Taking into account local and global epidemiological data in recent years, the CHP is of the view that COVID-19 has evolved into an endemic disease with a periodic pattern.”

    The CHP’s analysis suggested that the active periods are associated with the changes in the predominant circulating strains and declining herd immunity in Hong Kong.

    In early 2024, the predominant strains circulated locally changed from XBB to JN.1.

    In the third quarter of 2024, the strains changed from JN.1 to KP.2 and KP.3.

    Since late March this year, they have further changed to XDV.

    Dr Tsui said there is no evidence suggesting that XDV will cause more severe disease. 

    According to the latest surveillance data as of the week ending May 10, the viral load of the SARS-CoV-2 virus from sewage surveillance, the test positivity rate and the cases tested positive by nucleic acid tests in the laboratory have continued to rise over the past four weeks.

    In particular, the percentage of respiratory samples testing positive for the SARS-CoV-2 virus gradually increased to 13.66% from 6.21% four weeks ago, marking a record high in the past year.

    For sewage surveillance, the per capita viral load of SARS-CoV-2 virus was around 710,000 copy/litre, which was also significantly higher than that of about 390,000 copy/litre four weeks ago.

    During the same period, the consultation rate of COVID-19 cases at Accident & Emergency departments, general outpatient clinics and sentinel private medical practitioner clinics also recorded a significant increase.

    “Based on previous statistics, we expect the activity level of COVID-19 to remain at a higher level for at least the next few weeks,” Dr Tsui added.

    Regarding severe and fatal cases, the CHP recorded a total of 81 COVID-19 severe cases involving adults in the past four weeks, among which 30 were fatal cases.

    Epidemiological investigations showed that 83% of the patients were aged 65 or above.

    For children, the CHP has recorded five severe cases so far this year. Of which, two have underlying illnesses and three cases have not received the initial dose of the COVID-19 vaccine. 

    Dr Tsui noted that the currently prevalent XDV strain is a related variant of JN.1.

    “Therefore, the JN.1 vaccine used in Hong Kong is effective in preventing the disease, reducing the risk of severe illness and death, and enhancing herd immunity.”

    He urged high-risk groups, especially the elderly and those with underlying illnesses, to receive an additional booster dose of the COVID-19 vaccine as soon as possible.

    Meanwhile, parents should also bring their children to complete the initial dose of the COVID-19 vaccine as soon as possible.

    MIL OSI Asia Pacific News

  • MIL-OSI USA: Secretary Kennedy to Senator Marshall During HELP Committee Hearing: We’re Going to Make HHS Accountable to the American People

    US Senate News:

    Source: United States Senator for Kansas Roger Marshall

    Washington – U.S. Senator Roger Marshall, M.D. (R-Kansas) questioned the Secretary of Health and Human Services (HHS), Robert F. Kennedy, Jr., today during a hearing in the Senate Committee on Health, Education, Labor, & Pensions (HELP).
    During the hearing, Senator Marshall asked Secretary Kennedy about the chronic disease epidemic in America, efforts to make HHS more efficient, and vaccines.
    Senator Marshall has been a long-time ally of Secretary Kennedy and was heavily involved in his confirmation process. As an OB-GYN of over 25 years, Senator Marshall is also the Chairman of the Make America Healthy Again (MAHA) Caucus.

    [embedded content]

    Click HERE or on the image above to watch Senator Marshall’s full line of questioning.
    Highlights from the hearing include:
    On Making America Healthy Again:
    Senator Marshall: “This was going to be a question. I’m just going to make a statement. All the research that we do on MAHA, on soil health, on nutrition, in my heart, that’s research on cancer. It’s research on Alzheimer’s, at the end of the day… We should be spending as much money at the front side of this as we are trying to cure the end of it. We’re seeing epidemics of colorectal cancer, young age Alzheimer’s, all these things. And I think the research at the front end is every bit as important at the hind end.” 
    Secretary Kennedy: “…NIH made all these extraordinary breakthroughs, and particularly in treating cancer and, you know, reducing mortalities for colorectal cancer. But my question is, isn’t it as important to find out why kids are getting colorectal cancer?
    “When you and I were kids, there were zero kids with colorectal cancer. It’s an epidemic now, so it’s not really a badge for us when we say, ‘Oh, we can make it less lethal.’ Why don’t we go figure out what’s causing it and eliminate that exposure with all of these with Alzheimer’s, with heart disease? There’s something making Americans very, very sick, and our response should not be just ‘okay, we’ll develop a pharmaceutical fix for it, or medical fix.’ Let’s figure out what it is and get rid of it so we can have healthy kids again.”
    On efforts to make HHS more efficient:
    Senator Marshall: “Isn’t it true that under Joe Biden’s White House, they added 20,000 employees to HHS? When you were nominated, there were 28 divisions with HHS, 100 communication offices, 40 IT departments, and nine HR units as well? Can you answer that question?”
    Secretary Kennedy: “Yes, that’s right. There are dozens of IT departments. There’s eight senior finance officials. There are nine separate offices on women’s health, eight separate offices for minority health, 27 separate offices for HIV, 59 behavioral health programs, [and] 40 opioid programs.”
    “What we’re trying to do is consolidate, streamline, eliminate the redundancies, eliminate all those administrative costs for each one of those little departments, consolidate them and make them make sense, and make them accountable to the American people.
    “… As you point out, there’s 40 procurement departments with four separate computer systems that don’t talk to each other… [HHS] grew like 38% of the last four years. I would say that’s great if Americans got healthier, but they didn’t. They got worse.
    “So what we’re trying to do is go back to the pre-COVID levels and to start making the department function as it would… in a rational universe, and to bring in, you know, modern AI and telemedicine, and all the opportunities we have now, these new efficiencies and for medical delivery to the American people and for patient care.
    “And we’re not able to take advantage of any of them because there’s so much chaos and disorganization in this department, and everybody who’s gone up against it in the past has thrown their hands up and given up. What we’re saying is, let’s organize it in a way that I can quickly adopt and deploy all these opportunities we have to really deliver high-quality health care to the American people.”
    On vaccines:
    Senator Marshall: “Let’s stay on the measles vaccine, just for a second… I’m an obstetrician. If a 25-year-old pregnant woman asked me if she should take the measles vaccine, the MMR… I would give her the answer, ‘No, you shouldn’t.’ But if she was 25 and trying to get pregnant, I would give her different advice.
    “I’ve always valued the sanctity of the physician-patient relationship. I went to medical school for four years. I did four years of residency. I delivered thousands of babies. It’s my job to give that recommendation. What’s the role of the Secretary of HHS as far as recommendations of vaccines?”
    Secretary Kennedy: “Well, the vaccine recommendations, Senator, are normally made through ACIP, the Advisory Committee on Immunization Practices, which is an outside consulting committee at CDC [Centers for Disease Control and Prevention]. There’s another committee called VRBPC [the Vaccines and Related Biological Products Advisory Committee], which is within the FDA [Food and Drug Administration], that actually recommends whether the vaccines get licensed or not, and so that’s where the recommendations come from.
    “… Traditionally, they have not done evidence-based medicine. They only adopted evidence-based medicine about 12 years ago, and what we’ve said during our administration is we want to have safety studies prior to the licensure and recommendation of vaccines.
    “Vaccines are the only medical product that is exempt from pre-licensing safety testing. So the only vaccine that has been tested in a full-blown placebo trial against an inert placebo was the COVID vaccine. Of the other 76 shots that children in this country received between birth and 18 years old, none of them have been safety tested in pre-licensing studies against the placebo, which means we don’t understand the risk profile for those products, and that’s something that I intend to remedy.”

    MIL OSI USA News

  • MIL-OSI United Nations: 15 May 2025 News release WHO warns of slowing global health gains in new statistics report

    Source: World Health Organisation

    WHO published its World health statistics report 2025, revealing the deeper health impacts caused by the COVID-19 pandemic on loss of lives, longevity and overall health and well-being. In just two years, between 2019 and 2021, global life expectancy fell by 1.8 years—the largest drop in recent history— reversing a decade of health gains. Increased levels of anxiety and depression linked to COVID-19 reduced global healthy life expectancy by 6 weeks—erasing most of the gains made from lower mortality due to noncommunicable diseases (NCDs) during the same period.

    The report also summarizes global data on progress towards WHO’s triple billion targets, revealing impacts of not just the pandemic shock but also a longer trend of slowing progress starting before the pandemic, followed by a slower recovery since. WHO warns that overall progress is under threat and urgent global action is needed to get back on track.

    “Behind every data point is a person—a child who didn’t reach their fifth birthday, a mother lost in childbirth, a life cut short by a preventable disease,” said Dr Tedros Adhanom Ghebreyesus, WHO Director-General. “These are avoidable tragedies. They point to critical gaps in access, protection, and investment—especially for women and girls. Health progress is slowing. Every government has a responsibility to act, with urgency, commitment, and accountability to the people they serve.”

    Health progress and setbacks

    The World health statistics 2025 report presents mixed progress towards WHO’s Triple Billion targets. An estimated 1.4 billion more people were living healthier by the end of 2024, surpassing the 1 billion target. The progress in healthier lives was driven by reduction in tobacco use, improved air quality and better access to water, hygiene, and sanitation. But progress towards increased coverage of essential health services and protection from emergencies lagged; only 431 million more people gained access to essential health services without financial hardship, and close to 637 million more people were better protected from health emergencies.

    Maternal and child deaths are not falling fast enough to reach global targets. Progress has stalled, putting millions of lives at risk. This slowdown follows two decades of remarkable gains: between 2000 and 2023, maternal deaths dropped by over 40% and child deaths under 5 years of age more than halved. But underinvestment in primary health care, shortages of skilled health workers, and gaps in services like immunization and safe childbirth are now holding countries back.

    Without urgent course correction to meet the 2030 targets, the world risks losing the chance to prevent an additional 700 000 maternal deaths and 8 million under-5 deaths between 2024 and 2030.

    Chronic diseases leading to more loss of lives

    Premature deaths from NCDs—such as heart disease, stroke, diabetes, and cancer—are rising, driven by population growth and aging, and now account for most deaths among people under the age of 70, worldwide. The world is currently off track to reduce NCD premature mortality by one-third by 2030. Progress has been possible where governments and civil society have committed to action: tobacco use is declining, and global alcohol consumption dropped from 5.7 to 5.0 litres per capita between 2010 and 2022. Air pollution remains one of the top causes of preventable death worldwide. The impact of poor mental health continues to hold back progress.

    Recovery in essential health services remains incomplete. A shortfall of 11.1 million health workers is still projected by 2030, with nearly 70% of the gap concentrated in the WHO African and Eastern Mediterranean regions.

    “Strong health systems rely on strong health information. Timely, trusted data drives better decisions and faster results,” said Dr Haidong Wang, WHO Unit Head for Health Data and Analytics. “WHO is supporting countries through the SCORE strategy to strengthen health information systems, and through the World Health Data Hub, which is helping to standardize, improve, and unlock the value of data across countries and systems.”

    Uneven progress on infectious diseases

    HIV and TB incidence rates are falling, and fewer people need treatment for neglected tropical diseases. But malaria has been resurging since 2015, and antimicrobial resistance remains a public health challenge. In 2023, childhood vaccination coverage—including third dose diphtheria-pertussis-tetanus containing vaccine (DTP3)—had not returned to pre-pandemic levels. Many countries are also falling behind in addressing foundational health risks—such as malnutrition, air pollution, and unsafe living conditions.

    Recent disruptions in international aid further threaten to destabilize progress, particularly in countries with the greatest health-care needs. Sustained and predictable financing—from both domestic and international sources—is urgently needed to protect hard-won gains and respond to rising threats.

    “This report shows that the world is failing its health checkup. But countries have shown that rapid progress is possible,” said Dr Samira Asma, WHO Assistant Director-General for Data, Analytics and Delivery for Impact. “Together, we can achieve a world where data is timelier and more accurate, programmes improve continuously, and premature deaths become rare. With speed, scale, and smart investments, every country can deliver measurable gains.”

    Editors’ note: The World health statistics report is WHO’s annual compilation of the most recent available data on health and health-related indicators. For inquiries, contact healthstat@who.int

    MIL OSI United Nations News

  • MIL-OSI Economics: Gene therapies drive growth of genomics market, says GlobalData

    Source: GlobalData

    The integration of genomics into the pharmaceutical industry has allowed researchers to better understand the genetic factors underlying diseases, leading to the development of more targeted and effective therapies. Many of these therapies are designed to treat rare diseases that affect small patient populations. Generating $2.6 billion in sales in 2024, gene therapies are the key drivers of the growth of the genomics market, says GlobalData, a leading data and analytics company.

    GlobalData’s latest report, “Transformational Power of Genomics in Pharma,” reveals that the market for genomic therapies is demonstrating significant growth, with sales projected to increase from $20.1 billion in 2024 to $89.8 billion in 2030, at a compound annual growth rate (CAGR) of 28.3%. There are various types of genomic therapies, such as gene therapies, oncolytic viruses, oligonucleotides, messenger RNA (mRNA) vaccines, and recombinant vector vaccines.

    GlobalData estimates gene therapies to grow to $30.9 billion by 2030, representing the highest CAGR of 50.8% during 2024-30 in comparison to other key molecule types. This substantial growth in sales is forecast to be driven by Sarepta Therapeutics’ Elevidys (delandistrogene moxeparvovec) for the treatment of Duchenne muscular dystrophy (DMD), with sales forecast to reach $2.75 billion in 2030. Other key drivers include Novartis’ Zolgensma (onasemnogene abeparvovec) for the treatment of spinal muscular atrophy (SMA), with a sales forecast of $2.1 billion in 2030.

    Gaffar Aga, Strategic Intelligence Analyst at GlobalData, comments: “This growth is driven by factors such as the implementation of artificial intelligence (AI) and machine learning (ML) to efficiently analyze expanding genomic datasets, allowing researchers to accelerate processes such as drug discovery and development within the genomics landscape.”

    Furthermore, the oligonucleotide market is exhibiting growth in all sectors. The antisense RNAi oligonucleotide market is forecast to grow from $2.5 billion in 2024 to $18.7 billion in 2030, at a CAGR of 39.9%. The antisense oligonucleotide market is also exhibiting growth, with the market forecast to grow from $3.1 billion in 2024 to $14.3 billion in 2030 at a CAGR of 28.8%.

    Additionally, the mRNA vaccine market is forecast to exhibit steady growth, with sales increasing from $11 billion in 2024 to $17.9 billion in 2030 at a CAGR of 8.4%.

    Finally, the recombinant vector vaccine market is expected to generate the lowest number of sales, reaching $1.34 billion by 2030 at a CAGR of 31.4%.

    George El-Helou, Strategic Intelligence Analyst at GlobalData, concludes: “The field of genomics has the potential to revolutionize a wide range of diseases, offering alternative pathways of therapeutic options with high unmet medical needs. However, several market barriers remain, including the high costs associated with drug discovery, manufacturing, and logistical procedures within the industry.”

    MIL OSI Economics

  • MIL-OSI: Marex Group plc announces strong results for first quarter of 2025

    Source: GlobeNewswire (MIL-OSI)

    NEW YORK, May 15, 2025 (GLOBE NEWSWIRE) — Marex Group plc (‘Marex’ or the ‘Group’; Nasdaq: MRX) a diversified global financial services platform, providing essential liquidity, market access and infrastructure services to clients in the energy, commodities and financial markets, today reported financial results for the first quarter (‘Q1 2025’).

    Ian Lowitt, Group Chief Executive Officer, stated, “Robust levels of client activity across our businesses and positive market conditions led to a strong performance in the first quarter of the year. Adjusted profit before tax grew 42% year-on-year, driven by strong revenue growth in all our business segments. This reflects the continued successful execution of our strategy to expand our geographic footprint and product capabilities, growing our client base, increasing diversification and driving greater earnings resilience. In early April, we experienced some very high-volume days which we processed successfully, reflecting the operational resilience of our platform. We maintained record levels of liquidity and remained disciplined in managing our risk while supporting our clients. We were also delighted with the strong demand from investors for our second follow-on equity offering in challenging markets, further increasing our public float, as well as another successful debt issuance, further diversifying our sources of funding and increasing our liquidity position.”

    Financial and Operational Highlights:

    • Strong Q1 performance: Robust client activity and positive market conditions drove 42% growth in Adjusted Profit before Tax1 to $96.3 million
    • Revenue increased by 28% to $467.3m with strong revenue growth across all our business segments
      • Agency and Execution in particular increased revenue by 42% to $239.5m, driven by growth in Securities revenues across asset classes and continued build-out of Prime Services, as well as strong growth in the Energy business
    • April market conditions: At the start of April, we experienced highly elevated volumes which have since returned to more normalised levels. Our ability to process these volumes demonstrates the operational resilience of the firm and scalability of our platform. We also maintained record levels of liquidity and remained disciplined in managing our risk while supporting our clients
    • Executed growth strategy: Aarna Capital acquisition completed at the end of March, growing our Clearing presence in the Middle East, as we continued to diversify our platform and drive greater earnings resilience
    • Successful secondary equity placement: Significantly oversubscribed transaction resulted in existing shareholders placing an upsized 11.8 million shares with institutional investors in April, further increasing public float to approximately 70%
    • Prudent approach to capital and funding: Successfully issued $500 million 3-year senior unsecured notes in May, further diversifying our funding sources while maintaining a strong capital and liquidity position
    • Dividend: Q1 2025 dividend increased to $0.15 per share, to be paid in the second quarter of 2025
    Financial Highlights: ($m)   3 months ended 31 March 2025   3 months ended 31 March 2024   Change
                 
    Revenue   467.3   365.8   28%
    Profit Before Tax   98.0   58.9   66%
    Profit Before Tax Margin (%)   21%   16%   500 bps
    Profit After Tax   72.5   43.6   66%
    Profit After Tax Margin (%)   16%   12%   400 bps
    Return on Equity (%)   29%   23%   600 bps
    Basic Earnings per Share ($)2   0.98   0.60   63%
    Diluted Earnings per Share ($)2   0.92   0.56   64%
                 
    Adjusted Profit Before Tax1   96.3   67.7   42%
    Adjusted Profit Before Tax Margin (%)1   21%   19%   200 bps
    Adjusted Profit after Tax            
    Attributable to Common Equity1   68.2   48.9   39%
    Adjusted Return on Equity (%)1   30%   29%   100 bps
    Adjusted Basic Earnings per Share ($)1,2   0.97   0.74   31%
    Adjusted Diluted Earnings per Share ($)1,2   0.91   0.69   32%
    1. These are non-IFRS financial measures. See Appendix 1 “Non-IFRS Financial Measures and Key Performance Indicators” for additional information and for a reconciliation of each such non-IFRS measure to its most directly comparable IFRS measure. The Group changed the labelling of its non-IFRS measures during 2024 to better align to the equivalent IFRS reported metric and enhance transparency and comparability.
    2. Weighted average number of shares have been restated as applicable for the Group’s reverse share split (refer to Appendix 1 for further detail).
         
      Conference Call Information:
    Marex’s management will host a conference call to discuss the Group’s financial results today, 15 May 2025, at 9am Eastern Time. A live webcast of the call can be accessed from Marex’s Investor Relations website. An archived version will be available on the website after the call. To participate in the Conference Call, please register at the link here: https://edge.media-server.com/mmc/p/zudci4bx/

    Enquiries please contact:
    Marex
    Investors – Adam Strachan
    +1 914 200 2508 / astrachan@marex.com

    Media – Nicola Ratchford, Marex / FTI Consulting US / UK
    +44 7786 548 889 / nratchford@marex.com / +1.716.525.7239/ +44 7976870961
    | marex@fticonsulting.com

     
         


    Financial Review

    The following table presents summary financial results and other data as of the dates and for the periods indicated:

    Summary Financial Results

        3 months ended 31 March 2025   3 months ended 31 March 2024    
        $m   $m   Change
    – Net commission income   250.7   218.9   15%
    – Net trading Income   159.1   106.2   50%
    – Net interest income   53.4   35.6   50%
    – Net physical commodities income   4.1   5.1   (20)%
    Revenue   467.3   365.8   28%
                 
    Compensation and benefits   (291.7)   (229.9)   27%
    Depreciation and amortisation   (7.9)   (7.8)   1%
    Other expenses   (73.8)   (69.6)   6%
    Provision for credit losses     0.3   n.m.2
    Bargain purchase gain on acquisitions   3.4     n.m.2
    Other income   0.7   0.1   600%
    Profit Before Tax   98.0   58.9   66%
    Tax   (25.5)   (15.3)   67%
    Profit After Tax   72.5   43.6   66%
    Reconciliation to Adjusted Profit Before Tax1            
    Profit Before Tax   98.0   58.9   66%
    Bargain purchase gain   (3.4)     n.m.2
    Acquisition related costs     0.2   n.m.2
    Amortisation of acquired brands and customer lists   1.3   0.8   63%
    Activities relating to shareholders     2.4   n.m.2
    Owner fees   0.4   1.7   (76)%
    IPO preparation and public offering of ordinary shares     3.7   n.m.2
    Adjusting items   (1.7)   8.8   (119)%
    Adjusted Profit Before Tax1   96.3   67.7   42%
    1. These are non-IFRS financial measures. See Appendix 1 “Non-IFRS Financial Measures and Key Performance Indicators” for additional information and for a reconciliation of each such non-IFRS measure to its most directly comparable IFRS measure.
    2. n.m. = not meaningful to present as a percentage.

    Costs and Group Headcount

    The Board and Senior Management also monitor costs split between Front Office Costs and Control and Support Costs to better understand the Group’s performance. The table below provides the Group’s management view of costs:

        3 months ended 31 March 2025   3 months ended 31 March 2024    
        $m   $m   Change
    Front office costs1   (258.4)   (210.1)   23%
    Control and support costs1   (106.8)   (80.6)   33%
    Total   (365.2)   (290.7)   26%

    1) Management review Front Office Costs and Control and Support Costs when assessing Adjusted Profit Before Tax performance. These costs are included within compensation and benefits, other expenses and depreciation and amortisation in the Statutory Income Statement provided above.

    The following table provides a breakdown of Front Office and Control and Support Headcount

    Full Time Equivalent (‘FTE’) headcount1 31 March 2025   31 March 2024       31 March 2025   31 March 2024    
      Average   Average   Change   End of Period   End of Period   Change
    Front office 1,284   1,236   4%   1,288   1,250   3%
    Control and support 1,183   1,015   17%   1,215   1,030   18%
    Total 2,467   2,251   10%   2,503   2,280   10%

    1) For analysis purposes, average headcount is used in the performance commentary outlined below.

    Performance for the three months ended 31 March 2025

    Revenue grew by 28% to $467.3m (Q1 2024: $365.8m) with strong growth across all business segments, as we continue to diversify our platform and drive greater earnings resilience. This growth was driven by robust client activity and positive market conditions.

    Net commission income increased by 15% to $250.7m (Q1 2024: $218.9m). The growth was driven by Agency and Execution, which grew 22% to $182.9m (Q1 2024: $150.5m) reflecting a strong performance in Securities and Energy, supported by record transaction volumes.

    Net trading income increased by 50% to $159.1m (Q1 2024: $106.2m). The growth was driven by a $40.8m increase in Agency and Execution to $49.9m (Q1 2024: $9.1m), mainly due to Rates, FX and Equities. The most significant contribution came from the continued build-out of our Prime Services capabilities, which grew by $33.4m, including growth in our securities based swaps offering. In addition, Net trading income in our Market Making segment increased by $10.7m to $54.9m (Q1 2024: $44.2m) driven by growth in all asset classes.

    Net interest income increased by 50% to $53.4m (Q1 2024: $35.6m) reflecting $5.8bn growth in average balances to $17.1bn, which more than offset lower average Fed Funds rates compared to Q1 2024.

    Front office costs increased by 23% to $258.4m (Q1 2024: $210.1m), predominantly reflecting higher compensation costs on strong revenue performance across the Group. Front office headcount growth reflected restructuring activity in Agency and Execution and reallocation of FTE from front office to control and support in Q2 2024. Excluding these, average front office FTE headcount grew by 11% year on year.

    Control and support costs increased by 33% to $106.8m (Q1 2024: $80.6m). This was primarily driven by investment in technology to support automation and business growth, as well as investments in our finance, risk, and compliance functions to support our controlled growth and development as a public company. This also included specific investments relating to acquisitions and our compliance with Sarbanes-Oxley.

    Reported Profit Before Tax increased by 66% to $98.0m (Q1 2024: $58.9m), driven by strong revenue growth and improved operating margins.

    Adjusting items reduced by $10.5m to $(1.7)m (Q1 2024: $ 8.8m). These costs are primarily related to corporate activities and are recognised within our Corporate segment. Adjusting items reduced mainly due to IPO-related costs and owner fees in Q1 2024, as well as a bargain purchase gain on an acquisition in Q1 2025.

    As a result of the revenue and cost trends noted above, Adjusted Profit Before Tax1 increased by 42% to $96.3m (Q1 2024: $67.7m) and Adjusted Profit Before Tax Margin1 improved to 21% (Q1 2024: 19%), while Profit After Tax Margin increased to 16% (Q1 2024: 12%).

    1. These are non-IFRS financial measures. See Appendix 1 “Non-IFRS Financial Measures and Key Performance Indicators” for additional information and for a reconciliation of each such non-IFRS measure to its most directly comparable IFRS measure.
        3 months ended 31 March 2025   3 months ended 31 March 2024   Change
    Average Fed Funds rate   4.3%   5.3%   (100)bps
    Average balances ($bn)1   17.1   11.3   5.8
    Interest income ($m)   178.9   147.3   31.6
    Interest paid out ($m)   (59.6)   (60.9)   1.3
    Interest on balances ($m)   119.3   86.4   32.9
    Net yield on balances   2.8%   3.1%   (30)bps
    Average notional debt securities ($bn)   (4.1)   (2.5)   (1.6)
    Yield on debt securities %   6.6%   8.1%   (150)bps
    Interest expense ($m)   (65.9)   (50.8)   (15.1)
    Net Interest Income ($m)   53.4   35.6   17.8
    1. Average balances are calculated using an average of the daily holdings in exchanges, banks and other investments over the period. Previously, average balances were calculated as the average month end amount of segregated and non-segregated client balances that generated interest income over a given period.

    Segmental performance

    Clearing

    Marex provides clearing services across the range of energy, commodity and financial markets. We face the exchange on behalf of our clients providing access to 60 exchanges globally.

    Performance for the three months ended 31 March 2025

    Clearing performed well with revenue increasing 18% to $119.2m (Q1 2024: $100.7m). This was driven by net interest income which rose by $18.2m to $48.4m (Q1 2024: $30.2m) reflecting higher average balances as we continued to add new clients, more than offsetting lower average Fed Funds rates compared to Q1 2024. Net commission income reduced by 2%, $1.7m, as positive performance in energy and metals was offset by lower levels of activity in agriculture, which benefited from higher volatility in Q1 2024 relative to Q1 2025.

    Adjusted Profit Before Tax1 increased by 14% to $56.6m (Q1 2024: $49.8m). Adjusted Profit Before Tax Margin1 decreased by 200 bps to 47% (Q1 2024: 49%).

        3 months ended 31 March 2025   3 months ended 31 March 2024    
        $m   $m   Change
    Net commission income   67.8   69.5   (2%)
    Net interest income   48.4   30.2   60%
    Net trading income   3.0   1.0   200%
    Revenue   119.2   100.7   18%
    Front office costs   (42.2)   (33.5)   26%
    Control and support costs   (20.3)   (17.3)   17%
    Depreciation and amortisation   (0.1)   (0.1)   —%
                 
    Adjusted Profit Before Tax ($m)1   56.6   49.8   14%
    Adjusted Profit Before Tax Margin1   47%   49%   (200)bps
                 
    Front office headcount (No.)2   273   266   3%
                 
        12 months ended 31 March 2025   12 months ended 31 March 2024   Change
    Contracts cleared (m)   1,161   913   27%
    Market volumes (m)3   11,891   10,194   17%
    1. These are non-IFRS financial measures. See Appendix 1 “Non-IFRS Financial Measures and Key Performance Indicators” for additional information and for a reconciliation of each such non-IFRS measure to its most directly comparable IFRS measure.
    2. The headcount is the average for the period. Management have re-assessed headcount for Clearing and Market Making and re-allocated for Q1 25 and Q1 24.
    3. On a twelve month rolling basis.

    Agency and Execution

    Agency and Execution provides essential liquidity and execution services to our clients primarily in the energy and financial securities markets.

    Our energy division provides essential liquidity to clients by connecting buyers and sellers in the OTC energy markets to facilitate price discovery. We have leading positions in many of the markets we operate in, including key gas and power markets in Europe; environmental, petrochemical and crude markets in North America; and fuel oil, LPG (liquefied petroleum gas) and middle distillates globally. We achieve this through the breadth and depth of the service we offer to customers, including market intelligence for each product we transact in, based on the extensive knowledge and experience of our teams.

    Our presence in the financial markets is growing as we integrate and optimise recent acquisitions, enabling Marex to diversify its asset class coverage away from traditional commodity markets. We are starting to see a maturation of our offering across all asset classes, contributing to enhanced revenue growth and margin expansion for the overall business.

    Performance for the three months ended 31 March 2025

    Revenue increased by 42% to $239.5m (Q1 2024: $168.1m). Securities revenues, increased by $56.1m to $151.0m (Q1 2024: $94.9m) driven by growth in all asset classes from a significant increase in transaction volumes. The most significant contribution came from the continued build out of our Prime Services offering, including growth in securities based swaps. This was supplemented further by strong growth in our Energy business where revenues increased by $15.0m to $88.2m (Q1 2024: $73.2m), reflecting a combination of record volumes, good demand for our environmentals offering and the benefit of our bolt-on acquisitions.

    Adjusted Profit Before Tax1 increased by 152% to $56.7m (Q1 2024: $22.5m) while Adjusted Profit Before Tax Margin1 increased to 24% (Q1 2024: 13%) The margin improvement was driven by the benefit from restructuring in the business, as well as growth in higher margin activity, particularly Prime Services.

        3 months ended 31 March 2025   3 months ended 31 March 2024    
        $m   $m   Change
    Securities   151.0   94.9   59%
    Energy   88.2   73.2   20%
    Other revenue   0.3     n.m.3
    Revenue   239.5   168.1   42%
    Front office costs   (161.7)   (131.0)   23%
    Control and support costs   (21.0)   (14.1)   49%
    Provision for credit losses     (0.3)   n.m.3
    Depreciation and amortisation   (0.1)   (0.2)   (50)%
                 
    Adjusted Profit Before Tax ($m)1   56.7   22.5   152%
    Adjusted Profit Before Tax Margin1   24%   13%   1,100 bps
                 
    Front office headcount (No.)2   670   679   (1)%
                 
        12 months ended 31 March 2025   12 months ended 31 March 2024   Change
    Marex volumes: Energy (m)4   60   51   18%
    Marex volumes: Securities (m)4   302   249   21%
    Market volumes: Energy (m)4   1,816   1,477   23%
    Market volumes: Securities (m)4   11,330   9,872   15%
    1. These are non-IFRS financial measures. See Appendix 1 “Non-IFRS Financial Measures and Key Performance Indicators” for additional information and for a reconciliation of each such non-IFRS measure to its most directly comparable IFRS measure.
    2. The headcount is the average for the period.
    3. n.m. = not meaningful to present as a percentage.
    4. On a rolling twelve month basis

    Market Making

    Our Market Making business provides direct liquidity to our clients across a variety of products, primarily in the energy, metals and agriculture markets. This ability to make prices and trade as principal in a wide variety of energy, environmentals and commodity markets differentiates us from many of our competitors.

    Performance for the three months ended 31 March 2025

    Revenue increased by 27% to $52.9m (Q1 2024: $41.8m). This was driven by growth in all asset classes, in particular Securities revenues which increased by $7.2m primarily from growth in stock lending, which complements our Prime Services offering within Agency and Execution. Metals revenues growth was more muted, at 6%, due to the uncertainty arising from the potential implementation of global tariffs on base metals.

    Adjusted Profit Before Tax1 increased by 58% to $16.8m (Q1 2024: $10.6m), while Adjusted Profit Before Tax Margin1 increased to 32% (Q1 2024: 25%).

        3 months ended 31 March 2025   3 months ended 31 March 2024    
        $m   $m   Change
    Metals   22.7   21.4   6%
    Agriculture   7.2   5.6   29%
    Energy   8.6   7.6   13%
    Securities   14.4   7.2   100%
    Revenue   52.9   41.8   27%
    Front office costs   (28.9)   (22.9)   26%
    Control and support costs   (7.1)   (8.2)   (13)%
    Depreciation and amortisation   (0.1)   (0.1)   0%
                 
    Adjusted Profit Before Tax ($m)1   16.8   10.6   58%
    Adjusted Profit Before Tax Margin1   32%   25%   700 bps
                 
    Front office headcount (No.)2   144   125   15%
                 
    1. These are non-IFRS financial measures. See Appendix 1 “Non-IFRS Financial Measures and Key Performance Indicators” for additional information and for a reconciliation of each such non-IFRS measure to its most directly comparable IFRS measure.
    2. The headcount is the average for the period. Management have re-assessed headcount for Clearing and Market Making and re-allocated for Q1 25 and Q1 24.

    Hedging and Investment Solutions

    Our Hedging and Investment Solutions business provides high quality bespoke hedging and investment solutions to our clients.

    Tailored commodity hedging solutions enable corporates to hedge their exposure to movements in energy and commodity prices, as well as currencies and interest rates, across a variety of different time horizons.

    Our financial products offering allows investors to gain exposure to a particular market or asset class, for example equity indices, in a cost-effective manner through a structured product.

    Performance for the three months ended 31 March 2025

    Revenue grew by 9% to $45.0m (Q1 2024: $41.3m) driven by continued strong client demand and as we expanded the sales team which led to the onboarding of new clients. Financial products increased 41% to $30.7m (Q1 2024: $21.8m) as structured notes balances grew 49%. Hedging solutions decreased by 27% to $14.3m (Q1 2024: $19.5m) reflecting higher volatility in agriculture in Q1 2024 relative to Q1 2025.

    Adjusted Profit Before Tax1 decreased by 7% to $11.1m (Q1 2024: $11.9m), while Adjusted Profit Before Tax Margin1 decreased to 25% (Q1 2024: 29%), reflecting investment in our sales team and as a result of ongoing investment in our technology and platform to support future growth.

        3 months ended 31 March 2025   3 months ended 31 March 2024    
        $m   $m   Change
    Hedging solutions   14.3   19.5   (27)%
    Financial products   30.7   21.8   41%
    Revenue   45.0   41.3   9%
    Front office costs   (25.6)   (22.7)   13%
    Control and support costs   (8.1)   (6.6)   23%
    Depreciation and amortisation   (0.2)   (0.1)   100%
                 
    Adjusted Profit Before Tax ($m)1   11.1   11.9   (7)%
    Adjusted Profit Before Tax Margin1   25%   29%   (400 bps)
                 
    Front office headcount (No.)2   197   166   19%
    Structured notes balance ($m)3   3,123.3   2,095.6   49%
    1. These are non-IFRS financial measures. See Appendix 1 “Non-IFRS Financial Measures and Key Performance Indicators” for additional information and for a reconciliation of each such non-IFRS measure to its most directly comparable IFRS measure.
    2. The headcount is the average for the period.
    3. The Structured Notes portfolio consisted of 5,099 notes with an average maturity of 16 months and a total value of $3,123.3m (2024: 2,999 notes with an average maturity of 15 months and a total value of $2,095.6m).

    Corporate

    The Corporate segment includes the Group’s control and support functions. Corporate manages the resources of the Group, makes investment decisions and provides operational support to the business segments. Corporate Net Interest Income is derived through earning interest on house cash balances placed at banks and exchanges.

    Revenue decreased by $3.2m to $10.7m (Q1 2024: $13.9m) driven by lower investment returns on House cash balances from a reduction in the average Fed Funds rate.

        3 months ended 31 March 2025   3 months ended 31 March 2024    
        $m   $m   Change
    Revenue   10.7   13.9   (23%)
    Control and support costs3   (50.3)   (34.4)   46%
    (Provision)/recovery for credit losses     0.6   (100%)
    Depreciation and amortisation   (6.0)   (7.3)   (18%)
    Other income   0.7   0.1   600%
                 
    Adjusted Loss Before Tax ($m)1   (44.9)   (27.1)   66%
                 
    Control and support headcount (No.)2   1,183   1,015   17%
    1. These are non-IFRS financial measures. See Appendix 1 “Non-IFRS Financial Measures and Key Performance Indicators” for additional information and for a reconciliation of each such non-IFRS measure to its most directly comparable IFRS measure.
    2. The headcount is the average for the period.
    3. Control and support costs are presented on an unallocated basis.

    Summary Financial Position

    The Group’s equity base increased during Q1 25 with total equity increasing by $69.3m, 7% to $1,046.2m as a result of strong profitability during the quarter.

    Total assets and total liabilities have been steady during the first quarter. Our balance sheet continues to consist of high-quality liquid assets which underpin client activity on our platform. Total assets increased slightly from $24.3bn as at 31 December 2024 to $24.4bn as at 31 March 2025 with growth in Securities balances broadly offset by a reduction in Trade Receivables.

    Total liabilities remained steady at $23.3bn; an increase of $0.5bn due to issuance of Debt Securities was offset by a $0.5bn reduction in Trade Payables.

        31 March 2025   31 December 2024    
        $m   $m   Change
    Cash & Liquid Assets1   6,200.4   6,213.0   —%
    Trade Receivables   7,225.2   7,553.2   (4%)
    Reverse Repo Agreements   2,499.4   2,490.4   —%
    Securities2   6,749.0   6,459.7   4%
    Derivative Instruments   1,132.4   1,163.5   (3%)
    Other Assets3   268.6   199.7   35%
    Goodwill and Intangibles   279.5   233.0   20%
    Total Assets   24,354.5   24,312.5   —%
    Trade Payables   9,204.0   9,740.4   (6%)
    Repurchase Agreements   2,386.0   2,305.8   3%
    Securities4   6,450.3   6,656.7   (3%)
    Debt Securities   4,072.6   3,604.5   13%
    Derivative Instruments   798.4   751.7   6%
    Other Liabilities5   397.0   276.5   44%
    Total Liabilities   23,308.3   23,335.6   —%
    Total Equity   1,046.2   976.9   7%
    1. Cash & Liquid Assets are cash and cash equivalents, treasury instruments pledged as collateral, treasury instruments unpledged and fixed income securities.
    2. Securities assets are equity instruments and stock borrowing.
    3. Other Assets are inventory, corporate income tax receivable, deferred tax, investments, right-of-use assets, and property plant and equipment.
    4. Securities liabilities are stock lending and short securities.
    5. Other Liabilities are short term borrowings, deferred tax liability, lease liability, provisions and corporation tax.

     Liquidity

        31 March   31 December
        2025   2024
        $m   $m
    Total available liquid resources   2,682.4   2,439.8
    Liquidity headroom   1,217.4   1,060.0

    A prudent approach to capital and liquidity and commitment to maintaining an investment grade credit rating are core principles which underpin the successful delivery of our growth strategy. As at 31 March 2025, the Group held $2,682.4m of total available liquid resources, including the undrawn portion of the RCF (2024: $2,439.8m).

    Group liquidity resources consist of cash and high-quality liquid assets that can be quickly converted to meet immediate and short-term obligations. The resources include non-segregated cash, short-term money market funds and unencumbered securities guaranteed by the U.S. Government. The Group also includes any undrawn portion of its committed revolving credit facility (‘RCF’) in its total available liquid resources. The unsecured revolving credit facility of $150m remains undrawn as at 31 March 2025 (31 December 2024: $150m, undrawn). Facilities held by operating subsidiaries, and which are only available to that relevant subsidiary, have been excluded from these figures as they are not available to the entire Group.

    Liquidity headroom is based on the Group’s Liquid Asset Threshold Requirement, which is prepared according to the principles of the UK Investment Firms Prudential Regime (IFPR). The requirement includes a liquidity stress impact calculated from a combination of systemic and idiosyncratic risk factors.

    Regulatory capital

    The Group is subject to consolidated supervision by the UK Financial Conduct Authority and has regulated subsidiaries in jurisdictions both inside and outside of the UK.

    The Group is regulated as a MIFIDPRU investment firm under IFPR. The minimum capital requirement as at 31 March 2025 was determined by the Own Funds Threshold Requirement (‘OFTR’) set via an assessment of the Group’s capital adequacy and risk assessment conducted annually.

    The Group and its subsidiaries are in compliance with their regulatory requirements and are appropriately capitalised relative to the minimum requirements as set by the relevant competent authority. The Group maintained a capital surplus over its regulatory requirements at all times.

    The Group manages its capital structure in order to comply with regulatory requirements, ensuring its capital base is more than adequate to cover the risks inherent in the business and to maximise shareholder value through the strategic deployment of capital to support the Group’s growth and strategic development. The Group performs business model assessment, business and capital forecasting, stress testing and recovery planning at least annually. The following table summarises the Group’s capital position as at 31 March 2025 and 31 December 2024:

        31 March
    2025
      31 December
    2024
        $m   $m
    Core equity Tier 1 Capital1   652.5   623.9
    Additional Tier 1 Capital (net of issuance costs)   97.6   97.6
    Tier 2 Capital   1.4   1.6
    Total Capital resources   751.5   723.1
             
             
    Own Funds Threshold Requirement2   308.8   308.8
    Total Capital ratio3   243%   234%
    1. Total Capital Resources include unaudited results for the financial period.
    2. Own Funds Requirement presented as Own Funds Threshold Requirement based on the latest ICARA process.
    3. The Group’s Total Capital Resources as a percentage of Own Funds Requirement.

    At 31 March 2025, the Group had a Total Capital Ratio of 243% (31 December 2024: 234%), representing significant capital headroom to minimum requirements. The increase in the Total Capital Ratio resulted from an increase in total capital resources due to profit (unaudited) in 2025.

    Dividend

    The Board of Directors approved an interim dividend of $0.15 per share, expected to be paid on 10 June 2025 to shareholders on record as at close of business on 27 May 2025.

    Forward Looking Statements:

    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including expected financial results and dividend payments. In some cases, these forward-looking statements can be identified by words or phrases such as “may,” “will,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “is/are likely to” or other similar expressions.

    These forward-looking statements are subject to risks, uncertainties and assumptions, some of which are beyond our control. In addition, these forward-looking statements reflect our current views with respect to future events and are not a guarantee of future performance. Actual outcomes may differ materially from the information contained in the forward-looking statements as a result of a number of factors, including, without limitation: subdued commodity market activity or pricing levels; the effects of geopolitical events, terrorism and wars, such as the effect of Russia’s military action in Ukraine or the ongoing conflict in the Middle East, on market volatility, global macroeconomic conditions and commodity prices; changes in interest rate levels; the risk of our clients and their related financial institutions defaulting on their obligations to us; regulatory, reputational and financial risks as a result of our international operations; software or systems failure, loss or disruption of data or data security failures; an inability to adequately hedge our positions and limitations on our ability to modify contracts and the contractual protections that may be available to us in OTC derivatives transactions; market volatility, reputational risk and regulatory uncertainty related to commodity markets, equities, fixed income, foreign exchange; the impact of climate change and the transition to a lower carbon economy on supply chains and the size of the market for certain of our energy products; the impact of changes in judgments, estimates and assumptions made by management in the application of our accounting policies on our reported financial condition and results of operations; lack of sufficient financial liquidity; if we fail to comply with applicable law and regulation, we may be subject to enforcement or other action, forced to cease providing certain services or obliged to change the scope or nature of our operations; significant costs, including adverse impacts on our business, financial condition and results of operations, and expenses associated with compliance with relevant regulations; and if we fail to remediate the material weaknesses we identified in our internal control over financial reporting or prevent material weaknesses in the future, the accuracy and timing of our financial statements may be impacted, which could result in material misstatements in our financial statements or failure to meet our reporting obligations and subject us to potential delisting, regulatory investments or civil or criminal sanctions, and other risks discussed under the caption “Risk Factors” in our Annual Report on Form 20-F for the year ended 31 December 2024 filed with the Securities and Exchange Commission (the “SEC”) as updated by our other reports filed with the SEC.

    The forward-looking statements made in this press release relate only to events or information as of the date on which the statements are made in this press release. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events.

    In addition, statements that “we believe” and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this press release, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and investors are cautioned not to unduly rely upon these statements.

    Appendix 1

    Non-IFRS Financial Measures and Key Performance Indicators

    This press release contains non-IFRS financial measures, including Adjusted Profit Before Tax, Adjusted Profit Before Tax Margin, Adjusted Basic Earnings per Share, Adjusted Diluted Earnings per Share, Adjusted Profit After Tax Attributable to Common Equity and Adjusted Return on Equity. These non-IFRS financial measures are presented for supplemental informational purposes only and should not be considered a substitute for profit after tax, profit margin, return on equity or any other financial information presented in accordance with IFRS and may be different from similarly titled non-IFRS financial measures used by other companies. The Group changed the labelling of its non-IFRS measures during 2024 to better align to the equivalent IFRS reported metric and enhance transparency and comparability.

    Adjusted Profit Before Tax (formerly labelled Adjusted Operating Profit)

    We define Adjusted Profit Before Tax as profit after tax adjusted for (i) tax, (ii) goodwill impairment charges, (iii) acquisition costs, (iv) bargain purchase gain, (v) owner fees, (vi) amortisation of acquired brands and customer lists, (vii) activities in relation to shareholders, (viii) employer tax on the vesting of Growth Shares, (ix) IPO preparation costs, (x) fair value of the cash settlement option on the Growth Shares and (xi) public offering of ordinary shares. Items (i) to (xi) are referred to as “Adjusting Items.” Adjusted Profit Before Tax is the primary measure used by our management to evaluate and understand our underlying operations and business trends, forecast future results and determine future capital investment allocations. Adjusted Profit Before Tax is the measure used by our executive board to assess the financial performance of our business in relation to our trading performance. The most directly comparable IFRS Accounting Standards measure is profit after tax. We believe Adjusted Profit Before Tax is a useful measure as it allows management to monitor our ongoing core operations and provides useful information to investors and analysts regarding the net results of the business. The core operations represent the primary trading operations of the business.

    Adjusted Profit Before Tax Margin (formerly labelled Adjusted Operating Profit Margin)

    We define Adjusted Profit Before Tax Margin as Adjusted Profit Before Tax (as defined above) divided by revenue. We believe that Adjusted Profit Before Tax Margin is a useful measure as it allows management to assess the profitability of our business in relation to revenue. The most directly comparable IFRS Accounting Standards measure is profit margin, which is Profit after Tax divided by revenue.

    Adjusted Profit After Tax Attributable to Common Equity (formerly labelled Adjusted Operating Profit after Tax Attributable to Common Equity)

    We define Adjusted Profit After Tax Attributable to Common Equity as profit after tax adjusted for the items outlined in the Adjusted Profit Before Tax paragraph above. Additionally, Adjusted Profit After Tax Attributable to Common Equity is also adjusted for (i) tax and the tax effect of the Adjusting Items to calculate Adjusted Profit Before Tax and (ii) profit attributable to Additional Tier 1 (“AT1”) note holders, net of tax, which is the coupons on the AT1 issuance and accounted for as dividends, adjusted for the tax benefit of the coupons. We define Common Equity as being the equity belonging to the holders of the Group’s share capital. We believe Adjusted Profit After Tax Attributable to Common Equity is a useful measure as it allows management to assess the profitability of the equity belonging to the holders of the Group’s share capital. The most directly comparable IFRS Accounting Standards measure is profit after tax.

    Adjusted Return on Equity (formerly labelled Return on Adjusted Operating Profit after Tax Attributable to Common Equity)

    We define the Adjusted Return on Equity as the Adjusted Profit After Tax Attributable to Common Equity (as defined above) divided by the average Common Equity for the period. Common Equity is defined as being the equity belonging to the holders of the Group’s share capital. Common Equity is calculated as the average balance of total equity minus additional Tier 1 capital. For the period ended 31 March 2025 and 2024, Common Equity is calculated as the average balance of total equity minus additional Tier 1 capital as at 31 December of the prior year and 31 March of the current year. For the three months ended 31 March 2025 and 2024, Adjusted Return on Equity is calculated for comparison purposes on an annualised basis as Adjusted Profit After Tax Attributable to Common Equity for the period multiplied by four and then divided by average Common Equity for the period. It is presented on an annualised basis for comparison purposes.

    We believe Adjusted Return on Equity is a useful measure as it allows management to assess the return on the equity belonging to the holders of the Group’s share capital. The most directly comparable IFRS Accounting Standards measure for Adjusted Return on Equity is Return on Equity, which is calculated as profit after tax for the period divided by average equity. Average Equity for the period ended 31 March 2025 and 2024 is calculated as the average of total equity at 31 December of the prior year and 31 March of the current year. For the three months ended 31 March 2025 and 2024, Return on Equity is calculated for comparison purposes on an annualised basis as Profit After Tax for the period multiplied by four and then divided by Average Equity for the period. It is presented on an annualised basis for comparison purposes.

    Adjusted Basic Earnings per Share and Adjusted Diluted Earnings per Share

    Adjusted Basic Earnings per Share is defined as the Adjusted Profit After Tax Attributable to Common Equity (as defined above) for the period divided by weighted average number of ordinary shares for the period. We believe Adjusted Basic Earnings per Share is a useful measure as it allows management to assess the profitability of our business per share. The most directly comparable IFRS Accounting Standards metric is basic earnings per share. This metric has been designed to highlight the Adjusted Profit After Tax Attributable to Common Equity over the available share capital of the Group. Adjusted Diluted Earnings per Share is defined as the Adjusted Profit After Tax Attributable to Common Equity for the period divided by the diluted weighted average shares for the period. We believe Adjusted Diluted Earnings per Share is a useful measure as it allows management to assess the profitability of our business per share on a diluted basis. Dilution is calculated in the same way as it has been for diluted earnings per share. The most directly comparable IFRS Accounting Standards metric is diluted earnings per share.

    We believe that these non-IFRS financial measures provide useful information to both management and investors by excluding certain items that management believes are not indicative of our ongoing operations. Our management uses these non-IFRS financial measures to evaluate our business strategies and to facilitate operating performance comparisons from period to period. We believe that these non-IFRS financial measures provide useful information to investors because they improve the comparability of our financial results between periods and provide for greater transparency of key measures used to evaluate our performance. In addition these non-IFRS financial measures are frequently used by securities analysts, investors and other interested parties in their evaluation of companies comparable to us, many of which present related performance measures when reporting their results.

    These non-IFRS financial measures are used by different companies for differing purposes and are often calculated in different ways that reflect the circumstances of those companies. In addition, certain judgments and estimates are inherent in our process to calculate such non-IFRS financial measures. You should exercise caution in comparing these non-IFRS financial measures as reported by other companies.

    These non-IFRS financial measures have limitations as analytical tools, and you should not consider them in isolation or as substitutes for analysis of our results as reported under IFRS Accounting Standards. Some of these limitations are:

    • they do not reflect costs incurred in relation to the acquisitions that we have undertaken;
    • they do not reflect impairment of goodwill;
    • other companies in our industry may calculate these measures differently than we do, limiting their usefulness as comparative measures; and
    • the adjustments made in calculating these non-IFRS financial measures are those that management considers to be not representative of our core operations and, therefore, are subjective in nature.

    Accordingly, prospective investors should not place undue reliance on these non-IFRS financial measures.

    We also use key performance indicators (“KPIs”) such as Average Balances, Trades Executed, and Contracts Cleared to assess the performance of our business and believe that these KPIs provide useful information to both management and investors by showing the growth of our business across the periods presented.

    Our management uses these KPIs to evaluate our business strategies and to facilitate operating performance comparisons from period to period. We define certain terms used in this release as follows:

    “FTE” means the number of our full-time equivalents as of the end of a given period, which includes permanent employees and contractors.

    “Average FTE” means the average number of our full-time equivalents over the period, including permanent employees and contractors.

    “Average Balances” means the average of the daily holdings in exchanges, banks and other investments over the period. Previously, average balances were calculated as the average month end amount of segregated and non-segregated client balances that generated interest income over a given period.

    “Trades Executed” means the total number of trades executed on our platform in a given year.

    “Total Capital Ratio” means our total capital resources in a given period divided by the capital requirement for such period under the IFPR.

    “Contracts Cleared” means the total number of contracts cleared in a given period.

    “Market Volumes” are calculated as follows:

    • All volumes traded on Marex key exchanges (CBOT, CME, Eurex, Euronext, ICE, LME, NYMEX COMEX, SGX)
    • Energy volumes on CBOT, Eurex, ICE, NYMEX, SGX
    • Financial securities (corporate bonds, equities, FX, repo, volatility) on CBOE, CBOT, CME, Eurex, Euronext, ICE, SGX
    • Metals, agriculture and energy volumes on CBOT, CME, Eurex, Euronext, ICE, LME, NYMEX COMEX, SGX

    Reconciliation of Non-IFRS Financial Measures and Key Performance Indicators:

        3 months ended 31 March 2025   3 months ended 31 March 2024
             
        $m   $m
    Profit After Tax   72.5   43.6
    Taxation charge   25.5   15.3
    Profit Before Tax   98.0   58.9
    Goodwill impairment charge1    
    Bargain purchase gain (provisional accounting)2   (3.4)  
    Acquisition costs3     0.2
    Amortisation of acquired brands and customer lists4   1.3   0.8
    Activities relating to shareholders5     2.4
    Employer tax on vesting of the growth shares6    
    Owner fees7   0.4   1.7
    IPO preparation costs8     3.7
    Fair value of the cash settlement option on the growth shares9    
    Public offering of ordinary shares10    
    Adjusted Profit Before Tax   96.3   67.7
    Tax and the tax effect on the Adjusting Items11   (24.8)   (15.5)
    Profit attributable to AT1 note holders12   (3.3)   (3.3)
    Adjusted Profit After Tax Attributable to Common Equity   68.2   48.9
             
    Profit after Tax Margin   16%   12%
    Adjusted Profit Before Tax Margin13   21%   19%
             
    Basic Earnings per Share ($)   0.98   0.60
    Diluted Earnings per Share ($)   0.92   0.56
             
    Adjusted Basic Earnings per Share ($)14   0.97   0.74
    Adjusted Diluted Earnings per Share ($)14   0.91   0.69
             
    Weighted average number of shares14   70,541,771   65,683,374
    Period end number of shares14   71,231,706   68,375,690
             
    Common Equity15   913.7   676.0
    Return on Equity   29%   23%
    Adjusted Return on Equity (%)   30%   29%
    1. No goodwill impairment has been booked for either period.
    2. A bargain purchase gain was recognised as a result of the Group’s acquisition of Darton Group Limited (“Darton”) . Provisional accounting under IFRS 3 has been applied as at Q1 ’25.
    3. Acquisition costs are costs, such as legal fees incurred in relation to the business acquisitions of Cowen’s prime services and Outsourced Trading business.
    4. This represents the amortisation charge for the period of acquired brands and customers lists.
    5. Activities in relation to shareholders primarily consist of dividend-like contributions made to participants within certain of our share-based payments schemes.
    6. Employer tax on vesting of the growth shares represents the Group’s tax charge arising from the vesting of the growth shares.
    7. Owner fees relate to management services fees paid to parties associated with the ultimate controlling party based on a percentage of our EBITDA in each year, presented in the income statement within other expenses. This agreement ended once the Group became listed, however as the calculation in based on audited full year EBITDA, the payment in Q1 25 represents the final adjustments to the fees owed.
    8. IPO preparation costs related to consulting, legal and audit fees, presented in the income statement within other expenses.
    9. Fair value of the cash settlement option on the growth shares represents the fair value liability of the growth shares at $2.3m. Subsequent to the initial public offering when the holders of the growth shares elected to settle the awards in ordinary shares, the liability was derecognised.
    10. Costs relating to the public offerings of ordinary shares by certain selling shareholders.
    11. Tax and the tax effect on the Adjusting Items represents the tax for the period and the tax effect of the other Adjusting Items removed from Profit After Tax to calculate Adjusted Profit Before Tax. The tax effect of the other Adjusting Items was calculated at the Group’s effective tax rate for the respective period.
    12. Profit attributable to AT1 note holders are the coupons on the AT1 issuance, which are accounted for as dividends.
    13. Adjusted Profit Before Tax Margin is calculated by dividing Adjusted Profit Before Tax (as defined above) by revenue for the period.
    14. The weighted average numbers of diluted shares used in the calculation for the three months ended 31 March 2025 and 2024 were 74,934,788 and 70,383,309 respectively. Weighted average number of shares have been restated as applicable for the Group’s reverse share split. As at 31 March 2025, the dilution impact was 4,393,017 shares (31 March 2024: 4,699,934 shares).
    15. Common Equity is calculated as the average balance of total equity minus additional Tier 1 capital. For the three months ended 31 March 2025 and 2024, Adjusted Return on Equity is calculated as the average balance of total equity minus additional Tier 1 capital, as at 31 December of the prior year and 31 March of the current year.

    Appendix 2 – Supplementary Financial Information

    Revenue

    The following tables present the Group’s segmental revenue for the periods indicated:

    3 months ended 31 March 2025 Clearing   Agency and Execution   Market Making   Hedging and Investment Solutions   Corporate   Total
      $m   $m   $m   $m   $m   $m
                           
    Net commission income 67.8   182.9         250.7
    Net trading income 3.0   49.9   54.9   51.3     159.1
    Net interest income/(expense) 48.4   5.6   (5.0)   (6.3)   10.7   53.4
    Net physical commodities income   1.1   3.0       4.1
    Revenue 119.2   239.5   52.9   45.0   10.7   467.3
    3 months ended 31 March 2024 Clearing   Agency and Execution   Market Making   Hedging and Investment Solutions   Corporate   Total
      $m   $m   $m   $m   $m   $m
                           
    Net commission income/(expense) 69.5   150.5   (1.1)       218.9
    Net trading income 1.0   9.1   44.2   51.9     106.2
    Net interest income/(expense) 30.2   8.0   (5.9)   (10.6)   13.9   35.6
    Net physical commodities income   0.5   4.6       5.1
    Revenue 100.7   168.1   41.8   41.3   13.9   365.8


    Consolidated Income Statement

    For the Three Months Ended 31 March 2025

        31 March
    2025
      31 March
    2024
        $m   $m
    Commission and fee income   503.7   400.6
    Commission and fee expense   (253.0)   (181.7)
    Net commission income   250.7   218.9
    Net trading income   159.1   106.2
    Interest income   198.8   163.2
    Interest expense   (145.4)   (127.6)
    Net interest income   53.4   35.6
    Net physical commodities income   4.1   5.1
    Revenue   467.3   365.8
             
    Expenses:        
    Compensation and benefits   (291.7)   (229.9)
    Depreciation and amortisation   (7.9)   (7.8)
    Other expenses   (73.8)   (69.6)
    Provision for credit losses     0.3
    Bargain purchase gain on acquisition   3.4  
    Other income   0.7   0.1
    Profit before tax   98.0   58.9
    Tax   (25.5)   (15.3)
    Profit after tax   72.5   43.6
             

    Consolidated Statement of Financial Position

    As at 31 March 2025

        31 March   31 December
        2025   2024
        $m   $m
    Assets        
    Non-current assets        
    Goodwill   225.0   176.5
    Intangible assets   54.5   56.5
    Property, plant and equipment   22.8   20.8
    Right-of-use asset   64.0   59.9
    Investments   25.7   24.0
    Deferred tax   29.5   46.7
    Treasury instruments (unpledged)   3.8   53.5
    Treasury instruments (pledged as collateral)   153.9   46.1
    Total non-current assets   579.2   484.0
             
    Current assets        
    Corporate income tax receivable   22.5   12.5
    Trade and other receivables   7,225.2   7,553.2
    Inventory   104.1   35.8
    Equity instruments (unpledged)   210.2   231.4
    Equity instruments (pledged as collateral)   4,627.2   4,446.6
    Derivative instruments   1,132.4   1,163.5
    Stock borrowing   1,911.6   1,781.7
    Treasury instruments (unpledged)   478.8   556.2
    Treasury instruments (pledged as collateral)   2,827.5   2,912.9
    Fixed income securities (unpledged)   129.7   87.7
    Reverse repurchase agreements   2,499.4   2,490.4
    Cash and cash equivalents   2,606.7   2,556.6
    Total current assets   23,775.3   23,828.5
    Total assets   24,354.5   24,312.5
        31 March   31 December
        2025   2024
        $m   $m
    Liabilities        
    Current liabilities        
    Repurchase agreements   2,386.0   2,305.8
    Trade and other payables   9,204.0   9,740.4
    Stock lending   4,481.3   4,952.1
    Short securities   1,969.0   1,704.6
    Short-term borrowings   271.1   152.0
    Lease liability   9.7   10.5
    Derivative instruments   798.4   751.7
    Corporation tax   39.0   41.9
    Debt securities   2,609.9   2,119.6
    Provisions   0.7   0.6
    Total current liabilities   21,769.1   21,779.2
    Non-current liabilities        
    Lease liability   73.4   67.0
    Debt securities   1,462.7   1,484.9
    Deferred tax liability   3.1   4.5
    Total non-current liabilities   1,539.2   1,556.4
    Total liabilities   23,308.3   23,335.6
    Total net assets   1,046.2   976.9
             
    Equity        
    Share capital   0.1   0.1
    Share premium   220.0   202.6
    Additional Tier 1 capital (AT1)   97.6   97.6
    Retained earnings   775.3   722.4
    Own shares   (48.9)   (23.2)
    Other reserves   2.1   (22.6)
    Total equity   1,046.2   976.9
             

    The MIL Network

  • MIL-OSI United Nations: 15 May 2025 Statement Statement on the antigen composition of COVID-19 vaccines

    Source: World Health Organisation

    Key points:

    • Vaccination remains an important public health countermeasure against COVID-19. As per the WHO Director General’s standing recommendations for COVID-19, Member States are recommended to continue to offer COVID-19 vaccination based on the recommendations of the WHO Strategic Advisory Group of Experts on Immunization (SAGE).
    • SARS-CoV-2 continues to undergo sustained evolution since its emergence in humans, with important genetic and antigenic changes in the spike protein.
    • The objective of an update to COVID-19 vaccine antigen composition is to enhance vaccine-induced immune responses to circulating SARS-CoV-2 variants.
    • The WHO Technical Advisory Group on COVID-19 Vaccine Composition (TAG-CO-VAC) advises manufacturers that monovalent JN.1 or KP.2 vaccines remain appropriate vaccine antigens; monovalent LP.8.1 is a suitable alternative vaccine antigen.
    • In accordance with WHO SAGE policy, vaccination should not be delayed in anticipation of access to vaccines with an updated composition.

    The WHO Technical Advisory Group on COVID-19 Vaccine Composition (TAG-CO-VAC) continues to closely monitor the genetic and antigenic evolution of SARS-CoV-2 variants, immune responses to SARS-CoV-2 infection and COVID-19 vaccination, and the performance of COVID-19 vaccines against circulating variants. Based on these evaluations, WHO advises vaccine manufacturers and regulatory authorities on the implications for future updates to COVID-19 vaccine antigen composition. In April 2024, the TAG-CO-VAC recommended the use of a monovalent JN.1 lineage vaccine antigen as one approach to induce enhanced neutralizing antibody responses to JN.1 and its descendent lineages. In December 2024, the TAG-CO-VAC advised retaining the use of a monovalent JN.1 lineage vaccine antigen. Multiple manufacturers (using mRNA, recombinant protein-based, and adenovirus-vectored platforms) have updated COVID-19 vaccine antigen composition to monovalent JN.1 lineage formulations (JN.1 or KP.2). Several of these vaccines have been approved for use by regulatory authorities and introduced into vaccination programmes in some countries during the second half of 2024. Previous statements from the TAG-CO-VAC can be found on the WHO website.

    The TAG-CO-VAC reconvened on 6-7 May 2025 to review the genetic and antigenic evolution of SARS-CoV-2; immune responses to SARS-CoV-2 infection and/or COVID-19 vaccination; the performance of currently approved vaccines against circulating SARS-CoV-2 variants; and the implications for COVID-19 vaccine antigen composition.

    Evidence reviewed

    The published and unpublished evidence reviewed by the TAG-CO-VAC included: (1) SARS-CoV-2 genetic evolution with additional support from the WHO Technical Advisory Group on SARS-CoV-2 Virus Evolution (TAG-VE); (2) Antigenic characterization of previous and emerging SARS-CoV-2 variants using virus neutralization tests with animal antisera and further analysis of antigenic relationships using antigenic cartography; (3) Immunogenicity data on the breadth of neutralizing antibody responses elicited by currently approved vaccine antigens against circulating SARS-CoV-2 variants using animal and human sera; (4) Preliminary immunogenicity data on immune responses following infection with circulating SARS-CoV-2 variants; (5) Available vaccine effectiveness (VE) estimates of currently approved vaccines during periods of JN.1 lineage circulation; and (6) Preliminary non-clinical and clinical immunogenicity data on the performance of candidate vaccines with updated antigens shared confidentially by vaccine manufacturers with TAG-CO-VAC. Further details on the data reviewed by the TAG-CO-VAC can be found in the accompanying data annex. Confidential data reviewed by the TAG-CO-VAC are not shown.

    Summary of available evidence

    • There are persistent and increasing gaps in the reporting of cases, hospitalizations and deaths, from WHO Member States, making epidemiological trends difficult to infer. Nonetheless, in 2025, SARS-CoV-2 continues to circulate globally, causing severe disease, post COVID-19 condition, and death. The majority of COVID-19 deaths continue to occur in individuals aged 65 years and older and those with coexisting conditions. Some countries have reported an increase in incidence of COVID-19-related hospitalizations and deaths among children under 1 year of age, as compared to young adults, although this group still accounts for a small proportion of total COVID-19 hospitalizations and deaths.
    • As of May 2025, currently circulating SARS-CoV-2 variants are derived from JN.1. The weekly proportion of Variant Under Monitoring (VUM) LP.8.1 among all SARS-CoV-2 sequences submitted to GISAID continues to increase. The weekly proportion of JN.1 (Variant of Interest, VOI) is slowly increasing, largely due to increases in LF.7 and its descendent variants, while all other VUMs (KP.3, KP.3.1.1, XEC, and LB.1) are declining. 
    • Several JN.1 derived variants have independently evolved changes in the spike protein at epitopes known to be targeted by neutralizing antibodies.
    • Published and unpublished data using antisera from naïve hamsters infected with JN.1, KP.2, KP.3.1.1, XEC or LP.8.1 or mice immunized with mRNA vaccine antigens JN.1, KP.2 or KP.3 showed that JN.1, KP.2, KP.3.1.1, XEC, and LP.8.1 are antigenically closely related to each other (approximately 1 antigenic unit in cartographic analysis, which corresponds to a two-fold-difference in neutralization).
    • In published and unpublished data from humans, vaccination with monovalent JN.1 or KP.2 antigens significantly increased neutralizing antibody titers against all JN.1 descendent lineages tested:
      • Analysis of pre- and post-vaccination sera from JN.1 lineage (i.e. JN.1 or KP.2) immunized individuals demonstrated significant rises in neutralization of JN.1 and its descendent lineages, including KP.3.1.1, XEC, LF.7.2.1, and LP.8.1.
      • Neutralization titers against LP.8.1 were generally modestly lower (2-fold reduction) than those against the homologous JN.1 or KP.2 antigen.
    • Contemporary vaccine effectiveness (VE) estimates are relative (rVE), rather than absolute (comparing vaccinated to unvaccinated individuals), and demonstrate the added or incremental protection of recent vaccination over and above pre-existing infection- and vaccine-derived immunity. Monovalent JN.1 or KP.2 COVID-19 vaccines were introduced into some vaccination programmes in the second half of 2024. There are only a few studies estimating rVE for the monovalent JN.1 or KP.2 mRNA COVID-19 vaccines during periods of JN.1 descendent lineage circulation. Both vaccines demonstrated additional protection—relative to pre-existing immunity—against symptomatic and severe COVID-19 during the first three to four months after vaccination.
    • Data shared confidentially with the TAG-CO-VAC by vaccine manufacturers showed that:
      • Immunization of naïve mice, as well as of mice previously immunized with SARS-CoV-2 variants, with monovalent JN.1 or KP.2 vaccines resulted in high neutralizing antibody titers against JN.1 and its derivatives including KP.2, KP.3.1.1, XEC, LP.8.1, and LF.7.2. However, neutralization titers against LP.8.1 were typically lower than those against the homologous immunizing antigen.
      • Immunization of naïve mice, as well as of mice previously immunized with SARS-CoV-2 variants, with monovalent LP.8.1 vaccine candidates elicited high neutralizing antibody titers against the homologous antigen. Cross-neutralizing antibody titers elicited against other JN.1 lineage variants including JN.1, KP.2, KP.3, KP.3.1.1, XEC, and LF.7.2 were similar or modestly higher than those elicited by JN.1 or KP.2 antigens.
      • In humans, vaccination with monovalent JN.1 or KP.2 antigens resulted in robust neutralizing antibody responses to JN.1 and descendent variants, including KP.3.1.1, XEC, LP.8.1, and LF.7.2.
      • As in non-clinical data, analysis of pre- and post-vaccination sera from JN.1 or KP.2 immunized individuals showed some variation in neutralizing antibody titers against LP.8.1 and LF.7.2 across different studies. In most instances, they were similar or lower than those against the homologous JN.1 or KP.2 antigens.

    Overall, the currently approved monovalent JN.1 or KP.2 vaccines continue to elicit broadly cross-reactive immune responses to circulating JN.1-derived variants. LP.8.1 as a vaccine antigen offers similar or modestly increased cross-reactive antibody responses to circulating JN.1-derived variants, as compared to monovalent JN.1 or KP.2 vaccines. Mathematical modeling indicates that an increase in neutralizing antibody titers may translate into an improvement in vaccine effectiveness and duration of protection.

    The TAG-CO-VAC acknowledges several limitations of available data: 

    • There are persistent and increasing gaps in the reporting of cases, hospitalizations and deaths, from WHO Member States, as well as in genetic/genomic surveillance of SARS-CoV-2 globally, including low numbers of samples sequenced and limited geographic diversity. The TAG-CO-VAC strongly supports the ongoing work of the WHO Coronavirus Network (CoViNet) and the Global Influenza Surveillance and Response System (GISRS) to address this information gap.
    • The timing, specific mutations and antigenic characteristics of emerging and future variants are difficult to predict, and the potential public health impact of these variants remain unknown. There are JN.1-derived variants and long branch saltation variants that are currently detected in low or very low proportions, and which will continue to be monitored and/or characterized. The TAG-CO-VAC strongly supports the ongoing work of the TAG-VE. 
    • Although neutralizing antibody titers have been shown to be important correlates of protection from SARS-CoV-2 infection and of estimates of vaccine effectiveness, there are multiple components of immune protection elicited by infection and/or vaccination. Data on the immune responses following JN.1 descendent lineage infection or monovalent JN.1 or KP.2 vaccination are largely restricted to neutralizing antibodies. Data and interpretation of other aspects of the immune response, including cellular immunity, are limited. 
    • Immunogenicity data against currently circulating SARS-CoV-2 variants are not available for all COVID-19 vaccines. 
    • Estimates of rVE against recently circulating JN.1 variants are limited in terms of the number of studies, geographic diversity, vaccine platforms evaluated, populations assessed, duration of follow-up, and contemporary comparisons of vaccines with different antigen composition.

    Recommendations for COVID-19 vaccine antigen composition

    Monovalent JN.1 (NextStrain: 24A, GenBank: PP298019, GISAID: EPI_ISL_18872762) or KP.2 vaccines remain appropriate for ongoing use; monovalent LP.8.1 (NextStrain: 25A; GenBank: PV074550.1; GISAID: EPI_ISL_19467828) is a suitable alternative vaccine antigen.

    Other approaches that demonstrate broad and robust neutralizing antibody responses or efficacy against currently circulating JN.1 descendent lineage variants could also be considered.

    As per the WHO Director General’s standing recommendations for COVID-19, Member States are recommended to continue to offer COVID-19 vaccination based on the recommendations of the WHO SAGE. Vaccination should not be delayed in anticipation of access to vaccines with an updated composition.

    Further data requested

    Given the limitations of the evidence upon which the recommendations above are derived and the anticipated continued evolution of the virus, the TAG-CO-VAC strongly encourages generation of the following data (in addition to the types of data outlined in March 2025): 

    • Immune responses and clinical endpoints (i.e. VE and/or comparator rates of infection and severe disease) in varied human populations who receive currently approved COVID-19 vaccines against emerging SARS-CoV-2 variants, across different vaccine platforms.
    • Strengthened epidemiological and virological surveillance, as per the Standing Recommendations for COVID-19 in accordance with the International Health Regulations (2005), to determine if emerging variants are antigenically distinct and able to displace circulating variants.
    • Strengthened epidemiological surveillance to characterize disease severity in immunologically naïve and/ or immature individuals (i.e. birth cohorts).
    • Clinical evaluation of relevant new vaccine antigens derived from more recent SARS-CoV-2 variants.

    As previously stated, the TAG-CO-VAC continues to encourage the further development of vaccines that may improve protection against infection and reduce transmission of SARS-CoV-2.

    The TAG-CO-VAC will continue to closely monitor the genetic and antigenic evolution of SARS-CoV-2 variants, immune responses to SARS-CoV-2 infection and COVID-19 vaccination, and the performance of COVID-19 vaccines against circulating variants. The TAG-CO-VAC will also continue to reconvene every six months, or as needed, to evaluate the implications for COVID-19 vaccine antigen composition. At each meeting, recommendations to either maintain current vaccine composition or to consider updates will be issued. Prior to each meeting, the TAG-CO-VAC will publish an update to the statement on the types of data requested to inform COVID-19 vaccine antigen composition deliberations.

    MIL OSI United Nations News

  • MIL-OSI USA: Rep. Veasey Demands Critical Dallas County Funding be Restored to Contain Measles Outbreak in Texas

    Source: United States House of Representatives – Congressman Marc Veasey (33rd District of Texas)

    Headline: Rep. Veasey Demands Critical Dallas County Funding be Restored to Contain Measles Outbreak in Texas

    WASHINGTON, DC — Congressman Marc Veasey (TX-33), along with Congresswoman Julie Johnson (TX-33) and Congresswoman Jasmine Crockett (TX-30), demanded that $7.7 million in public health grants for Dallas County Health and Human Services (DCHHS) abruptly terminated by the Trump Administration be restored to address the measles outbreak that has reached the Dallas-Fort Worth area.  

    “DCHHS relied on this critical funding to safeguard public health in one of the most populous and fastest-growing metroplexes in the nation,” the Members wrote. “Stripping these resources without warning, amid a serious and unprecedented outbreak, significantly undermines Dallas County’s ability to respond to measles and other communicable diseases, placing millions of residents at immediate risk. We demand answers regarding this decision and urge the CDC to take swift corrective action to mitigate the harm caused by the revocation of these life-saving funds.”

    In the midst of a surging measles epidemic, the revoked funding included three major pandemic grants totaling $70 million, including a Vaccination Capacity Grant that was being used to coordinate measles vaccination clinics throughout Dallas County. Without this grant, DCHHS has had to cancel these vaccination clinics, just as the first case of measles was reported in the Dallas-Fort Worth area in a middle-school child on April 23rd

    The members are demanding answers from CDC on why this critical funding was revoked in the middle of an unprecedented measles outbreak, and how DCHHS can have the funding restored, immediately. 

     

    To read the full letter, click here.

    MIL OSI USA News

  • MIL-OSI USA: The Make America Sick Agenda: Senator Markey Compiles Stories from Trump, RFK Jr.’s First Five Months

    US Senate News:

    Source: United States Senator for Massachusetts Ed Markey
    Read stories from Massachusetts and across the country
    Washington (May 14, 2025) – Senator Edward J. Markey (D-Mass.), top Democrat on the Senate Health, Education, Labor, and Pensions Subcommittee on Primary Health and Retirement Security, today unveiled a selection of dozens of stories received by his office on Department of Health and Human Services (HHS) Secretary Robert F. Kennedy (RFK) Jr.’s first five months. The stories, titled “The Make America Sick Agenda,” contains stories from people who have shared their experiences under the Trump administration’s Health and Human Services, including the impacts of cutting billions in life-saving research into diseases like Alzheimer’s and cancer, revoking grants to hospitals and community health centers, and firing staff dedicated to helping families pay their utility bills. All the while, RFK, Jr. spreads misinformation about vaccines amidst an uncontrolled measles outbreak.
    “The stories included here are from the voices of people across the country who the Trump administration has betrayed. They are terrified of losing life-saving care. They are angry that their government would treat them this way. And they are frustrated that protecting billionaires is more important to the Administration than ensuring their ability to get the care they need, when they need it, without going into debt,” wrote Senator Markey. “These are the stories of the Trump administration’s Make America Sick Agenda. The American people deserve better.”
    Selected excerpts from the compilation:
    “My parents were the first generation in their families to go to college and I was a Pell Grant recipient. I am not from an ‘elite’ upbringing. I am a mother, a pediatrician and public health professor have dedicated my career to trying to address the health disadvantages accrued by people in lower income and otherwise socially disadvantaged and stigmatized populations with a specific focus on women and children. One of my NIH grants that sought to understand and improve the experiences in behavioral/mental health care of LGBTQIA+ youth ages 14-17 was terminated. The message sent is that these vulnerable youth do not matter, further making them feel unwelcome in this society. It also has had a chilling effect on my students and staff who are funded through this research, discouraging them from continuing to be part of the workforce trying to understand and make better the care and opportunities for those whom our societal decisions have disadvantaged for reasons that are beyond their control.” – Anonymous, Amherst, MA 
    “I have kidney cancer. As an active patient receiving extremely expensive immunotherapy treatment, if I lose my job, I’ll also lose health insurance. That is literally a death sentence.” – Joe, Bridgewater, MA 
    “I am a stage 4 cancer patient at Dana-Farber Cancer Institute and am currently enrolled in a clinical trial there. I have a rare cancer that has no cure and few drugs to treat it. In the past 20 years, clinical trials and research about my cancer have been instrumental in helping people live longer. Cuts to the NIH and cancer research are devastating to cancer patients. Cuts to vaccine research also indirectly affect cancer patients as we are typically immunocompromised and need vaccines and for the population around us to be vaccinated. Anti-vaccine sentiments from HHS and the CDC could be detrimental to cancer patients like myself.” – Jennifer, Shrewsbury, MA
    “These drastic cuts aren’t just going to devastate local jobs and people’s livelihoods and a generation of scientists. They’re rapidly destroying the infrastructure for scientific research in this country, and that’s going to have very real effects on the public’s health. The treatment and prevention advances we need for ourselves and our loved ones just won’t be there. I cannot overstate how critical it is that we act NOW. The scientific research infrastructure is far easier to break than it will be to rebuild.” – Julia, Newton, MA
    “It is a sad commentary, that in a high-income country such as the US, we lagged behind other similar high-income countries in all healthcare indicators and now we are jeopardizing the even further the health of all Americans and our scientific reputation in the world. There is always room for improved organization and being efficient with our taxpayer monies but the restructuring that is taking place is without any reasonable justification based on evidence and thus, lacks in transparency to the American people. The future of all Americans is at risk here and the damage being done to the health of our people and the education system as well as our scientific innovation is devastating. We must push back.” – Anonymous, East Longmeadow, MA

    MIL OSI USA News

  • MIL-OSI USA: As Historic Measles Outbreak Worsens, Murphy Blasts RFK Jr. On Vaccine Lies

    US Senate News:

    Source: United States Senator for Connecticut – Chris Murphy
    [embedded content]
    WASHINGTON—U.S. Senator Chris Murphy (D-Conn.), a member of the U.S. Senate Health, Education, Labor, and Pensions Committee, on Wednesday questioned U.S. Secretary of Health and Human Services Robert F. Kennedy Jr. on President Trump’s Fiscal Year 2026 skinny budget request for the U.S. Department of Health and Human Services. Murphy pressed Kennedy on broken promises made during his confirmation hearing and accused him of misleading the Committee and the public about his support for vaccines, especially for the measles vaccine.
    “I want to talk to you about the statements that you made to the Chairman of this committee and to members of this committee during your confirmation hearing about vaccines,” said Murphy. “You did not tell the truth. I find that to be really dangerous for our relationship. If I were the Chairman, who believes in vaccines and voted for you because he believed what you said about supporting vaccines, my head would be exploding. In the hearing, you told us ‘I will not work to impound, divert, or otherwise reduce any funding appropriated by Congress for the purpose of vaccination programs.’ That is not the truth. You have canceled $12 billion in public health grants to states. Whether you know this or not, that funding is used by the states in part to be able to administer and dispense information about vaccines.”
    Murphy called out Kennedy for putting public health at risk by lying to Congress during his nomination hearing and spreading misinformation that undermines trust in vaccines: “You also promised Chairman Cassidy that the FDA would not change vaccine standards from ‘historical norms.’ But what happened as soon as you were sworn in? You announced new standards for vaccine approvals that you proudly referred to in your own press release as a radical departure from current practice. And experts say that that departure will delay approvals. You also said, specific to the measles vaccine, that you support the measles vaccine, but you have consistently been undermining the measles vaccine. You told the public that the vaccine wanes very quickly. You went on the Dr. Phil show and said the measles vaccine was never fully tested for safety. You said there was fetal debris in the measles vaccine.”
    “Just this morning, in front of the House of Representatives, you also said that you in fact would not recommend that kids get vaccinated for measles,” Murphy continued. “You said you would just lay out the pros and cons. This is the summation of everything that you have said to compromise people’s faith in the measles vaccine in particular. It is contrary to what you said before this committee. You said you support the measles vaccine, but then you have laid out a set of facts that are contested, and I will submit information for the record from experts who contest what you have said about the vaccine. And the result is to undermine faith in the vaccines. Kind of like saying ‘Listen, I think you should swim in that lake, but, you know, the lake is probably toxic, and there are probably a ton of snakes and alligators in that lake, but I think you should swim in it.’ Nobody is going to swim in that lake, if that’s what you say. And so I want you to acknowledge that when you say you support the measles vaccine and then go out and repeatedly undermine the vaccine with information that is contested by public health experts, that is not supporting the vaccine.”
    After Kennedy refused to say he supports the measles vaccine, Murphy concluded: “I think you’re answering the question, and that’s really dangerous for the American public and for families in this country. The Secretary of Health and Human Services is no longer recommending the measles vaccine.”
    As of early May, the Centers for Disease Control and Prevention have confirmed over 1,000 measles cases across the country, making this the single largest measles outbreak in the 21st century. Those cases have led to 126 hospitalizations and three deaths.
    A full transcript of Murphy’s exchange with RFK Jr. can be found below:
    MURPHY: “Thank you very much, Madame Chair. Secretary Kennedy, I want to talk to you about your relationship with this committee and this Congress. I want to talk to you about the statements that you made to the Chairman of this committee and to members of this committee during your confirmation hearing about vaccines. You did not tell the truth. I find that to be really dangerous for our relationship. If I were the Chairman, who believes in vaccines and voted for you because he believed what you said about supporting vaccines, my head would be exploding.
    “In the hearing, you told us ‘I will not work to impound, divert, or otherwise reduce any funding appropriated by Congress for the purpose of vaccination programs.’ That is not the truth. Let me finish my question.”
    KENNEDY: “I didn’t hear what you said. I’m just asking you to repeat it so I can understand your question.”
    MURPHY: “I’ll repeat it. During the hearing you said to this committee, and to the Finance Committee, ‘I will not work to impound, divert, or otherwise reduce funding appropriated by Congress for the purpose of vaccination programs.’ That is not what happened. You have done the opposite. You canceled $12 billion in grants to the states, including my state, that are used to administer and track vaccines. You promised Chairman Cassidy– ”
    KENNEDY: “When did I do that?”
    MURPHY: “Madam Chair, would you allow me to finish my question?”
    MURKOWSKI: “Keep going with your question.”
    KENNEDY: “When did I do that?”
    MURPHY: “Let me finish my question.”
    KENNEDY: “You’re making these accusations, just tell me when I did it so I can understand what the question is.”
    MURPHY: “You have canceled $12 billion in public health grants to states. Whether you know this or not, that funding is used by the states in part to be able to administer and dispense information about vaccines. Mr. Secretary, let me give you the full panoply of things you said before this Committee that didn’t turn out to be true. You also promised Chairman Cassidy that the FDA would not change vaccine standards from ‘historical norms.’ But what happened as soon as you were sworn in? You announced new standards for vaccine approvals that you proudly referred to in your own press release as a radical departure from current practice. And experts say that that departure will delay approvals. You also said, specific to the measles vaccine, that you support the measles vaccine, but you have consistently been undermining the measles vaccine. You told the public that the vaccine wanes very quickly. You went on the Dr. Phil show and said the measles vaccine was never fully tested for safety. You said there was fetal debris in the measles vaccine. And this morning–”
    KENNEDY: “All true! All true. Do you want me to lie to the public?”
    MURPHY: “None of that is true.”
    KENNEDY: “Of course it’s true. Of course it’s true, Senator. Senator, begging your pardon, but you do not know what you are talking about.”
    MURKOWSKI: Let’s have a little bit of order so that you can get your question and that he can get his answer.
    MURPHY: “I didn’t ask for a response yet. I’d like to lay out the predicate of my question before I’m interrupted by the witness. He should have some respect for this Committee.”
    MURKOWSKI: “Go ahead.”
    MURPHY: “Just this morning, in front of the House of Representatives, you also said that you in fact would not recommend that kids get vaccinated for measles. You said you would just lay out the pros and cons. This is the summation of everything that you have said to compromise people’s faith in the measles vaccine in particular. It is contrary to what you said before this committee. You said you support the measles vaccine, but then you have laid out a set of facts that are contested, and I will submit information for the record from experts who contest what you have said about the vaccine. And the result is to undermine faith in the vaccines. Kind of like saying ‘Listen, I think you should swim in that lake, but, you know, the lake is probably toxic, and there are probably a ton of snakes and alligators in that lake, but I think you should swim in it.’ Nobody is going to swim in that lake, if that’s what you say. And so I want you to acknowledge that when you say you support the measles vaccine and then go out and repeatedly undermine the vaccine with information that is contested by public health experts, that is not supporting the vaccine. 
    “And so I guess I have two simple questions for you. One is, can you clarify what you said in the House this morning? Are you or are you not recommending that families get their children vaccinated? Or are you just giving people the pros and cons? And do you understand that when you say these things about the measles vaccine, what ends up happening is less people get the vaccine. That may be what you want, but do you understand that the result of constantly questioning the efficacy or safety of the vaccine results in less people getting the vaccine? I don’t necessarily want to spend the remaining 20 seconds in an argument over the science. But do you at least understand that that is the consequence of what you are saying? And are you actually still recommending people get the vaccine or are you not?”
    KENNEDY: “Senator, if I advise you to swim in a lake that I knew there to be alligators in, wouldn’t you want me to tell you there were alligators in it?”
    MURPHY: “So are you recommending the measles vaccine or not?”
    KENNEDY: “What I have said, and what I said in–”
    MURPHY: “It doesn’t sound like you are, if that’s–”
    KENNEDY: “Are you going to let me answer, or are you going to keep interrupting me?”
    MURPHY: “Are you, or are you not?”
    KENNEDY: “Are you going to let me answer? What I pledged before this committee during my confirmation is that I would tell the truth, and that I would have radical transparency. I’m going to tell the truth about everything we know and we don’t know about vaccines.”
    MURPHY: “Are you recommending the measles vaccine or not?”
    KENNEDY: “I am not going to just tell people everything is safe and effective if I know that there’s issues. I need to respect people’s intelligence.”
    MURPHY: “I think you’re answering the question. I think you’re answering the question, and that’s really dangerous for the American public and for families in this country.”
    KENNEDY: “The reason people have lost faith in this program is because they’ve been lied to by public officials for year after year after year.”
    MURPHY: “The Secretary of Health and Human Services is no longer recommending the measles vaccine.”

    MIL OSI USA News